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Keywords:  Hydrogels, smart hydrogels, controlled drug delivery, beta 
 cyclodextrin, solid inclusion complexes, swelling characteristics,        
in vitro drug release, cytotoxicity assay. 
 
Hydrogels are polymeric networks with three-dimensional configuration capable of 
imbibing large amounts of water or biological fluids. Owing to their ability to retain a 
significant amount of water, hydrogels mimic the natural structure of the body’s 
cellular makeup, which renders them important for an array of biomedical applications 
including tissue engineering, artificial organ and contact lens designing and most 
importantly in drug delivery. A truly amazing class of hydrogels that has found 
profound interests as drug delivery systems is the class of smart/ intelligent hydrogels. 
These hydrogels are endowed with the unique property to exhibit unusual volume 
changes in response to environmental stimuli. Efforts have focused mostly on 
designing hydrogel systems that make use of changes in response to pH and 
temperature. Despite numerous advantages, hydrogels are also associated with some 
inherent pharmacological limitations. The poor mechanical strength of many 
hydrogels results in their premature disintegration. The high water content and porous 
nature of the hydrogels often result in a relative rapid release of drug thereby reducing 
the therapeutic value. 
The present study aims at addressing the above problems by incorporating preformed 
drug-cyclodextrin inclusion complexes (ICs) into the hydrogel matrix. Cyclodextrins 
are of interest in this context given their amphiphilic nature; a hydrophilic exterior and 
a hydrophobic pocket. The hydrophilic exterior can be useful for effective partitioning 
into the hydrogel matrix and maintaining the bulk hydrophilicity and swelling state of 
the hydrogel and the hydrophobic interior can facilitate the entrapment and controlled 
release of hydrophobic drugs and therapeutics. Of the parent α−, β− and 
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−cyclodextrins, β−cyclodextrin (CD) is widely employed for pharmaceutical 
purposes in comparison to the other two. The scope of the present study particularly 
emphasizes the role of CD in controlled drug delivery from hydrogels.  
Chapter 1 introduces the concept of hydrogels and their numerous applications in 
various fields. The utility of hydrogels as target-specific drug delivery agents has been 
discussed at length. The importance of cyclodextrins as drug delivery agents is hereby 
introduced. The different strategies of integrating hydrogels and cyclodextrins to 
achieve improved physico-chemical properties have also been discussed. The 
objective of the present thesis work is also given. 
Chapter 2 provides information on the materials used and the methodologies 
employed for the studies. 
Chapter 3 demonstrates the applicability of poly(vinyl alcohol) (PVA) hydrogels 
containing drug−CD ICs as controlled drug delivery systems. Different compositions 
of pure PVA hydrogels and CD−incorporated PVA hydrogels were synthesized with 
varying amount of the cross-linker glutaraldehyde (GA) by the solution casting 
technique. Hydrogels containing the free drug and ICs were also prepared and 
explored for their drug releasing properties. In this study, salicylic acid (SA) and 
ibuprofen (IBF) were chosen as the drugs of interest. The solid ICs of the drug in CD 
were prepared by the co-precipitation method. The swelling evaluation of the 
hydrogels indicated the decreased swelling with increasing GA content for both PVA 
and PVA-CD hydrogels. The role of CD, the effect of nature of drug and degree of 
cross-linking on the drug release process has also been investigated. The probable 
mechanism of drug release has also been addressed by fitting the release data to 
various mathematical equations. Controlled release of drug was achieved from the 
hydrogels containing the ICs. The effect of degree of cross-linking on the release 
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pattern is strikingly different from hydrogels containing free drug and that with the 
ICs. The role of CD in the drug release process is not only because of its inclusion 
ability but also its effect on the polymer relaxation. GA, apart from cross-linking 
PVA, probably interacts with the hydroxyl groups of CDs thereby influencing the 
matrix structure. The nature of drug in terms of its binding efficacy with CD plays an 
important role. Thus the drug release is accomplished as a combination of the effects 
of drug diffusion, the polymer relaxation, the binding affinity of the drugs with CD 
and the effect of CD on the macromolecular relaxation. The cytotoxicity assay 
performed on the hydrogels by MTT colorimetric technique suggested a high 
compatibility of these hydrogels with the living tissues. Hence the strategy of 
incorporating pre-formed ICs into PVA hydrogels to achieve controlled delivery of 
drugs works quite well.  
Chapter 4 presents the design of pH-responsive smart hydrogels based on chitosan 
(CS) and poly(acrylic acid) (PAA) for controlled drug delivery. This chapter consists 
of two parts; Part I: To explore the potential of GA cross-linked CS−PVA hydrogels 
towards the controlled delivery of non-steroidal anti-inflammatory drugs (NSAIDs), 
Naproxen (NX) and Diclofenac sodium (DS), to the intestine and Part II: To inspect 
the utility of PAA hydrogel microspheres towards controlled delivery of 
Dexamethasone (DX) and investigate the influence of method of preparation of IC on 
the drug release phenomenon from the microspheres.  
Part I: pH-Sensitive CS−PVA hydrogels with varying amounts of PVA and cross-
linked with GA were synthesized and explored for the delivery of NX and DS. The 
preformed solid NX−CD and DS−CD inclusion complexes were added directly into 
the CS−PVA hydrogels. With increased amount of PVA in CS−PVA hydrogels, the 
degree of swelling decreased due to increased hydrogel density. All the synthesized 
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hydrogels exhibited maximum swelling at neutral pH. The presence of CD did not 
have any drastic effect on the swellability of the hydrogels. The antimicrobial property 
of CS was not compromised in the presence of PVA and/or CD in the hydrogels. The 
drug release from the IPN hydrogels was much prolonged as compared to pure CS 
hydrogels. The hydrogels containing the ICs released the drug considerably slower 
than those containing the free drug. With increasing PVA content, the rate of drug 
release was found to decrease. The in vitro drug release of hydrogels in simulated 
gastric fluid (SGF) showed negligible release of drug over a period of 2 h while it 
increased significantly in the simulated intestinal fluid (SIF). This release profile is 
suitable for the oral delivery of the drug. The pH-specific release of NX and DS from 
these hydrogels can be utilised for intestine−targeted delivery. The cytotoxic assay 
ensured them to be non-toxic and biocompatible and suggested their potential as 
controlled and intestine-specific drug delivery agents. Thus, it can be proposed that 
the deleterious effects of NSAIDs on the epithelium of the gastrointestinal tract (GIT) 
could be minimized by using the IC loaded hydrogels as drug delivery system (DDS) 
given that they provide a controlled release resulting in a reduced concentration of free 
NSAIDs. 
Part II: In view of the importance of microspheres in drug delivery, PVA−PAA 
microspheres have been synthesized and examined for the controlled delivery of the 
common anti-inflammatory and immunosuppressant drug DX to the intestine. To 
regulate the release rate of DX, preformed solid ICs of DX with CD was added to the 
hydrogel microspheres. In order to study the influence of the method of preparation of 
IC on the release behaviour, the IC was prepared by two different methods: the co-
precipitation (CP) and freeze-drying (FD). The GA cross-linked PVA−PAA hydrogel 
microspheres containing free drug, the physical mixture and the ICs were synthesized 
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to investigate their drug release behaviour. The swelling characteristics of the 
microspheres indicated higher swelling in neutral pH than in acidic pH. The 
microspheres exhibited negligible drug release in pH 1.2 whereas significant release in 
pH 7.4. Slowest release was observed from the microspheres which contained the FD 
inclusion product. The drug release in SGF and SIF revealed approximately 5% of DX 
release during the initial 2 h in SGF and increasing significantly upon transferring to 
SIF. Thus the synthesized microspheres could be effectively employed for the 
controlled delivery of DX and their pH sensitivity could be exploited for the delivery 
to the intestine. Moreover, the compatibility of the synthesized microspheres with the 
living tissues further validates them as promising drug delivery systems.  
Chapter 5 deals with regulating the delivery of the anticancer drug 5-Fluorouracil 
(5FU) from temperature-sensitive interpenetrating polymer network (IPN) hydrogels 
of guar gum (GG) and Poly (N−isopropylacrylamide) (PNIPAAm). In lieu of 
utilization of natural polysaccharides in drug delivery systems, GG is of particular 
interest because of its susceptibility to microbial degradation in the large intestine. The 
IPN hydrogels were synthesized using a non-toxic cross-linker, tetraethyl orthosilicate 
(TEOS). 5FU−CD solid ICs, prepared by freeze-drying method, were directly added 
to the hydrogel matrix. Incorporation of GG did not disturb the arrangement of 
PNIPAAm chains and the lower critical solution temperature (LCST) remained 
invariant. The hydrogels exhibited temperature-responsive swelling characteristics. 
The hydrogels also exhibited temperature dependence in their drug releasing 
characteristics. At higher temperature (above LCST) the release rate was considerably 
slower than that at lower temperature (below LCST). Presence of IC in the hydrogel 
matrix is capable of significantly controlling the drug release rate despite the fact that 
the matrix is undergoing a drastic morphological change above its LCST. The 
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presence of CD in the hydrogels as ICs was vital in influencing the polymer relaxation 
and retarding the drug release rate from the hydrogels containing the ICs. The 
cytotoxicity assay performed on rat fibroblasts certified these hydrogels to be safe, 
nontoxic and biocompatible with living tissues thereby validating their potential as 
controlled drug delivery systems. 
Chapter 6 focuses on the evaluation and comparison of the efficacy of GG-PAA-CD 
hydrogels with CD as a part of their network structure, and GG-PAA hydrogel 
containing the preformed DX-CD IC, for the controlled delivery of DX. IPN 
hydrogels composed of GG and PAA have been developed by using TEOS as cross-
linker by varying the ratio of GG and PAA. The corresponding GG−PAA−CD 
hydrogels with CD as a part of the network structure were also synthesized. The 
swelling characteristics revealed maximum swelling at neutral pH. Controlled release 
of drug was obtained from CD-incorporated hydrogels as opposed to the fast release 
from the hydrogels without CD. Upon comparison it was found that the hydrogels 
containing preformed ICs performed better in terms of controlled release 
characteristics than the hydrogels containing CD as a part of their network structure. 
The cytotoxicity study revealed the biocompatible and nontoxic nature of these 
hydrogels validating them as promising drug delivery systems.   
Chapter 7 provides the summary of the important findings of the work and also 
suggests the scope for future work.      
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INTRODUCTION 
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1.1 Hydrogels 
Hydrogels are polymeric networks with three-dimensional configuration capable of 
imbibing large amounts of water or biological fluids. Hydrogels can be made from 
virtually any water-soluble polymer, encompassing a wide range of chemical 
compositions and bulk physical properties. The three-dimensional network, formed by 
cross-linking of polymer chains, provides resistance to the hydrogels to dissolute (Qiu 
and Park, 2001). They can be designed in a variety of architectures such as slabs, 
microparticles, coatings and films. The high hydrophilicity of hydrogels is mainly due 
to the presence of hydrophilic moieties such as hydroxyl, carboxyl, amino and amide 
groups in the backbone of the polymer strands. In general, the more hydrophilic is the 
polymer, the higher is the total water retention capacity of the hydrogel. The hydrogels 
in their dried forms are called xerogels. When dried by freeze-drying, solvent 
extraction or supercritical drying techniques, the resulting hydrogels are extremely 
porous in nature and are known as aerogels (Bhattacharya, 2000). In their fully 
swollen state, hydrogels are soft and have a rubbery consistency. Owing to their 
ability to retain a significant amount of water, hydrogels mimic the natural structure of 
the body’s cellular makeup, rendering them important for biomedical applications e.g. 
tissue engineering, artificial organ and contact lens designing, and most importantly in 
drug delivery (Hoare and Kohane, 2008). 
The terms 'gels' and 'hydrogels' are often misinterpreted and are used interchangeably 
in the world of polymer science. Both, gels and hydrogels, are polymeric networks 
and might be chemically similar, however they are physically very distinct. Gels are 
semi-solid polymeric materials comprising small amounts of solids dispersed in 
relatively large amounts of liquid, yet possessing more solid-like character (Kleech, 
1990). Conventional gels can acquire a low level of virtual cross-linking under the 
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influence of shear forces, but this is reversible because of involvement of weak 
physical forces (Gupta et al., 2002). Therefore, gels are defined as a substantially 
dilute cross-linked polymeric system, and are categorised principally as weak or 
strong depending on their flow behaviour in steady-state (Ferry, 1980). Because of the 
weak or virtual cross-linking, the polymer strands in gels often dissolute in aqueous 
environment resulting in the loss of network structure. The hydrogels, on the other 
hand, are cross-linked hydrophilic polymers which retain their three-dimensional 
structure even after absorbing large amount of water (Gehrke and Lee, 1990). Thus 
hydrogels are different from gels in the sense that they are already swollen matrices, 
and the further addition of fluids results only in their network dilution. The feature that 
is important to the functioning of a hydrogel is its inherent strong cross-linking. The 
distinct behaviour of gels and hydrogels is illustrated in Figure 1.1. 
 
Figure 1.1. Distinct behaviour of gels and hydrogels in an aqueous environment. Solid 
circles represent strong covalent cross-linking while the hollow circles 
represent weak/virtual cross-linking (Gupta et al., 2002). 
 General Introduction 
 
3 
 
1.2 Classification of Hydrogels 
A proper knowledge of polymer network, quantitative features of the materials, 
interaction parameters, disintegration kinetic and transport phenomena are paramount 
to achieve a hydrogel with predetermined and well-defined physico-chemical 
parameters for various applications. In general, hydrogels can be classified based on a 
variety of characteristics. These include the source, network electrical charge, 
polymeric composition, network structure, type of cross-linking and responses to 
environmental stimuli (pH, temperature, ionic strength, glucose strength, light, 
enzymes etc.). (Peppas and Merrill, 1976; Peppas, 1986; Stauffer and Peppas, 1992; 
Hickey and Peppas, 1995) 
Classification based on source (Zhao et al., 2013): 
Polymers that are generally employed for hydrogel synthesis and directed towards 
pharmaceutical or biomedical applications can be from natural or synthetic origins 
(Hoffman, 2002; Hamidi et al., 2008). Typical examples of natural and synthetic 
polymers used in hydrogel preparations are summarized below. 
Natural polymers: 
 Anionic polymers: Hyaluronic acid, Alginic acid, Pectin, Carrageenan 
 Cationic polymers: Chitosan, Polylysine, Gelatin, Dextran, Cellulose 
 Amphipathic polymers: Collagen, Fibrin, Carboxymethyl chitin 
 Neutral polymers: Agarose, Pullulan 
Synthetic polymers: 
 Poly(hydroxyethyl methacrylate) (PHEMA) 
 Poly(ethylene glycol) (PEG) and derivatives 
 Poly(vinyl alcohol) (PVA) and derivatives 
 Poly(acrylic acid) (PAA) and derivatives 
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 Poly(ethylene oxide) (PEO) 
 Poly(acrylonitrile) (PAN) 
 Poly(N-isopropylacrylamide) (PNIPAAm) 
 Poly(N-vinyl pyrrolidone) (PVP) and derivatives. 
A summary of the monomers mostly employed in the design of hydrogels for 
pharmaceutical and biomedical interests are briefed in Table 1.1. 
Table 1.1. List of a few monomers widely used in hydrogel preparation for 
biomedical applications 
Monomer Abbreviation 
Hydroxyethyl methacrylate HEMA 
Hydroxyethoxyethyl methacrylate HEEMA 
Methoxyethyl methacrylate MEMA 
Ethyleneglycoldimethacrylate EGDMA 
N-vinyl-2-pyrrolidone NVP 
N-isopropylacrylamide NIPAAm 
Acrylic acid AAc 
Methacrylic acid MAAc 
Ethylene glycol EG 
Vinyl acetate VAc 
 
Classification according to network electrical charge (Hacker and Mikos, 2011): 
Hydrogels may be categorized into four groups on the basis of presence or absence of 
electrical charge located on the cross-linked chains: 
 Nonionic (neutral) 
 Ionic (anionic or cationic) 
 Amphoteric electrolyte (ampholytic) containing both acidic and basic groups 
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 Zwitterionic containing both anionic and cationic groups in each structural 
repeating unit 
Among all, the ionic hydrogels composed of either cationic or anionic polymers are 
extensively investigated for various therapeutic applications. Anionic polymers have 
the ability to form ionic complexes with cationic biomolecules including basic 
peptides, blood proteins and cationic drugs (Kobayashi et al., 2003; Olson and 
Chuang, 2002). Cationic polymers, on the other hand, form electrostatic complexes 
with anionic biomolecules, nucleic acids (DNA, RNA and PNA) and proteins. In 
addition, the inherent bioactive properties such as stimuli-responsiveness, 
antimicrobial, antioxidant, antitumor and anti-inflammatory properties makes cationic 
hydrogels more promising materials for therapeutics. Widely studied cationic 
polymers include poly (ethylene imine), poly-L-(lysine) and chitosan. The review 
article by Putnam (2006) highlights the use of cationic polymers in gene delivery 
applications. Samal and co-authors (2012) have also discussed the development and 
modification of cationic polymers into various architectures such as hydrogels, 
scaffolds, micelles, membranes and have addressed their therapeutic applications. 
Classification based on polymeric composition (Ahmed, 2013): 
Based on polymeric composition the hydrogels can be classified as: 
 Homopolymeric hydrogels where the polymer network is derived from a 
single monomer species. 
 Copolymeric hydrogels which comprise of two or more different monomer 
species arranged in a random, block or alternating configuration along the 
chain of the polymer network. 
 Multipolymer interpenetrating polymeric network (IPN) hydrogels 
composed of two or more independent cross-linked synthetic or natural 
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polymers contained in a network. In semi-IPN hydrogels, one component is a 
cross-linked polymer and other component is a non-cross-linked linear 
polymer. 
Classification based on network structure (Ahmed, 2013): 
Hydrogels can be categorized based on their network structure as: 
 Amorphous (non-crystalline): The polymer chains are randomly arranged 
 Semi-crystalline: Dense regions of ordered macromolecules or crystallites 
present in an amorphous matrix i.e. a complex mixture of amorphous and 
crystalline phases 
 Crystalline: The polymer chains are arranged in systematic manner in ordered 
array 
Classification based on type of cross-linking (Hacker and Mikos, 2011): 
Hydrogels can be classified into two categories based on the chemical and physical 
nature of the cross-link junctions. Chemically cross-linked networks have permanent 
junctions while the physically cross-linked hydrogels have transient junctions that 
arise from either chain entanglement of the polymers or physical interactions such as 
hydrogen bonds or hydrophobic interactions (Jen et al., 1996).  
Classification based on responses to external stimuli: 
A truly amazing class of hydrogels that has found potential use for a wide variety of 
applications is the class of “smart” or “intelligent” hydrogels. These hydrogels exhibit 
changes in the gel structure in response to environmental stimuli. Smart hydrogels are 
a special class of hydrogels which are equipped with the exceptional property of 
undergoing extensive conformational changes such as reversible volume-phase 
transitions or sol-gel transitions, in response to very small changes in environmental 
factors (Rossi et al., 1991). The physical stimuli include temperature, electric field, 
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light, pressure, and magnetic field while the chemical stimuli include pH, ions, and 
molecular recognition events etc. (Qiu and Park, 2001). The sensitivity of smart 
hydrogels to the minute changes in the environmental factors makes them appropriate 
to be used in a diversity of applications. Figure 1.2 describes the various stimuli 
actions on hydrogels that render them useful in diverse pharmaceutical applications 
and mostly as targeted drug delivery systems. 
 
 
Figure 1.2.Various stimuli actions that impart stimuli-sensitivity to hydrogels. 
Of the several environmental factors that render a hydrogel smart; the most common 
are pH, ion, temperature, glucose, electric current, light and enzymes. The properties 
and utilities of such smart hydrogels have been briefed below.   
1.2.1 pH−sensitive Hydrogels 
pH-sensitive polymers are those, whose solubility or conformation in aqueous solution 
changes reversibly or irreversibly as a function of environmental pH (Huh et al., 
2012). These polymers are a class of polyelectrolytes which have ionizable groups in 
the backbone of their structures, side-group or end-group and demonstrate pH-
responsive physico-chemical properties. Most commonly studied ionic polymers for 
pH-responsive behaviour are poly(acrylamide), poly(acrylic acid), poly(methacrylic 
acid), poly(diethylaminoethyl methacrylate) and poly(dimethylaminoethyl 
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methacrylate) (Gupta et al., 2002). Apart from synthetic polymers, natural 
polysaccharides such as chitosan, dextran, albumin and gelatin are also known to 
exhibit pH-sensitive behaviour (George and Abraham, 2007; Altimari et al., 2012). 
When the pH of the external medium is above the pKa of the ionizable group of the 
anionic hydrogels, ionization occurs. This results in increased hydrophobic 
interactions between the polymer chains and enhances the swelling ratio. The reverse 
is the case with cationic hydrogels which swell at lower pH. The pH-dependent 
swelling/ deswelling behaviour of cationic and anionic hydrogels is demonstrated in 
Figure 1.3. 
 
Figure 1.3. pH-responsive swelling and deswelling of ionic hydrogels. 
1.2.2 Ion−sensitive Hydrogels 
Ions play a crucial role in many biological processes. Thus, utilization of ion-sensitive 
polymeric hydrogels could be effective in drug delivery. Ionic hydrogels are swollen 
polymeric networks which exhibit sudden or gradual changes in their equilibrium and 
dynamic swelling behaviour as a result of the external ionic strength. In aqueous 
media of particular ionic strength, the groups ionize thereby developing a fixed charge 
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on the hydrogel which are responsible for the swelling or deswelling of the hydrogel. 
The mechanism of ion-mediated drug release from an ion-sensitive hydrogel is 
represented in Figure 1.4. Rasool et al., (2010) designed a novel pH-, ionic strength 
and temperature-sensitive hydrogel composed on kappa carrageenan and AAc and 
investigated the delivery features for insulin. The hydrogels exhibited potential for 
controlled delivery of insulin. 
 
Figure 1.4. Mechanism of ion-mediated drug release at different ionic strengths 
(Sutani et al., 2002). 
1.2.3 Temperature−sensitive Hydrogels 
Temperature-sensitive or thermo-sensitive hydrogels are probably the most commonly 
studied class of smart polymer systems in drug delivery research. The release as well 
as the mechanical characteristics of the hydrogels is altered with changes in the 
temperature of the environment (Bromberg and Ron, 1998). The common 
characteristic of temperature-sensitive polymers is the presence of hydrophobic groups 
such as methyl, ethyl or propyl groups. Of the many temperature-sensitive polymers, 
PNIPAAm and poly(N,N-diethylacrylamide) (PDEAAm) are widely employed 
because their lower critical solution temperatures (LCST) are in the range of 25−32°C, 
close to the body temperature which make them apt as drug delivery carriers (Qiu and 
Park, 2001). Most polymers have increased water-solubility with increased 
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temperature. But polymers with LCST have decreased water-solubility at higher 
temperatures. Hydrogels having LCST shrink as the temperature goes above their 
LCST. Such a property is known as inverse or negative temperature-dependence. 
These hydrogels are composed of either moderately hydrophobic groups or a mixture 
of hydrophobic and hydrophilic segments. At lower temperatures, the hydrogen 
bonding between the hydrophilic segments of the polymer backbone increases which 
results in an enhanced swelling of the matrix. As the temperature is increased, the 
hydrophobic interaction between the hydrophobic segments increases while the 
hydrogen bonding weakens.  The net result is the shrinking of the hydrogels due to 
inter-polymer chain association through hydrophobic interaction. In general, negative 
thermo-sensitive hydrogels contract when heated above their LCST.  
 
Figure 1.5. Thermo-reversible polymer showing lower critical solution temperature    
  (LCST). 
On the other hand, positive thermo-sensitive hydrogels swell at higher temperature 
and shrink at lower temperature (Schild, 1992). Such hydrogels are known to exhibit 
upper critical solution temperature (UCST). Currently, Poly(N-acryloyl glycinamide) 
(PNAGA) is the most studied polymer that forms sol-gel thermo-responsive systems 
with a UCST in aqueous media. Boustta and co-workers (2014) have designed 
thermo-responsive hydrogels based on the above polymer for loco-regional sustained 
delivery of drug. Seuring and Agarwal (2012) have focused on the applicability and 
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potential of polymers having UCST and also addressed the largely unknown 
importance of such polymers in their review article.  
1.2.4 Glucose−sensitive Hydrogels 
Such hydrogels are sugar-sensitive and show variability depending on the 
concentration of sugar present. Glucose-sensitive hydrogels are necessary for the 
development of self-regulated delivery systems, which can deliver therapeutic doses 
of insulin in response to blood sugar concentration (Kost and Langer, 1992; Ishihara 
and Matsui, 1986). Many hydrogel systems have been developed for modulating 
insulin delivery and all are equipped with a glucose sensor built in the system. 
Glucose oxidase is the most widely used enzyme in glucose sensing. It oxidizes 
glucose to gluconic acid, resulting in a pH change of the environment (Qiu and Park, 
2001). This makes it possible for the design of pH-sensitive hydrogels for insulin 
delivery. Hydrogels composed of polycations exhibit higher swelling at lower pH. 
This membrane swelling property can be utilized for the delivery of insulin (Albin et 
al., 1985). Hydrogels made of polyanions have also been used for localized insulin 
delivery. Hydrogel containing polyanion such as PAA-grafted porous cellulose film 
and immobilised glucose oxidase was synthesized for insulin delivery in response to 
glucose concentration (Ito et al., 1989). At neutral pH, in the absence of glucose, the 
repulsion between the negatively charged carboxylate groups lead to closing of the 
pores of the membrane. Glucose oxidase catalyzes oxidation of glucose to gluconic 
acid that protonates the polymer chains. This, in turn, opens up the closed pores of the 
membrane and thus regulates the delivery of insulin. Concanavalin A (Con A) has also 
been frequently used in modulated insulin delivery. Con A is a glucose-binding 
protein obtained from the jack bean plant, Canavalia ensiformi. An injectable in-situ 
forming glucose-responsive dextran and lectin Con A based hydrogels have been 
 General Introduction 
 
12 
 
synthesized to deliver the adipogenic factor of insulin to human tissues (Tan and Hu, 
2012). In another formulation, insulin loaded microhydrogels fabricated from 
methacrylate derivatives of dextran and Con A as an insulin delivery system has been 
evaluated by Yin et al., (2012). The results indicated that insulin release was 
reversibly in response to different glucose concentrations. 
Hydrogels can be made to undergo reversible sol-gel phase transformations depending 
on the glucose concentration in the environment. The sol-gel transition of glucose-
sensitive hydrogel is shown in Figure 1.6.  
 
Figure 1.6. Sol-gel phase transition of a glucose-sensitive hydrogel (Qiu and Park,  
 2001).  
As the external glucose molecules diffuse into the hydrogels, individual free glucose 
molecules compete with the polymer-attached glucose molecules and an exchange 
occurs. Thus the concentrations of Con A and glucose-containing polymers can be 
adjusted to make hydrogels responsive at specific glucose concentrations. 
1.2.5 Electric current−sensitive Hydrogels 
Electro-responsive hydrogels, made of polyelectrolytes, are sensitive to electric 
signals and undergo shrinking or swelling in presence of an electric field. These 
hydrogels sometimes show swelling on one side and deswelling on the other leading 
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to the bending of the hydrogel. A Pluronic bis-methacrylate hydrogel modified with 
hydrolyzed methacrylic acid developed by Jackson et al., (2013) was found to deswell 
uniformly without any visual deformations due to electrical bias. Recently, an 
electrical-sensitive hydrogel based on PVP and PAA was synthesized using potassium 
persulfate as the radical initiator (Jin et al., 2013). The swelling behaviour indicated 
the bending of the hydrogel towards the cathode irrespective of the pH of buffer 
solution and applied voltage. Thus the utilities of these hydrogels as sensors, actuators, 
switches or drug delivery systems are demonstrated. Electro-conductive hydrogels 
based on the blends of poly(ethyleneimine) and 1-vinylimidazole were synthesized 
and investigated for the delivery of indomethacin (Indermun et al., 2014). A natural 
amphoteric electroactive hydrogel based on chitosan and carboxymethyl chitosan has 
been prepared (Shang et al., 2008). The hydrogel bended either towards anode (pH ≤ 
7) or cathode (pH > 7) depending on the pH of the external medium. The report 
suggested improved mechanical properties and electrical sensitivity indicating 
potential as microsensors and actuators. Hydrogels comprising of PAA-co-poly(vinyl 
sulfonic acid)-polyaniline have been developed as actuator by Kim et al., (2006). The 
hydrogels displayed a reversible change in volume on switching the electric stimulus 
between the positive and negative electrodes, showing a contraction and expansion of 
the hydrogels, respectively. The electro-sensitive behaviour of these hydrogels pointed 
their greater applications as actuators. Polythiophene-based conductive hydrogel has 
shown to undergo swelling-deswelling transition in response to an applied potential 
over -0.8 to 0.5 square wave potential (Irvin et al., 2001). IPN hydrogels composed of 
PVA and PMA were prepared which exhibited electrical sensitivity behaviour (Kim et 
al., 2004). The hydrogels showed bending behaviour in Hank's solution of pH 7.4 
which is desirable in biomedical applications. In the review article by Murdan (2003), 
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the responses of hydrogels to external electric field and electrically-stimulated drug 
releases have been well summarized.     
1.2.6 Photo−sensitive Hydrogels 
Light-sensitive hydrogels have potential applications in optical switches, display units 
and ophthalmic drug delivery devices. Photo-responsive hydrogels are also potentially 
useful as drug delivery carriers and cell culture media. The utilization of 
photopolymers provides a possibility for the temporal and spatial controlling of 
hydrogel cross-linkers. 
 
Figure 1.7. Sol-gel phase transition of a photo-sensitive hydrogel (Tomatsu et  
  al., 2011).  
 
Torqersen et al., (2012) have produced 3-D hydrogel scaffolds by means of the two-
photon polymerization technique. The results demonstrated the feasibility and 
potential for bio-fabricating 3-D tissue constructs in the micrometer-range via near-
infrared lasers in direct contact with a living organism. Wang et al., (2014) have 
mechanically prepared strong light-sensitive hydrogels by photoinitiated 
copolymerization of spiropyran-containing monomer, 2-vinyl-4,6-diamino-1,3,5-
triazine, hydrogen bonding polymer, oligo(ethylene glycol)methacrylate and 
polyethylene glycol diacrylate. It was observed that the multiple hydrogen bonding 
contributed to the increase in compressive strength of the photo-sensitive hydrogels. 
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Also selective detachment of cells was achieved by UV light illumination on the 
specified hydrogel surface. The hydrogels were found to be suitable platform for 
operating gene delivery and controlled harvesting of drugs for tissue engineering 
purposes. A photo-sensitive copolymer hydrogel based on polyacrylamide, 
poly(acrylamide-co-acrylamidoazobenzene) was synthesized in tetrahydrofuran 
solvent following free-radical polymerization route using azo bis isobutrylonitrile 
(AIBN) as an initiator (Zhao et al., 2008).  Photopolymerized hydrogels were 
evaluated for their degradation and cytocompatibility by Vermonden et al., (2008). 
The LIVE/ DEAD cell viability/ cytotoxicity assay on goat mesenchymal cells 
demonstrated the biocompatibility of the synthesized hydrogels. The review articles 
by Tomatsu et al., (2011) and Alvarez-Lorenzo et al., (2009) investigate photo-
sensitive hydrogels as emerging biomaterials for various applications. 
1.2.7 Enzyme−sensitive Hydrogels 
Biodegradable polymers are becoming increasingly important in biomedical fields 
because of their high potential in tissue engineering, drug delivery devices etc. Since 
some of the biodegradable polymers can be digested by specific enzymes, enzyme-
sensitive hydrogels can be designed from such polymers (Miyata et al., 2002). The 
microbial enzymes that are mostly present in the colon can be utilized for designing 
colon-specific drug delivery systems. Hovgaard and Brǿnsted (1995) focussed on the 
fact that microbial enzymes such as dextranases can degrade the polysaccharide 
dextran.  Dextran hydrogels cross-linked by diisocyanate were synthesized for colon 
targeted drug delivery. The hydrogels were degraded by dextranases in vivo in rats and 
also in human colonic fermentation. Azoreductase is one of the most useful enzymes 
for colon-specific drug delivery as it is produced by the microflora of the colon. To 
fabricate colon-specific delivery systems, researchers have used azoaromatic bonds 
 General Introduction 
 
16 
 
which can be degraded by azoreductases (Ghandehari et al., 1997; Akala et al., 1998). 
Prodrug is another important approach for targeting drugs to colon. A large number of 
enzyme based prodrugs are available but azo prodrugs have clinically proven to be 
most efficient. The azo bonds of the prodrugs of 5-aminosalicylic acid and 
sulphasalazine were reduced specifically in the caecum of rats (Schellekens et al., 
2007).   
 
Figure 1.8. Diagrammatical representation of mechanistic aspect of azo-based 
prodrugs (Sharma et al., 2013).  
 
1.3 Technologies Adopted in Hydrogel Preparation 
A hydrogel is simply a hydrophilic polymeric network cross-linked to produce an 
elastic structure to avoid dissolution of the hydrophilic polymer chains (Hennink and 
van Nostrum, 2002). A number of cross-linking approaches have been developed to 
obtain hydrogels with desired properties. The most common cross-linking methods 
used in hydrogel fabrication are summarized in Figure 1.9. 
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Figure 1.9. Various cross-linking approaches used in hydrogel preparation. 
In chemically cross-linked hydrogels, covalent bonds are present between the polymer 
chains while physical interactions predominate in physically cross-linked hydrogels. 
1.3.1 Chemically Cross-linked Hydrogels 
Chemical cross-linking usually refers to grafting of monomers to the polymer 
backbone or the use of a chemical agent to link two polymer chains. Various 
approaches such as radical copolymerization, energy irradiation, use of enzymes and 
by chemical reaction with complementary groups have been adopted to design 
chemically cross-linked hydrogels. 
Chemically cross-linked hydrogels can be obtained by radical copolymerization of 
low molecular weight monomers in presence of a cross-linker. The first reported 
PHEMA hydrogel by Wichterle and Lim (1960) was obtained by polymerizing 
HEMA in presence of the cross-linking agent ethylene glycol dimethacrylate 
(EGDMA). A great variety of other hydrogels have also been synthesized using 
radical polymerization procedures.  
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Radiation cross-linking is another widely used technique for fabrication of hydrogels 
(Lugao and Malmonge, 2001).  
Increasing interest has also been focussed on enzyme cross-linked hydrogels mainly 
due to the mildness of this type of reaction. Recent research has demonstrated enzyme 
cross-linking as an emerging and competitive method for in situ formation of 
hydrogels within few minutes to be explored in the field of cartilage tissue engineering 
(Jin et al., 2008; Jin et al., 2010; Jin et al., 2011). Yu et al., (2014) have successfully 
synthesized injectable hyaluronic acid/ PEG hydrogel by integrating enzymatic cross-
linking (tyramine hydrochloride) and Diels-Alder "click chemistry" for cartilage tissue 
engineering. The studies by da Silva and co-workers (2014) concerns about the gel 
properties and cellular responses of chitosan and tilapia fish gelatin hydrogels cross-
linked by the microbial enzyme transglutaminase.  
The presence of functional groups such as −OH, −COOH, −NH2 are susceptible to 
form covalent linkages between polymer chains by reaction with complementary 
groups. Polymers containing hydroxyl groups such as PVA can be cross-linked using 
the cross-linking agent glutaraldehyde (GA) (Kudo et al., 2010; Belder et al., 2001). 
Amine containing polymers have also been cross-linked with GA under mild 
conditions whereby Schiff bases are formed. Condensation reactions between 
hydroxyl groups or amines with carboxylic acids or derivatives have been frequently 
employed in polymer synthesis. Such reactions have also been utilized in the 
preparation of hydrogels.  
Michael addition reactions have become promising routes for in situ cross-linking of 
hydrogels. The fact that Michael addition can happen by simply mixing the 
components under mild conditions without any by-products makes it a better choice to 
form in situ cross-linked hydrogels (Pritchard et al., 2011; Fu and Kao, 2011). A novel 
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Michael addition type in situ forming chitosan-ɛ-polylysine hydrogel was developed 
by Nie et al., (2013). The obtained hydrogel had four times higher adhesive properties 
than commercial glue and found to be non-toxic to L−929 cells and exhibited prompt 
haemostatic property.  
1.3.2 Physically Cross-linked Hydrogels 
Various approaches have been adopted to design physically cross-linked hydrogels. 
Such approaches include ionic interactions between polymers, using multiblock 
copolymers or graft copolymers and stereocomplex formation between polymers. 
Alginate is an exemplary polymer which can be cross-linked by ionic interactions. 
Alginate-chitosan-alginate multilayer hydrogel encapsulation systems were developed 
by Wasiak and Ciach (2014) for encapsulation of chondrocytes. The cross-linking of 
hydrogels occurred due to the ionic interactions between cationic chitosan and anionic 
alginate and calcium ions as additive.  
Physically cross-linked hydrogels can also be obtained from multiblock copolymers or 
graft copolymers. Amphiphilic block and graft copolymers self-assemble in water to 
form organized structures such as polymeric micelles and hydrogels, in which the 
hydrophobic segments are aggregated. Albumin-conjugated pH- and thermo-
responsive poly(amino urethane) multiblock copolymers were synthesized by 
Manokruang and Lee (2013). Novel thermo-responsive cross-linked hydrogels with 
controlled multiblock copolymer structure have been prepared from α,ω-diamino PPG 
and diepoxy-terminated PEGs (Anghelache et al., 2014).  
Hydrogels based on stereocomplex formation are well studied. The ability of 
poly(lactic acid) (PLA) to form stereocomplexes was first described by Ikada et al., 
(1987). Biocompatible and biodegradable hydrogels composed of 2-
methacryroyloxyethyl phosphorylcholine and oligo(L- or D-lactic acid) macro-
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monomers have been developed into injectable hydrogel matrix (Takami et al., 2011). 
Aqueous solutions containing the polymers along with oligo(L- or D-lactic acid) 
underwent spontaneous gelation upon mixing. This was attributed to the formation of 
stereocomplex between the lactic acid side-chains which act as cross-linking 
component in the hydrogel. Similarly, in another study, hydrogels were obtained by 
mixing aqueous solutions of dextran grafted with L-lactic acid oligomers and dextran 
grafted with D-lactic acid oligomers (Bos et al., 2005). These hydrogels degraded in 
vivo within 15 days and showed good biocompatibility which make them suitable 
candidates in pharmaceuticals.  
PVA being a hydrophilic polymer; PVA hydrogel possesses very low mechanical 
strength. Interestingly when PVA gel is subjected to freeze-thaw process, a highly 
elastic gel is obtained (Yokoyama et al., 1986). PVA hydrogels prepared in this way 
were found to be stable for six months at 37°C. The crystallization that occurs during 
the freeze-thawing process has been cited in the literature as the primary mechanism 
responsible for imparting tougher mechanical properties to the resultant hydrogel. The 
roles of crystallization and phase separation in the formation of physically cross-
linked PVA hydrogels have been discussed eloquently by Holloway and co-authors 
(2013).   
The review article by Zhang et al., (2013) addresses the recent developments in 
polysaccharide-based cryogels, which are a type of physical hydrogels prepared by 
freeze-thaw technique under mild conditions and in the absence of added cross-linking 
agents and organic solvents.  
1.3.3 Cross-linking by Protein Interactions 
The major advantage of protein engineering is that the sequence of the peptides and 
thus, the physical and chemical properties can be tuned into desirable properties. 
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Cappello and co-workers (1998) prepared for the first time copolymer containing silk-
like and elastin-like blocks in which the silk-like segments are associated through 
hydrogen bonded beta strands or sheets. Dinerman et al., (2010) synthesized networks 
of genetically engineered silk-elastin-like protein polymer and have investigated the 
influence of solute hydrophobicity and charge on partition and diffusion of the 
hydrogels. The results indicated the possibility of controlling solute release from the 
hydrogel by modifying its hydrophobicity. Recombinant protein domains have also 
been used to cross-link hydrogels (Chen et al., 2000).  
1.4 Applications of Hydrogels 
The pioneering report on hydrogels dates back to more than fifty years where PHEMA 
was investigated for contact lens applications (Wichterle and Lim, 1960). Since then, 
the research in the areas pertaining to hydrogels has expanded dramatically, especially 
in the last decade. The utility of hydrogels can be classified broadly into two 
categories: (i) non-medical and (ii) biomedical and pharmaceutical applications. 
(Hoffman, 2001; Peppas et al., 2000; Scherman, 2013; Aguilar and Roman, 2014).  
1.4.1 Non-medical Applications of Hydrogels 
Hydrogel technologies have been applied to various non-medical applications e.g. 
agriculture, coal dewatering, food packaging, membranes etc. 
Hydrogels in Agriculture 
Hydrogels have potential as eco-friendly water-saving materials and serve as soil 
conditioner for agricultural applications in sandy soil in view of their increasing water 
and/ or nutrition retaining capacity. Acrylamide is the major component for hydrogel 
designed for agricultural utilities (Singh et al., 2010). Raafat and co-workers (2012) 
have proposed a series of superabsorbent hydrogels based on PVP and carboxymethyl 
cellulose (CMC) for application in agriculture. The prospective of cellulose hydrogels 
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in agricultural fields has been compiled in the review article by Chang and Zhang 
(2011).  
Hydrogels for Coal-dewatering 
Although water is a necessary medium in most coal preparation processes, its presence 
in the final product however reduces its value. Thermal drying is the only process that 
was used to dewater coal. The associated high operational costs and safety hazards 
have invited widespread reluctance for this method. Studies have now pointed to the 
use of superabsorbent polymers for the same. Dzinomwa et al., (1997) dewatered fine 
coal upto 29.4% from a plant in Queensland, Australia using pH-sensitive hydrogels. 
Hydrogels in Food Packaging 
Bio-based polymeric hydrogels for food packaging applications have invited attention 
as an alternative approach to plastic packaging materials. Hydrogels constructed using 
PVP and CMC demonstrated promising features as food packaging material (Roy et 
al., 2012). PNIPAAm hydrogels developed by Fucinos et al., (2012) were found 
potential in packaging because the hydrogels provided protection to the antifungal 
drug pimaricin such that its controlled release regulated the presence of unnecessary 
fungal in food. 
Hydrogels as Membranes 
Poly(acrylamide) (PAAm) hydrogels are one of the most powerful tools in the 
analysis of biomolecules and bio-macromolecules (Chrambach and Rodbard, 1971). 
They have the unique property to separate molecules based on their size and 
electrophoretic mobility. Even PAAm membranes have been used to separate, isolate 
and concentrate biomolecules including the separation of monoclonal antibodies, 
proteins from plasma, certain recombinant proteins and viruses. Valade and co-
workers (2013) have recently prepared PAAm hydrogel networks cross-linked with 
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poly(N,N-dimethylacrylamide)-coated Au nanoparticles. The study was found to have 
greater implications in the development of hydrogel membranes for nanoparticle and 
protein separation. Polyvinylidene fluoride (PVDF) hydrogel membranes have been 
potentially utilized for the removal of carbon dioxide in air (Xu et al., 2002). 
1.4.2 Biomedical and Pharmaceutical Applications of Hydrogels 
Hydrogel technologies have also been utilized in pharmaceutical applications e.g. 
stem cell therapy, scaffolds, sealing applications, gene delivery, implants etc. 
Hydrogels in Stem Cell Therapy 
One of the most recent clinical applications of hydrogels that has dramatically evolved 
into a huge territory is the area of stem cell encapsulation and their release for stem 
cell therapy. The major disadvantage associated with the conventional methods is the 
use of liquid nitrogen for effective transfer of stem cells which necessitates a small 
time of delivery, thus offering great challenges (Choumerianou et al., 2008). Chen et 
al., (2013) have demonstrated the use of alginate based hydrogels for encapsulation, 
storage and release of stem cells. Human mesenchymal stem cells and mouse 
embryonic stem cells were successfully stored in these hydrogels in air tight bottles.  
In another study, degradable and injectable alginate based hydrogel microbeads have 
been established to deliver stem cells for bone regeneration (Leslie et al., 2013). A 
double stimulus-sensing hydrogel biopolymer has been reported by Tan et al., (2013) 
for inducing stem cell aggregation and sparking their subsequent release.    
Hydrogels as Scaffolds in Regenerative Medicine 
Hydrogels have been developed to serve as scaffolds in regenerative medicine to 
regenerate numerous tissues such as nerve (Park et al., 2010), bone (Patterson et al., 
2010), cartilage (Park et al.,  2009) and vasculature (Chui et al., 2011). The review 
article by Mather and Tomlins (2010) briefly summarizes the nature of hydrogel-
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structure relationships in regenerative medicine by highlighting the key attributes that 
modulate their functions. Hydrogels can also be readily tailored for the inclusion of 
biochemical cues known to guide cellular processes such as cellular adhesion peptides 
(e.g., RGD, YIGSR, VAPG) to mimic the extracellular space or growth factors (e.g., 
nerve growth factor (NGF)) to trigger proliferation, migration and cell survival (Zhu, 
2010; Anderson et al., 2009). The functionality of hydrogels in regenerative medicine 
has been enhanced with localized gene delivery to promote tissue morphogenesis.  
Hydrogels for Sealing Applications 
Hydrogels are particularly attractive for sealant applications because the mechanical 
properties of swollen hydrogels are comparable to native soft tissues (Shazly et al., 
2010). Incisional cerebrospinal fluid (CSF) leakage remains a significant complication 
after cranial surgery. Standard closure techniques such as sutures, grafts or collagen 
sponges sometimes fail to achieve watertight closure because the suture pinholes and 
the gaps between the sutures create defects that allow CSF seepage. Dura Seal Dural 
Sealant System is a PEG hydrogel based sealant approved by US Food and Drug 
Administration (FDA) (Osbun et al., 2012; Bhatia, 2010). Preul et al., (2010) have 
successfully utilized PEG-based hydrogel as dural sealant that prevented intra-
operative CSF leaks by 100% and reduced the incidence of postoperative CSF leaks 
by 90%.   
Hydrogels in Gene Delivery 
The high water content of hydrogels supports their use for gene delivery by preserving 
the activity of lentiviral vectors and acting to shield vectors from any host immune 
response.  Natural and synthetic hydrogels have been employed to provide a sustained 
release of viral and non-viral vectors (Quick and Anseth, 2004). Kimura et al., (2007) 
have formed PVA−DNA hydrogels by using ultra-high pressure (UHP) technology 
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and studied the controlled release of DNA for gene delivery. It was found that DNA 
release was much less from the hydrogels prepared by the UHP technology than from 
the hydrogels prepared by freeze-thaw process. The cutaneous delivery of nucleic 
acids has a number of therapeutic applications and most notably the genetic 
vaccination. Unfortunately the non-viral gene expression in skin is generally 
inefficient and transient. Pearton et al., (2008) have employed hydrogel formulations 
for improved delivery of plasmid DNA in skin using hydrogels composed of Carbopol 
polymers and thermo-sensitive PLGA-PEG-PLGA triblock copolymers. In the review 
article by Seidlits and co-authors (2013), the ability of hydrogels to control the 
transgene expression profile and also the capacity of hydrogels to protect vectors from 
any host immune response has been presented comprehensively. 
Hydrogels as Implants 
The numerous health hazards exposed by the potential use of silicone gel in breast 
implants have raised the need for a filler material with minimum risk and cost-
effectiveness. CMC hydrogels have higher radio-translucency than silicone gel and the 
integrity of such hydrogels as breast implants has been clinically proven (Brunner and 
Groner, 2006). Polyimplant prosthesis hydrogel breast implants were successfully 
tested clinically for their efficacy by Choi et al., (2010). Hydrogels has also been used 
as optical implants (Kopecek, 2009), nerve implants (Lesny et al., 2002) and for skin 
regeneration (Miguel et al., 2013).  
The ever growing spectrum of functional monomers and polymers further widen the 
scope of applicability of hydrogels. Apart from the uses discussed above, hydrogels 
also find significant applications as drug delivery systems.  
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1.5 Hydrogels as Drug Delivery Systems 
Hydrogels, as drug delivery systems, have inevitably flourished in recent years. 
Indeed, the benefits of hydrogels for drug delivery are plenty. Hydrogels are highly 
biocompatible as reflected in their successful use in the peritoneum and other sites in 
vivo (Lee and Mooney, 2001). The biocompatible nature has been attributed to the 
high water content and the physico-chemical similarity to the native extracellular 
matrix both compositionally and mechanically. Biodegradability may be designed into 
the hydrogels by enzymatic, hydrolytic or environmental (pH, temperature or electric 
field) pathways. Hydrogels are easily deformable and can conform to the shape of the 
surface where they are applied (Singh et al., 2010). In comparison to other synthetic 
biomaterials, hydrogels show minimal tendency to absorb proteins from body fluids 
because of low interfacial tension. Moreover, the muco- or bio-adhesive properties of 
some hydrogels can be advantageous in immobilizing them at the site of application or 
in applying them in uneven surfaces. Further the ability of different molecules to 
diffuse into (drug loading) and diffuse out of (drug release) the hydrogel allows the 
possible use of the dry or swollen hydrogel matrix for oral, nasal, buccal, rectal, 
vaginal, ocular and parenteral drug delivery systems. 
Various polymers, natural as well as synthetic, have been explored to design novel 
hydrogels to be utilized as drug delivery systems. A polymeric material must possess 
the foremost characteristic properties of biocompatibility, biodegradability and non-
toxicity to be rendered as drug delivery devices. Recent advancements in polymer 
science have led to the development of biocompatible hydrogels employing various 
natural and/or synthetic polymers to be employed as delivery vehicles (El-Leithy et 
al., 2010; Liang et al., 2012; Cavalli et al., 2012; Xiong et al., 2013). A summary of 
the natural and synthetic polymers utilized for drug delivery purposes can be obtained 
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in the excellent review articles by Liechty et al., (2010) and Kim et al., (2014). Below 
given is a brief account of different hydrogels utilized for site specific delivery of 
drugs to different parts of body.     
1.5.1 Hydrogels in Ocular Drug Delivery  
Anatomy and physiology of the eye makes it a highly protected organ. Designing an 
effective therapy for ocular diseases has been a formidable task. Recently, the 
fabrication of drug delivery systems targeting to the anterior and posterior segments of 
the eyes have become more challenging. In clinical practice, the anterior segments of 
the eye (cornea, sclera, conjunctiva, anterior uvea) can be treated with ocular eye drop 
which is the most commonly used dosage form in ocular drug treatment. 
Unfortunately, the eye drops are rapidly drained from the ocular surface, therefore 
bioavailability is very low, typically less than 5%. Topical ocular medications do not 
reach the posterior segment drug targets. The posterior segment (retina, vitreous and 
choroid) are treated by high drug doses given intravenously or by intravitreal 
administration. However, many posterior segment diseases such as age related 
macular degeneration, retinitis pigmentosa, diabetic retinopathies cannot be treated 
with current methods (Urtti, 2006). The scope of implantable hydrogels for ocular 
drug delivery has thus gained momentum in recent years. Polymeric hydrogel 
implants are on high demand for topical applications to eyes for improved drug 
retention time on ocular surfaces. Silicone hydrogels have proven to be a breakthrough 
for traditional contact lenses. These hydrogels allow oxygen penetration three times 
more than conventional lenses (Raul et al., 2012). Gordon et al., (2010) found 
doxycycline hydrogels as a potential therapy for ocular vesicant injury. Hydrogels 
based ophthalmic drug delivery systems offer an increase in the precorneal drug 
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residence time to a sufficient extent such that the drug can exhibit maximum 
biological action (Kushwaha et al., 2012; Wassmer et al., 2013). 
1.5.2 Hydrogels in Transdermal Drug Delivery  
Hydrogels have received enormous attention for their biomedical applications for skin 
(Varghese and Jamora, 2012). Skin is the first line of defence for protecting the entire 
body against pathogens and major loss of water. Helary et al., (2013) found that the 
fibroblasts within collagen hydrogels favour chronic skin wound healing and are 
found to be advantageous over the currently used gel formulations for chronic skin 
wound treatment. The efficacy of hydrogels as dermatological patches is well 
demonstrated (Onuki et al., 2005; Chen et al., 2013). Matsuo et al., (2013) developed 
a glycerine based hydrogel patch, which could promote antigen penetration through 
stratum corneum. They have also examined its safety and efficacy in animals and 
humans and found positive results. Photo cross-linked PAA hydrogels containing 
indomethacin have been developed as anti-inflammatory dermatological patches 
(Nishikawa, 2008). The results evidenced a highly functional anti-inflammatory patch 
in terms of its adhesive properties and drug bioavailability. The development of 
hydrogel nanocomposites has been a breakthrough in biomedical applications for skin. 
Incorporation of nanocomposite fillers in the network resulted in superior hydrogel 
properties (Bait et al., 2011). Recently, Bait and co-workers (2013) have investigated 
the properties of PAAm based hydrogels to be utilized in applications for skin contact. 
The authors have prepared poly(acrylamide-co-hydroxyethyl methacrylate) hydrogels 
and nanocomposite copolymer poly(acrylamide-co-hydroxyethyl methacrylate) 
hydrogels filled with poly(Bu-acrylate) nanoparticles, which are found to be suitable 
for transdermal drug delivery. Si et al., (2013) have synthesized methacrylated gelatin 
hydrogel films with in situ generated TiO2 nanoparticles. The anti-bacterial activities 
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of these films suggested good performance after introduction of TiO2 nanoparticles. 
The cytotoxicity assay on L−929 cells indicated their biocompatible nature. A 
chitosan-PVP matrix loaded with TiO2 has been studied as wound dressing material 
(Archana et al., 2013). Compared to conventional gauze treatment; the prepared 
hydrogel dressing caused an accelerated healing of open excision type wounds in 
albino rat models. In addition, they showed excellent antimicrobial efficacy and good 
biocompatibility against NIH3T3 and L−929 fibroblast cells.   
1.5.3 Hydrogels in Nasal Drug Delivery 
The prolonged residence of drug formulation in nasal cavity is of paramount 
importance for intranasal drug delivery. In situ thermo-reversible muco-adhesive gels 
using blends of Poloxamer 407, Poloxamer 188 and Carbopol 934P have been 
developed by Parmar and Lumbhani (2012) for improving the nasal bioavailability of 
the antiemetic drug, metoclapramide hydrochloride. In vitro release of the drug from 
the muco-adhesive system in simulated nasal fluid was improved significantly by 
varying the concentrations of the polymers. The hydrogels also exhibited enhanced 
drug bioavailability. Chen et al. (2013) have established an intranasal thermo-sensitive 
hydrogel comprising of Pluronic F127 and Poloxamer 188. The developed nasal 
hydrogels showed shorter gelation time, longer mucociliary transport time and 
produced prolonged curcumin retention in the rat nasal cavity at body temperature. 
One of the major disadvantages of mucosal vaccinations is the fast mucosal self-
clearance and tight arrangement of nasal epithelial cells, which eventually lead to 
shorter residence time of antigen in nasal cavity and hence the low antigen penetration 
through nasal mucosal surface. Typically cationic chitosan salts not only can bind 
strongly to negatively charged mucosal surfaces but can also loosen the tight 
conjugation between epithelial cells (Islam et al., 2012). Wu et al., (2012) have 
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developed novel thermo-sensitive hydrogels formulated with N-[(2-hydroxy-3-
trimethylammonium) propyl] chitosan chloride (HTCC) and α, β-glycerophosphates 
and evaluated them for intranasal vaccine delivery with adenovirus based Zaire Ebola 
virus glycoprotein antigen. The hydrogels displayed low toxicity to nasal tissues and 
epithelial cells even after frequent intranasal dosing. The HTCC and α, β-
glycerophosphates hydrogels have also been explored as adjuvant-free vaccine 
delivery system for H5N1 intranasal immunization (Wu et al., 2012).  In another 
study, an in situ thermo-gelling, muco-adhesive formulation based on N-trimethyl 
chitosan chloride has been evaluated for its potential for the trans-mucosal delivery of 
insulin via the nasal route (Nazar et al., 2013). The in vivo potential of these 
formulations for the intranasal delivery of insulin has been demonstrated in a diabetic 
rat model and found to act as once-a-day dosage form. A broad picture on the different 
nasal dosage forms based on chitosan hydrogels can be obtained from the review 
article by Luppi et al., (2010). In this review, the intranasal delivery of drugs has been 
discussed at length for local and systemic treatments; chitosan based hydrogels are 
described with a focus on their muco-adhesive and permeation-enhancing ability and a 
detailed discussion regarding the different nasal dosage forms are reported considering 
the in vitro, in vivo and ex vivo studies.  
1.5.4 Hydrogels in Pulmonary Drug Delivery 
Delivery of therapeutic agents through pulmonary route is expected to provide 
significant improvements in patient compliances and reduce systemic toxicity for a 
range of diseases. However, many inhalable drug formulations suffer from low 
respirable fractions, rapid clearance by alveolar macrophages, target non-specificity 
and difficulties in combining aerodynamic properties with efficient cellular water 
uptake (Courrier et al., 2002). Hydrogel chemistry has offered the scope of 
 General Introduction 
 
31 
 
synthesizing nanoparticles incorporated with pharmaceutical moieties embedded 
within the hydrogel matrix. An enzyme-responsive, nanoparticles-in-microgel delivery 
system was devised by Wanakule et al., (2012) for intracellular drug delivery to deep 
lung. The microgels exhibited triggered release of various nanoparticles and biologics 
in the presence of physiological levels of enzyme. They also showed little uptake by 
microphages indicating potential for increased lung residence time. El-Sherbiny et al., 
(2010) have formulated swellable microparticles based on PEG graft copolymerized 
onto chitosan in combination with Pluronic F-108 and found that the microparticles 
delayed phagocytosis and have the potential for sustained drug delivery to deep lung. 
A copolymer of PLGA-PEG-PLGA developed by Gao et al., (2011) provided a 
promising profile for local delivery of Docetaxel, a chemotherapeutic agent used for 
non-small cell lung cancer, to attain prolonged release with greater efficacy.         
1.5.5 Hydrogels in Drug Delivery to Brain 
Drug delivery to the brain is particularly challenging because systemic delivery 
requires high doses to achieve diffusion across the blood-brain barrier which often 
results in systemic toxicity. Intracerebroventricular implantation of a minipump/ 
catheter system provides local delivery but results in brain tissue damage and can be 
prone to infection. Wang et al., (2012) have employed epi-cortical delivery using 
hyaluronan/ methyl cellulose hydrogels for the local release of erythropoietin to 
induce endogenous neural stem and progenitor cells of the subventricular zone to 
promote repair after stroke injury in the mouse brain. Caicco et al., (2013) have 
studied the sustained epi-cortical delivery of cyclosporin A from PLGA encapsulated 
microspheres to the brain for stroke treatment. Hyaluronic acid hydrogels have been 
developed by covalently attaching antibodies via hydrazone linkage to deliver the 
antibodies to the injured brain (Tian et al., 2005). Hydrophobic drugs such as 
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paclitaxel are in demand due to their effective loading in polymeric hydrogels. In a 
recent study by Torres et al., (2011) the delivery of paclitaxel from hydrogels 
indicated that the effective therapeutic concentration of the drug could be maintained 
for more than 30 days. Paclitaxel-loaded PLGA hydrogel microspheres have been 
fabricated for the treatment of malignant brain tumour (Ranganath et al., 2009). 
Diblock co-polypeptide hydrogels have been employed for the sustained local release 
of protein effector molecules to the central nervous system (CNS). The results show 
that the hydrogels can provide sustained delivery when injected into CNS (Song et al., 
2012). Stearic acid-g-chitosan hydrogels were also studied for the brain-targeted 
delivery of doxorubicin (DOX) (Xie et al., 2012). 
1.5.6 Hydrogels in Drug Delivery to Colon 
Targeting of drugs to colon has received much interest recently for the local treatment 
of a variety of colonic diseases as well as systemic absorption of proteins and 
peptides. While the stomach is hostile to many drugs for its highly acidic pH; the 
colon, on the other hand, offers numerous therapeutic advantages as a site of drug 
delivery (Sharma and Harikumar, 2013). Natural polysaccharides such as pectin, 
chitosan, guar gum sustain the acidic environment of the stomach and remain intact in 
the small intestine but are degraded by the vast anaerobic microflora of the colon; thus 
are rendered as suitable drug carriers for colon specific delivery. Hydrogel discs of 
guar gum cross-linked by GA were prepared and studied for the colonic delivery of 
ibuprofen (Das et al., 2006). Significant increase in drug release was observed in the 
medium containing the rat cecal content. Sinha et al., (2004) studied the colonic 
delivery of 5-fluorouracil from guar gum and xanthan gum tablets for the treatment of 
colorectal cancer. The prospective of guar gum and its derivatives as colon specific 
and controlled drug delivery systems have been well documented by Prabaharan 
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(2011). Chitosan based hydrogels have also shown promising results for colonic drug 
delivery (Sareen et al., 2013).  The review article by Gulbake and Jain (2012) reflects 
the potential of chitosan hydrogels as colon specific drug delivery systems. This 
review focuses on various aspects of chitosan based formulations such as coatings, 
tablets, capsules, beads, gels, microparticles and nanoparticles, for the development of 
colonic drug delivery. Araujo et al., (2013) demonstrated the colonic delivery of 
prednisolone and insulin from calcium alginate chitosan-coated matrices. Sustained 
release of antitumor drug β-lapachone was observed from alginate-chitosan hydrogel 
beads prepared by coacervation with prolonged gastrointestinal release and good 
stability in acidic medium (Torelli-Souza, 2012). Vaghani et al., (2012) have 
synthesized pH-sensitive hydrogel composed of carboxymethyl chitosan using GA as 
the cross-linker and explored the colon targeted delivery efficacy for ornidazole. The 
in vitro drug release evaluation indicated maximum release in pH 6.8 and negligible 
release in pH 1.2, thus demonstrating both the pH-sensitivity and colon-specificity. 
Saboktakin et al., (2010) have developed chitosan nanogels which have shown 
promising results for the colonic delivery of 5-aminosalicylic acid. Pectin is an edible 
plant polysaccharide widely employed in colonic drug delivery systems. The review 
by Liu et al., (2007) describes the flexibility and possibility to tailor pectin 
macromolecules into a variety of architectures. Methoxyl citrus pectin hydrogel beads 
were compared for their encapsulation efficiency of indomethacin and drug release 
characteristics were evaluated in simulated gastric fluid (SGF) and simulated intestinal 
fluid (SIF) for the use in oral drug formulation targeting to colon (Jung et al., 2013). A 
colon targeted tablet formulation using pectin as a carrier and diltiazem hydrochloride 
and indomethacin as model drugs has been developed (Ravi et al., 2008). Gelatin, a 
protein based biodegradable polymer derived from collagen, is an attractive material 
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for preparing smart hydrogels because of its unique gelling properties and large 
number of functional side groups available for chemical cross-linking. Zheng et al., 
(2013) have prepared composite hydrogel films of gelatin-chitosan-pectin and studied 
the release of BSA in SGF and SCF media. The dissolution and in vitro drug release 
profiles established these formulations as controlled delivery vehicles for BSA. pH-
responsive gelatin based biodegradable hydrogels containing PAA were evaluated for 
oral colon specific delivery of ketoprofen (Raafat, 2010). Bajpai et al., (2003) have 
synthesized hard gelatin capsules containing riboflavin-loaded PVP-PAAm hydrogels 
and studied for the release of vitamin B2 and found the device to be suitable for colon 
targeted drug delivery.  
1.6 Limitations of Hydrogels as Drug Delivery Systems 
Despite numerous advantages, hydrogels are also associated with some inherent 
pharmacological limitations. Ease of application of hydrogels can be problematic 
sometimes. The poor mechanical strength of many hydrogels hinders their use in load-
bearing applications and sometimes results in their premature dissolution from the 
targeted site. In addition, greater problems arise relating to drug delivery properties of 
the hydrogels when a hydrophobic drug is taken into consideration. The quantity and 
homogeneity of drug loading is highly doubtful, particularly for hydrophobic drugs. 
The high water content and large pore size of the hydrogels often result in a relative 
rapid release of drug thereby reducing the therapeutic value of the drug (Hoare and 
Kohane, 2008).  
1.7 Concept of Controlled Drug Release Technology 
A device that delivers therapeutic agents to desired body locations and provides timely 
release of these agents is highly in demand in pharmaceutical fields. Some drugs have 
an optimum concentration range within which maximum benefit is derived and 
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concentrations below or above this range can prove to be less efficient therapeutically. 
The very slow progress in the efficacy of the treatment of severe diseases has 
suggested an urgent need for a multidisciplinary approach for the delivery of 
therapeutic agents to the tissues. In this regard, new ideas on controlling the 
pharmacokinetics and pharmacodynamics of drugs have emerged. These new 
strategies, referred to as controlled drug delivery (CDD), are often based on 
interdisciplinary approaches that combine pharmaceutics, polymer science, analytical 
chemistry, bioconjugate chemistry and molecular biology. Controlled drug delivery is 
the use of formulation components and devices to release a therapeutic agent at a 
predictable rate in vivo upon administration. Controlled drug delivery occurs when a 
polymer, whether natural or synthetic, is judiciously combined with a drug or other 
active agent in such a way that the active agent is released from the material in a 
predesigned manner. The release of the active agent may be constant over a prolonged 
period, it may be cyclic over a long period or it may be triggered by environmental 
factors. In any case, the sole purpose behind controlling the drug delivery is to achieve 
more effective therapies while eliminating the adverse effects of both under- and 
overdosing (Uhrich et al., 1999; Siegel and Rathbone, 2012).  
In the past few decades, pharmaceutical formulations that target specific areas and 
control the rate and period of drug delivery (i.e. timed-release medications) have 
gained much impulse. Conventional drug dosage forms which include pills, tablets, 
capsules, injections, ointments, creams etc. release the drug instantaneously in a bolus 
form; which calls for frequent dosing and increases patience non-compliances. With 
conventional formulations, the drug level in the blood follows the profile shown in 
Figure 1.10 A. 
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Figure 1.10. Typical pharmacokinetic profiles of (A) conventional and (B) controlled 
drug release formulations (Martin del Velle et al., 2009). 
 
As shown in Figure 1.10 A, the drug level rises rapidly after each administration of the 
drug and then decreases steeply until next administration. This might typically lead to 
higher concentrations of the drug in the blood plasma which represents the toxicity 
level. Sometimes the drug concentration lies below a particular minimum value where 
the drug remains mostly ineffective therapeutically. In controlled drug delivery 
systems (Figure 1.9 B), the drug level remains constant at an optimum level between 
the desired maximum and minimum, for a prolonged period of time therefore 
increasing the therapeutic value (Martin del Velle et al., 2009). Controlled release of 
drugs reduces the dosing frequency, enhances activity of short half-life drugs, 
eliminates side-effects and drug wastage, optimizes therapy and improves patient 
compliances. Some of the main advantages of controlled drug release technology are 
listed in Figure 1.11. 
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Figure 1.11. Major advantages of controlled drug release technology. 
Drug release mechanism from a hydrogel matrix can be broadly classified into three 
categories in accordance to the three main processes (Siegel and Rathbone, 2012): 
 Drug diffusion from hydrogel matrix (diffusion-controlled system) 
 Enhanced drug diffusion due to hydrogel swelling (swelling-controlled 
system) 
 Drug release due to polymer degradation and erosion (erosion-controlled 
system) 
The phenomenon of diffusion is inherent to all types of drug release systems. For a 
non-biodegradable polymer matrix, the drug diffusion is mainly due to the 
concentration gradient between the matrix and the releasing medium. For a swelling 
controlled release the drug diffusion happens as the water/ fluid enters the polymer 
network during the swelling process. For a polymer matrix prone to degradation, the 
drug release is controlled by the hydrolytic cleavage of polymer chains that leads to 
matrix erosion. The phenomena of the three classes of drug release mechanism from 
polymeric hydrogels are illustrated in Figure 1.12. 
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Figure 1.12. Mechanisms of drug release from polymeric hydrogels 
1.8 Improving the Drug Delivery Efficacy of Hydrogels 
The high water content of hydrogels often induces rapid release of drugs from the 
matrix. In response, a range of strategies have been explored to reduce the burst 
release of drugs from the hydrogel matrices. These strategies can be categorized on 
the basis of whether they enhance the drug-hydrogel interactions or increase the 
diffusive barrier to drug release from the hydrogels (Hoare and Kohane, 2008). 
1.8.1 Drug−Hydrogel Interactions 
Both physical and chemical methods have been utilized to enhance the interaction 
between the hydrogel and the drug to control the release rate. 
1.8.1.1 Physical Interactions 
Interactions between ionic polymers and charged drugs have often been employed as a 
strategy for controlling the rate of release of drug.  
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Figure 1.13. Ionic interactions between a polymer and loaded drug to control drug  
 release. 
 
The ability of the anionic polymer CMC sodium to influence the release of four 
cationic drugs (chlorpheniramine maleate, venlafaxine hydrochloride, propanolol 
hydrochloride and verapamil hydrochoride) from hydrophilic PEO matrices was 
investigated by Palmer et al., (2013). Slower drug release was observed from the 
hydrogels as compared to the matrices of single polymers. This was mainly attributed 
to the ionic interaction and hydrogen bonding between anionic polymer and cationic 
drugs leading to a reversible drug-polymer complexation. Marras-Marquez and 
colleagues (2014) discussed the effect of anionic/ non-ionic surfactants such as 
sodium lauryl sulphate, Tween-80 and Pluronic F-68 when introduced into agarose 
hydrogels for the release of the hydrophilic drug theophylline and hydrophobic drug 
tolbutamide. Controlled drug release was observed which was attributed to the 
charged interactions between the drug loaded micelles and agarose and also to the 
hydrogel microstructure. A dual ionic interaction system composed of a positively 
charged polyelectrolyte complex containing human growth hormone (hGH) and 
anionic thermo-sensitive poly(organophosphazene) hydrogel has been developed by 
Park et al., (2013) for sustained delivery of bioactive hGH. The hydrogels were found 
to suppress the initial burst release of hGH and extend the release period in vitro and 
in vivo. Thermo-sensitive poly(NIPAAm-co-NVP)-chitosan hydrogels were explored 
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for the sustained release behaviour of the anionic drug, naproxen (Li et al., 2012).The 
strong interaction between chitosan chains and the anionic drug led to improved 
swelling behaviour of the hydrogels and showed a continuous naproxen release 
without any burst effect. 
1.8.1.2 Covalent Bonding 
Drugs or prodrugs can also be covalently bound to the hydrogel matrix such that the 
release of drug is primarily controlled by the rate of the cleavage of drug-polymer or 
prodrug-polymer bond.   
 
Figure 1.14. Drug-polymer interaction by covalent linkages to control drug release. 
 
In a recent study by Ke et al., (2014) DOX has been covalently conjugated with 
amphiphilc diblock copolymers of PEG. The release studies indicated pH-triggered 
intracellular drug release and established these hydrogels as promising candidates for 
anticancer drug delivery. Bezuidenhout and co-workers (2013) have employed a 
variety of techniques to locally deliver dexamethasone from injectable PEG hydrogels. 
The drug was acrylated, pegylated and tethered to hydrolytically degradable (acrylate 
based) and non-degradable (vinyl sulfone based) PEG hydrogels. Sustained release 
was observed in the cases where dexamethasone was covalently bonded in comparison 
to the controls where the drug was simply dispersed. The recently published review 
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article by Duncan and Vincent (2013) on "polymer therapeutics" briefly describes 
polymeric drugs, polymer conjugates of proteins, drugs and aptamers, with block 
copolymer micelles and multicomponent non-viral vectors containing covalent 
linkages and the subsequent applications in drug delivery .  
1.8.2 Gel Engineering 
Several approaches have been explored to control the rate of release of drugs from 
hydrogel matrices by modifying the microstructure of the hydrogel, either through the 
full hydrogel network or locally at the hydrogel surface. Some of the approaches are 
discussed below. 
1.8.2.1 Interpenetrating Polymer Networks (IPNs) 
An interpenetrating polymer network (IPN) is formed when a secondary polymer 
network is polymerized within a pre-formed polymer network. IPNs can be classified 
as full-IPN or semi-IPNs depending upon the presence or absence of a cross-linker. 
Full-IPNs are formed in the presence of a cross-linker while in the absence of the 
cross-linker; a semi-IPN is generated. The semi-IPN comprises of linear polymers 
entrapped within the original hydrogel matrix. This is illustrated in Figure 1.16. 
 
Figure 1.15. Formation of semi− and full−interpenetrating polymer networks (IPNs). 
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The formation of IPNs leads to denser hydrogel matrices with tougher and stiffer 
mechanical properties, controllable physical properties and sustained drug release 
characteristics than conventional hydrogels. Drug loading is also carried out in 
conjugation with polymerization process (Mohamadnia et al., 2007). IPNs can also 
regulate the rate of drug release because of their ability to restrict the swelling 
capacity of both the polymer networks depending on the cross-linking density. For 
example, pH- and temperature-responsive IPN hydrogels based on soy protein and 
poly(NIPAAm-co-acrylate) were successfully prepared by Liu et al., (2014). BSA 
release from the hydrogels was sustained with good pH- and temperature sensitivity. 
In another study, Chen and colleagues (2014) observed a controlled and pH-sensitive 
delivery of riboflavin from carboxymethyl chitosan/ (PNIPAAm-co-methacrylic acid) 
IPN hydrogels. The drug release rate from the hydrogels was very low at pH 1.2 and 
increased at pH 7.4 suggesting them as site-specific drug carriers. The design and 
applications of various IPN hydrogels have been finely addressed in the recently 
published review article by Dragan (2014). The influence of the second network on 
IPN properties, deswelling and mechanical improvements in IPN has been discussed 
eloquently. 
1.8.2.2 Surface Grafting  
Surface modification of the hydrogel is another approach that can be performed at the 
hydrogel surface employing a stimuli-responsive polymer. This method prevents the 
modification of the bulk structure of the hydrogel.  The mechanism of surface grafting 
of hydrogels is shown in Figure 1.16. 
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Figure 1.16. Controlling drug diffusion from a hydrogel with a stimuli-responsive 
surface graft. 
By this method, polymers sensitive to environmental stimuli such as pH, temperature, 
light, ionic strength etc. can be grafted to the surface of the parent hydrogel network. 
For example, PNIPAAm or PAA can be grafted on the surface of a hydrogel to 
provide temperature or pH-dependent surface permeability, respectively. This, in turn, 
will affect the drug release kinetics. PNIPAAm oligomers were grafted onto PHEMA 
hydrogels and utilized as delivery devices for insulin and theophylline (Ankareddi and 
Brazel, 2007). Drug release was observed to be rapid at low temperatures but 
significantly slower at higher temperatures owing to the phase transition behaviour of 
PNIPAAm. Alternatively, a drug-loaded hydrogel can be coated with a polyelectrolyte 
multilayer (PEM) film that would limit the drug diffusion out of the hydrogel matrix. 
Matsusaki and co-workers (2007) prepared alginate hydrogels nano-coated with PEM 
films composed of chitosan and dextran sulphate. The release of vascular endothelial 
growth factor (VEGF) was monitored from these hydrogels. The nano-coated 
hydrogels were found to be more stable than the non-coated ones. The release of 
VEGF from the nano-coated hydrogels continued for one month, thus establishing 
them suitable for controlled and sustained drug delivery systems. Sakaguchi et al., 
(2006) have also synthesized alginate hydrogels nano-coated with PEM films 
composed of poly(diallyldimethyl ammonium chloride) and poly(sodium 4-
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sytrenesulfonate). The pH-sensitive swelling behaviour of the hydrogels indicated 
their potential in biomedical applications. 
1.8.3 Composite/ "Plum pudding" Hydrogels 
In order to overcome the inherent pharmacological limitations of hydrogels, growing 
interest has been focussed on the incorporation of particulate systems such as 
microparticles, liposomes, micelles etc. into the hydrogel matrix to form composite/ 
"plum pudding" hydrogels. This has been illustrated in Figure 1.17. 
 
Figure 1.17. "Plum pudding"/ Composite hydrogel containing drug encapsulated in a 
secondary delivery vehicle; D1 and D2 represent the diffusion 
coefficients of drug out of hydrogel (D1→ release from secondary 
delivery vehicle; D2→ drug diffusion out of hydrogel).  
 
The hydrogel template method for generation of homogenous nano/ microparticles has 
drawn much focus in recent years for optimal drug loading and release properties. 
Acharya et al., (2010) first reported the hydrogel template approach for pH-sensitive 
gelatin hydrogels. It was observed that gelatin hydrogels could be tailored to possess 
various properties for microparticle encapsulation. The drug loading was found to be 
higher than 50% with minimal initial burst and near zero-order kinetics. In a recent 
study by Lu and co-authors (2014) hydrogel template method was employed to 
produce homogeneous PLGA microparticles that were embedded in PVA matrix and 
investigated for drug delivery. Drug release was found to be sustained for weeks. 
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Insulin-like-growth factor-1, an important growth factor in cartilage regenartion, was 
encapsulated within PLGA microspheres embedded in PVA hydrogels (Spiller et al., 
2012). Sustained release was obtained from these hydrogels which pointed their 
potential in cartilage tissue engineering.  
Xu et al., (2006) have synthesized PNIPAAm-poly(methyl methacrylate) micelles and 
physically incorporated the micelles into the thermo-sensitive bulk PNIPAAm 
hydrogel to form composite hydrogels. The composite hydrogels exhibited faster 
shrinking kinetics than pure PNIPAAm hydrogels. In addition, the release of 
prednisolone acetate was monitored from the hydrogels which showed excellent 
thermo-sensitivity.  
Liposomes have also been entrapped in hydrogels. Liposomes embedded in PLGA-
PEG-PLGA hydrogels released 2-methoxyestradiol in a prolonged manner (Xing et 
al., 2014). Propylene glycol liposomes in Carbopol hydrogels containing 
metronidazole and clotrimazole were synthesized for the treatment for vaginal 
microbial infections (Vanic et al., 2014). In vitro studies of drug release indicated 
sustained behaviour of the drugs in simulated human conditions. Chitosan containing 
liposomes and cubosomes have also been developed as sustained release vaccine 
delivery systems (Gordon et al., 2014). The potential of liposomal hydrogels as wound 
dressing materials have been well documented in the review article by 
Thirumaleshwar and co-authors (2012). PNIPAAm hydrogels containing temperature-
sensitive liposomes have been prepared by Han et al., (2005) to obtain a hydrogel 
complex at room temperature. The release behaviour of calcein was explored from 
these hydrogels. A sustained release was observed which indicated the prospective of 
this system as drug delivery carriers. The review articles by Mufamadi et al. (2011) 
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and Alinaghi et al. (2013) summarize comprehensively the recent developments in the 
area of composite liposomal-hydrogel technologies.  
Cyclodextrins are of particular interest in the context of designing composite hydrogel 
systems, given their hydrophilic exterior which is useful for maintaining the bulk 
hydrophilicity and swelling state of the hydrogel, and their hydrophobic interior which 
can facilitate entrapment and controlled release of hydrophobic drugs.  
1.9 Cyclodextrins and Drug Delivery 
1.9.1 Introduction to Cyclodextrins 
Cyclodextrins (CDs) are a family of macrocyclic oligosaccharides linked by α−1,4 
glycosidic bonds derived from starch. These are extensively studied in diverse fields 
since their discovery by Villiers in 1891 (Villiers, 1891). α−, β− and −CDs are the 
most common naturally occurring CDs composed of six, seven and eight glucose 
rings, respectively (Connors, 1995; Szejtli, 1998). The truncated cone shape of CDs 
possess a hollow tapered cavity of 0.79 nm depth while the top and bottom diameters 
increase with corresponding increase in the  number of glucose units (Figure 1.18). 
The hydrophobic inner cavity of CDs gives them the capability to include a variety of 
compounds ranging from small molecules, proteins and oligonucleotides. The 
pharmaceutical and biomedical applications of CDs are extremely attractive due to 
their low toxicity and low immunogenicity. Apart from being used exhaustively in 
pharmaceuticals, CDs find extensive demand in the fields of cosmetics and toiletries, 
food industries, agricultural and chemical industries and also as adhesives and 
coatings (Martin del Velle, 2004). 
 General Introduction 
 
47 
 
 
Figure 1.18. Truncated cone or torus shape of various CDs; (A) α−CD, (B) β−CD and   
   (C) − CD. 
The internal cavity of CDs enables to complex "guest" drug molecules and in doing 
so, enhance the physico-chemical properties of the drug. The guest molecules can 
either be included totally or partially into the CD cavity. This process occurs 
spontaneously in the aqueous medium, since the displacement of water from the 
apolar cavity and the establishment of hydrophobic, electrostatic, van der Waals or 
hydrogen bonding interactions with the guest, and the release of conformational strain 
in the CD structure lead to thermodynamically favourable balance (Liu and Guo, 
2002). 
The complexation of drug with CD can be defined by an association constant (Kb) 
which is given by the following formula: 
    
         
          
 
Where, [Drug] and [CD] represent the free concentration of drug and CD and [Drug-
CD] is the concentration of drug-CD inclusion complex. No covalent bonding exists 
between CD and the guest and the complexation is a dynamic process. High values of 
Kb indicate the high stability of the drug-CD complexes in aqueous solution. 
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The phenomenon of inclusion of guest inside CD cavity brings remarkable physico-
chemical consequences (Figure 1.19).  
 
Figure 1.19. Changes in physico-chemical properties of drug caused by inclusion 
complex formation with CD in solution.  
Advantages of CD complexation in pharmaceutical formulations are due to: 
 Greater solubility and dissolution of hydrophobic moieties (Brewster and 
Loftsson, 2007). 
 Enhanced drug absorption/ bioavailability (Vyas et al., 2008). 
 Reduction in drug toxicity (Challa et al., 2005). 
 Increase in shelf-life of drugs or increased drug stability (Larsen, 2002). 
 Control of drug release (Tiwari et al., 2010). 
Detailed appraisal of physico-chemical properties of CDs and the usefulness of CD 
inclusion technology in pharmaceutical industries have been beautifully articulated in 
several review articles (Szejtli, 2004; Uekama, 2004; Astakhova and Demina, 2004; 
Loftsson et al., 2005; Stella and He, 2008; Salustio et al., 2011; Mura, 2014; Sharma 
and Baldi, 2014). 
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1.9.2 Applications of CDs in Drug Delivery Systems 
CDs, because of their unique features, are greatly employed as drug delivery agents. 
Pharmaceuticals formulated using CDs have been evaluated for oral, nasal, ocular, 
rectal and dermal drug delivery. 
1.9.2.1 Oral Drug Delivery 
Oral route has always been the preferred route of drug administration because of the 
ease of the method. Advantages of CDs in oral drug delivery include improvement of 
drug bioavailability due to increased drug solubility, enhanced drug dissolution, drug 
stability at absorption site and reduction in drug-induced irritation (Stella and 
Rajeswski, 1997). CDs enhance the mucosal drug permeability mainly by increasing 
the free drug concentration at the absorptive surface (Yoo et al., 1999). CD 
complexation provides better and uniform absorption of low-soluble drugs and also 
enhances their activity on oral administration (Veiga et al., 2000; Fathy and Sheha, 
2000). The review article by Perchyonok and Oberholzer (2012) focuses on the 
applicability of CDs as oral drug carrier molecular devices and also demonstrates the 
practical in vitro models. 
1.9.2.2 Nasal Drug Delivery 
Nasal drug delivery is an attractive approach for the systemic delivery of high potency 
drugs with low oral bioavailability due to extensive gastrointestinal breakdown and 
high hepatic first-pass effect. CDs have the ability to enhance drug delivery through 
biological barriers without affecting their barrier function, a property which makes 
them highly commendable for intranasal drug delivery purposes (Merkus et al., 1999). 
The solubility of the anti-allergic drug loratadine was enhanced by complexing with 
β−CD and targeted for nasal delivery of the drug (Singh et al., 2013). A nasal delivery 
system for lorazepam has been developed by Jug and Becirevic-Lacan, (2008).  
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1.9.2.3 Ocular Drug Delivery  
The ideal route of drug administration in ocular drug delivery is the eye drop 
formulation due to its simple method of application. But the major disadvantage 
associated with this form of dosage is its inability to sustain local drug concentrations. 
CDs have been used to increase the solubility and chemical stability of drugs and 
prevent side-effects such as ocular drug irritation. Applications of CDs have also led 
to enhanced drug permeability by making the drug available at the ocular surface. 
Hydrophilic CDs, especially 2HP−β−CD and SBE−β−CD are found to be non-toxic to 
the eye and are well tolerated in aqueous eye drop formulations (Challa et al., 2005). 
The review article by Kang-Mieler (2014) discusses the utility of cyclodextrins in 
ocular drug delivery with particular emphasis on the posterior segment. 
1.9.2.4 Rectal Drug Delivery 
Applications of CDs in rectal drug delivery include enhancing drug absorption from a 
suppository base either by enhancing the drug release from the base or by increasing 
drug mucosal permeability, providing sustained release and alleviating drug-induced 
discomfort and irritation (Matsuda and Arima, 1999). CDs enhance the rectal 
absorption of inabsorbable hydrophilic drugs such as antibiotics, peptides and proteins 
by their direct action on rectal epithelial cells. α−CD enhanced the rectal absorption of 
morphine and human chorionic gonadotropin by increasing their mucosal permeability 
and decreasing their degradation (Uekama et al., 1995; Kowari et al., 2002). 
1.9.2.5 Colon-specific Drug Delivery 
CDs are slightly absorbed in the stomach and small intestine but are absorbed in the 
large intestine after fermentation by the colonic microflora. This unique hydrolyzable 
nature of CD makes them apt in the design of colon targeted drug delivery systems. 
The CD based prodrug approach has been widely employed to delay the drug release 
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and ensure its degradation in colon. Active molecules can be covalently attached to 
the primary or secondary hydroxyl groups of β−CD producing prodrugs with the 
ability to remain intact in the upper GIT. Once these molecules reach the colon, they 
are subsequently cleaved to release the drug (Uekama, 2004). Moreover, the 
fermentation of β−CD leads to production of short chain fatty acids that contribute to 
the health and maintenance of the colonic epithelium (Giardina and Inan, 1998). In a 
recent study by Vieira et al., (2013) microwave assisted diclofenac and β−CD 
conjugates were prepared and assessed for colonic delivery. The conjugate was found 
to be stable in SGF and liberated the drug in SIF which confirmed the potential of this 
diclofenac prodrug for colonic delivery. Macromolecular prodrug of 4-aminosalicylic 
acid with β−CD was prepared by Vadnerkar and Dhaneshwar (2013) and the release 
was studied in rat cecal/ faecal buffers. The produgs suggested the targeted delivery of 
the drug to the colon.  
1.9.2.6 Drug Delivery to Brain (Brain Targeting) 
The blood-brain barrier (BBB) restricts the transfer and delivery of most drugs to the 
brain. A novel lactoferrin-modified β−CD nanocarrier was designed by Ye and co-
workers (2013) for brain targeting drug delivery. The results of tissue distribution 
indicated that the nanocarriers greatly improved BBB transport efficiency. The study 
also evaluated lactoferrin-β-CD nanocarriers as potential brain targeting drug delivery 
system for hydrophobic drugs and diagnostic reagents which normally fail to pass 
through BBB. The short half-life of pituitary adenylate cyclase activating polypeptide 
(PACAP), a potent neurotrophic and neuroprotectant, makes it difficult to be 
administered peripherally. Nonaka and co-workers (2012) demonstrated that 
therapeutic amounts of PACAP can be delivered to brain by intranasal administration 
by the use of CDs. It was also observed that CDs targeted the peptides to specific 
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regions of the brain. In another study, galanin-like peptide (GALP), which is potential 
in treatment of obesity and related conditions showed greater uptake with CDs 
(Nonaka et al., 2008). The studies also proclaimed that targeting of GALP to the brain 
regions is possible with the use of various CDs. 
1.9.3 CD-based Hydrogels for Drug Delivery 
The combination of CDs and hydrogels can overcome the limitations of poor loading 
of drugs into hydrogels and improve the controlled delivery features of the hydrogels 
(Otero-Espinar et al., 2010). It has been found that incorporation of CD into polymeric 
drug release systems could change the drug-polymer interactions and as a result, the 
mechanisms of drug release may be greatly modified (Bibby et al., 2000). Moreover, 
the hydrogel phase improves the kinetic release profile of the particulate system by 
providing an additional diffusion barrier to drug release, extending the release period 
of drugs (Chen et al., 2004; Barreiro-Iglesias et al., 2001). Therefore, composite 
systems integrating hydrogels and cyclodextrins complement the advantages, while 
avoiding the disadvantages, of the two discrete systems, as a consequence this is used 
as a strategy to design more effective formulations. 
CDs are pivotal in improving the loading of drugs and controlling the rate of release of 
drugs from the hydrogel matrix. In case of physically cross-linked hydrogels, the 
larger hydrodynamic radius of the drug-CD inclusion complex, than the free drug, 
effectively reduces the rate of drug diffusion and controls the delivery (Bibby et al., 
2000). When CDs are incorporated into hydrogels, they can act as binding points 
which can either be utilized as drug-CD interaction platform or for improving the 
mesh size of the hydrogels. These cross-linked networks effectively limit the entrance 
of physiological fluids and as a result the covalently attached CDs cannot move apart 
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from each other. In such an environment, the drug-CD affinity becomes the driving 
force to retain the drug and control the delivery.  
When the hydrogels come in contact with the physiological fluids, they swell but the 
volume of water taken up is limited by the polymer network and consequently, the 
polymeric chains do not dissolve. This creates a microenvironment rich in cavities 
available to interact with the guest drug molecules. In such cases, the affinity of the 
drug molecules for the CD cavities drives the drug delivery.  The covalent attachment 
of CDs to polymer networks might not decrease their inclusion ability but sometimes 
improve the same, particularly in the cases of large molecules which require one or 
more CD for complexation (Li et al., 2004; Crini et al., 1998; Layre et al., 2002). 
Decomplexation of a drug molecule from one CD cavity makes the drug available to 
form complexes with the neighbouring empty CD cavity and the likelihood of 
recomplexation is strongly dependent on the drug-CD affinity. 
 
Figure 1.20. Drug release from a chemically cross-linked CD network. 
Therefore, drug release from a hydrogel can be visualized as successive escapes of 
drug molecules from CD cavities until the drug reaches the surface (Figure 1.20). The 
higher the drug-CD affinity, the slower is the drug release.  Figure 1.21 describes the 
different states in which CDs can be found in a polymeric network. 
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Figure 1.21. Different modes in which CDs can be found in polymeric networks; (a) 
movable CDs, (b) polypseudorotaxanes in which the CDs are chemically 
threaded, (c) CDs forming part of polymer chains to act as tie-junctions 
of other polymeric chains with complexable moieties, (d) CDs forming 
part of the polymer backbone and (e) CDs hanging from the network 
structure (Concheiro and Alvarez-Lorenzo, 2013). 
Different synthetic strategies have been employed to prepare polymeric CD based 
systems. Hydrogels in which CDs form a part of the network structure can be obtained 
by direct cross-linking of the CDs or by copolymerization of the CDs with other 
monomers.  
1.9.3.1 Hydrogels Obtained by Cross-linking of CDs  
Although originally designed as a column material for separation chromatography, the 
first CD containing polymeric networks were developed in the 1980s (van de 
Manakker et al., 2009). CD polymers and hydrogels were first obtained by the 
condensation reactions of the hydroxyl groups of the CDs with various cross-linking 
agents such as aldehydes, ketones, epoxides and epichlorohydrin (EPI) (Crini and 
Morcellet, 2002). Under alkaline conditions, the two reactive functional groups of EPI 
react with the hydroxyl groups of CDs or with other EPI molecules which results in a 
mixture of cross-linked CDs joined by repeating glyceryl units of polymerized EPI 
(Kobayashi et al., 1989). EPI-CD hydrogels have been utilized as selective traps for 
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removal of components from food (Crini, 2008), bioremediation (Sevillano et al., 
2008), separation science (Scriba, 2008) and as drug delivery systems (Mok and Kim, 
2014). 
Studies pioneered by Szetjli et al., (1978) focused on mixed networks of CDs and 
hydrophilic polymers such as PVA using EPI and ethylene glycol bis(epoxypropyl) 
ether with a rational of achieving greater hydrophilicity and better mechanical 
properties for biomedical applications. The hydrogels were then modified with 
carboxymethyl and acetyl groups to render hydrophobicity. This approach ensured 
that CDs retained their inclusion capability and the hydrogels demonstrated high 
loading capacity for drugs. A great many research has been dedicated towards EPI-CD 
hydrogels for diverse applications (Crini and Crini, 2013). Although EPI-CD 
hydrogels have demonstrated potential for pharmaceutical and biomedical 
applications, the relatively high toxicity of EPI and its pollutant character limits its 
applicability and has invited further research on alternative cross-linking agents 
(Mocanu et al., 2001). The use of diisocyanates has received attention for preparing 
CD hydrogels or beads. This approach has been particularly aimed for PEG hydrogels 
which is a highly hydrophilic and biocompatible polymer. The PEG chains previously 
end-capped with isocyanate groups react with β−CD forming urethane links. The 
molecular weight of PEG and PEG/β−CD molar ratio was central in determining the 
structure of the hydrogel, its swelling properties and its capability to load naphthol by 
forming inclusion complexes with β−CD. PEG hydrogels were first obtained by 
activating the β−CD with hexamethylenediisocyanate (HMDI) in anhydrous DMSO. 
These hydrogels exhibited high hydrophilicity and biocompatibility and higher 
loading efficacy and sustained release of estradiol, quinine and lysozyme. Following a 
more sophisticated approach PEG-diamine networks had been created in which the tie 
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junctions were polyrotaxanes having isocyanate-activated β−CD groups (Ooya et al., 
2007). Comparative studies on the performance of CD hydrogels cross-linked with 
EPI, succinyl chloride and HMDI revealed the importance of the nature of the cross-
linker regarding the affinity of the guest molecules for the CD cavities. The results 
suggested that diisocyanates lead to formation of networks of smaller mesh size and a 
lower swelling degree in water while the use of EPI provides longer bridges in CDs.  
Condensation of CDs with poly(carboxylic acids) has been reported to be one of the 
clean methods to obtain cross-linked CD networks. Polyesterification of native CDs 
can be carried out with citric acid or PAA but not with dicarboxylic acids. These 
results stressed the use of poly(carboxylic acids) with at least three neighbouring 
carboxylic groups. A phosphate catalyser (e.g. NaH2PO4) is also required to form an 
intermediate cyclic anhydride of the poly(carboxylic acid) that will react with the CDs 
(Martel et al., 2005).  
One-step direct cross-linking of CDs using ethylene glycol diglycidyl ether (EGDE) 
has ensured hydrogel synthesis in aqueous conditions under mild conditions. EGDE is 
a relatively nontoxic reagent. Most of the glycidyl groups are consumed in the 
reaction, while washing with dilute HCl opens the remaining rings to give hydroxyl 
groups which give rise to highly biocompatible hydrogel (Huang et al., 1998). 
With the aim of modulating the mechanical properties and broadening the spectrum of 
applicability of CD hydrogels as drug delivery agents; linear cellulose ethers and 
dextran were incorporated during cross-linking. HP−β−CD−co−HPMC and 
Me−β−CD−co−HPMC hydrogels absorbed water 10 times their own weight and 
loaded upto 24 mg of estradiol per gram, which is 500 times greater than the amount 
of drug that can be dissolved in aqueous phase (Rodriguez-Tenreiro et al., 2007). This 
work highlighted the major role of CD in drug loading and the high drug-CD affinity 
 General Introduction 
 
57 
 
led to the achievement of sustained delivery of estradiol for one week. The role of 
cellulose ethers in improving the physical properties of the hydrogels was pertinent. 
β−CD / HP−β−CD−co−HPMC cross-linked with 1, 4-butanediol diglycidyl ether have 
been developed to prevent wound infection (Pinho et al., 2014). The hydrogels were 
able to incorporate high amounts of gallic acid and sustain the release for more than 
48 h.    
1.9.3.2 Hydrogels Obtained by Covalent Linking of Polymers and CDs  
Covalently cross-linked polymeric CD systems have also been developed by coupling 
either modified or un-modified CDs to a wide variety of pre-existing polymers. Cross-
linked networks of PAA and β-CD were obtained and the network formation was 
ascribed to the esterification of the hydroxyl group of the CDs with the carboxylic 
acid groups of PAA. Bibby and co-workers (1999) have performed this reaction in 
water-in-oil emulsion to get CD containing microspheres. The microspheres were then 
loaded with two dyes, phenolphthalein and rhodamine B, as model drugs and their 
release was monitored. More recently, hydrogel formation has been accomplished by a 
highly selective copper (I) catalyzed 1, 3-dipolar cycloaddition ("click chemistry") 
between alkyne-modified CD and an azide-functionalized poly(NIPAAm-co-HEMA) 
copolymer. This reaction provided several advantages including relatively mild 
conditions and reduced gelation rate (van Dijk et al., 2009). 
The most commonly employed strategy to generate CD-polymer networks is through 
copolymerization of vinyl- or acryloyl-modified CD monomers with other vinyl 
monomers such as AAc, NIPAAm or HEMA. Following this approach, several 
research groups have created hydrogels for pharmaceutical applications.  
Wang et al., (2009) reported the preparation of dual-stimuli responsive gels using the 
complexation of α-CD onto PEG grafts present in random copolymers of PEG-
 General Introduction 
 
58 
 
methacrylate and 2-(dimethyl-amino) ethyl methacrylate. The α-CD slides onto the 
PEG side-chains of the polymer allowing for gel formation at high pH, while the 
pendant dimethylamino-functionality allows for pH-sensitivity leading to disruption of 
hydrogel structures at low pH. Based on a combination of PNIPAAm and -CD, novel 
hydrogels, having both thermal and pH sensitivities were synthesized. Semi-IPN 
hydrogels composed of PNIPAAm and -CD-g-polyethylenimine were prepared by 
radical polymerization. Propranolol as a model drug was loaded into the gels, and the 
release results showed that compared to that of the normal PNIPAAm hydrogel, the 
release time of propranolol from the CD-containing gel was prolonged (Wang et al., 
2007). CDs were grafted to the PVP/PEG-DMA polymer matrix that changed both the 
release rate and the release profile of ibuprofen (dos Santos et al., 2008). 
Copolymerization of HEMA with a methacrylated-derivative of -CD was evaluated 
to obtain hydrogels with tunable mechanical, drug loading and release properties, 
particularly to be used as medicated soft contact lenses. The hydrogels sustained the 
drug delivery for several days, the acetazolamide release rate being dependent on the 
-CD content (Rodriguez-Tenreiro et al., 2003). Mono-acrylated CD monomer was 
copolymerized with hydroxyethyl acrylate to produce a hydrogel network with CDs as 
pendent groups. The hydrogel showed a sustained release of N-acetyl-5-
methoxytryptamine owing to the formation of drug/ β-CD inclusion complexes 
(Victor and Sharma, 2007). PHEMA/β-CD hydrogels have been investigated for 
sustained release of ophthalmic drugs. The incorporation of β-CD in the hydrogels 
increased the equilibrium swelling ratio and tensile strength. Puerarin was used as a 
model to evaluate drug loading and in vitro and in vivo release behaviour. Puerarin 
loading and in vitro release rate were dependent on -CD content in the PHEMA/-
CD hydrogels (Liu and Fan, 2005). Liu and co-authors (2005) prepared -CD 
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containing hydrogels by copolymerization of maleic anhydride-modified -CD and 
NIPAAm. The resulting hydrogels were loaded with the anticancer agent chlorambucil 
and the drug release was investigated at pH 1.4 and 7.4 and compared to a gel without 
-CD. The results indicated that increasing -CD content led to faster release of drug. 
The faster release of drug from the -CD hydrogels compared to -CD free gels was 
attributed to the hydrophobic interactions between the drug and the dehydrated 
PNIPAAm chains which were prevented by drug-CD inclusion complexes. Anirudhan 
and Mohan (2014) have synthesized novel pH-switchable gelatin based hydrogel by 
grafting β-CD to the gelatin gel and cross-linking by oxidized dextran. This composite 
hydrogel was investigated for the colonic delivery of the anticancer drug 5-
fluorouracil.  
1.9.3.3 Self-assembled Polymer Systems Based on Host-Guest CD Inclusion 
Complexes 
The inclusion complex forming ability of CD has also been utilized as a non-covalent 
binding motif for the development of a wide variety of dynamic polymeric networks 
and assemblies in aqueous media. Such polymeric systems have been widely 
recognized in pharmaceutical, biomedical and drug delivery applications. From a 
topological point of view, it is possible to differentiate two families of non-covalently 
bonded CD polymeric hydrogels: (a) polypseudorotaxane hydrogels containing CDs 
threaded onto one or more polymer chains and (b) hydrogels in which the polymer 
chains are held together by host-guest inclusion between CDs and guest molecules 
(Appel et al., 2012).    
Recently CD based polyrotaxanes and polypseudorotaxanes have led to interesting 
developments in the field of supramolecular hydrogels intended for drug delivery 
purposes. The pioneering report on the synthesis of CD based polyrotaxanes dates 
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back to 1992 in which the first preparation of the supramolecular compound 
composed of multiple α−CD rings threaded on a PEO chain and trapped by end-
capping the chain with bulky end groups was described (Figure 1.22) (Harada et 
al.,1992). Since then, an overwhelming research has been devoted to the studies of 
supramolecular structures of polyrotaxanes and polypseudorotaxanes formed by CD 
threaded on polymers and their various applications as biomaterials (Li and Loh, 
2008). 
 
Figure 1.22. The synthesis of polyrotaxane from α−CD and PEO-diamine. 
Research in CD based supramolecular hydrogels has developed since the 1990s and 
taken a huge leap forward in the next two decades. Cross-linking in these cases occurs 
from H-bonding interactions between exteriors of bound CD units and the formation 
of crystalline domains. Supramolecular hydrogels can be developed either by 
interaction of CDs with the polymer chains or by grafting copolymers onto the grafted 
polymer backbone (Figure 1.23 a & b).  
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Growing attention has been focussed on inclusion complex formation between CDs 
and block copolymers comprising blocks of different cross-sectional areas and 
properties. It was observed that CDs selectively complex with different blocks 
forming supramolecular structures containing partially complexed and un-complexed 
polymer segments. PEO and oligoethylene of various molecular weights formed 
inclusion complexes with α−CD to form polypseudorotaxanes in high yields. 
However, PPO formed inclusion complexes with β−CD and −CD in high yields but 
not with α−CD (Harada et al., 1995). It was suggested that the PPO chains were too 
large to penetrate the cavity of α−CD. 
 
Figure 1.23. Schematic representation of polypseudorotaxane formation utilizing CD-
based interactions with either (a) polymer chains or (b) grafted polymer 
chains from grafted copolymers as the driving force for hydrogel 
preparation. 
Supramolecular structures formed between CDs and polymers have inspired 
interesting developments of novel supramolecular biomaterials. Of late, many new 
supramolecular CD hydrogel technologies have evolved as drug delivery systems. 
Supramolecular hydrogels consisting of triblock PLGA-PEG-PLGA copolymers and 
α-CD have been fabricated and investigated as drug delivery agents for naltrexone 
hydrochloride and vitamin B12 (Khodaverdi et al., 2014). In a novel attempt by 
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Tabassi and co-workers (2014), supramolecular hydrogels based on the triblock 
copolymers of PCL-PEG-PCL and α-CD were developed and evaluated for their drug 
delivery efficacies of naltrexone hydrochloride and vitamin B12. Apart from 
controlled drug delivery purposes, the thixotropic nature of these hydrogels makes 
them injectable. The review article by Li (2010) summarizes the potential of CD-
based self-assembled supramolecular hydrogels for drug and gene delivery 
applications. Supramolecular hydrogels based on self-assembly between PEO-PPO-
PEO triblock copolymers and α-CD were prepared by Ni et al., (2009) and found to be 
potentially suitable for drug delivery applications. The advancement in CD-based 
supramolecular assemblies and hydrogels has been well articulated in the recently 
published review by Tan et al., (2014). Thermo-responsive supramolecular hybrid 
hydrogels formed by graphene oxide-grafted-PEG and α-CD have been developed by 
Kong and colleagues (2013).  
Several attempts have also been made to develop hydrogels from CDs by covalently 
attaching a CD host to the polymer chain and mixing with a similarly-functionalized 
guest-containing polymer (Figure 1.24 a). Supramolecular hydrogels self-assembled 
by α-CD and methoxypolyethylene glycol-poly(caprolactone)-(dodecanoic acid)-
poly(caprolactone)-methoxypolyethylene glycol  (MPEG-PCL-MPEG) triblock 
polymers were prepared by Wu and co-workers (2008) for drug delivery and stem cell 
encapsulation. The sustained delivery of dextran-fluorescein isothiocyanate (FITC) 
from the hydrogels lasted for more than one month indicating the hydrogels to be 
promising for drug delivery application. ECV 304 and mesenchymal cells were 
encapsulated and the cell morphologies could be preserved during the cell culture. The 
in vitro cytotoxicity and the in vivo histological studies demonstrated the hydrogels as 
promising injectable scaffolds for tissue engineering applications. Koopmans and 
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Ritter (2008) presented a novel host-guest hydrogel system employing β−CD 
polymers and copolymers bearing adamantyl (ADA) groups.  The construction of 
polymeric hydrogel networks through host-guest complexation between β−CD 
substituents and adamantyl substituents have also been reported by Wang et al., 
(2010).   
 
Figure 1.24. Schematic representation of hydrogel structures prepared by employing 
functional polymers bearing guests for CD complex formation either by 
(a) CD-functionalized polymers or (b) small molecule CD dimers. 
A CD dimer could also be employed for fabrication of hydrogels using guest-
functional polymer (Figure 1.24 b). Guan et al., (2014) reported a triply stimuli-
responsive hydrogel constructed by the formation of host-guest complexes between 
PNIPAAm containing azobenzene groups and CD dimers connected by disulfide 
bonds. Copolymers of NIPAAm containing adamantyl groups have been cross-linked 
non-covalently with CD dimers to give intelligent hydrogels (Kretschman et al., 
2006).  
Tian et al., (2014) designed an assembly of organophosphazene material based on the 
host-guest interactions between an ADA end-functionalized polyphosphazene and a 4-
armed β−CD initiated poly(PEG- methyl ether methacrylate) branched-star type 
polymer. The resultant polymeric materials demonstrated useful properties including 
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self-aggregation, supramolecular gelation and stimuli-responsive behaviour. Rodell 
and co-workers (2013) have developed a shear-thinning hyaluronic acid (HA) 
hydrogel based on the host-guest interactions of ADA modified HA (guest macromer) 
and β−CD modified HA (host macromer). The hydrogel sustained the release of BSA 
for more than 60 days and showed potential as a minimally invasive injectable 
hydrogel for biomedical applications. Kandoth and co-authors (2013) developed a 
hydrogel by the spontaneous self-assembly of a poly-β−CD polymer, hydrophobically 
modified dextran and nitric oxide (NO) photo-donor bearing an adamantyl group. The 
formation of the hydrogel was attributed to a "lock-and-key" mechanism in which the 
adamantly moiety forms inclusion complexes with β−CD cavities. The utility of this 
photo-releasing NO platform showed highly effective and strictly light-dependent 
bactericidal activity against Gram-negative E.coli. A novel star-star supramolecular 
architecture self-assembled between a star-shaped adamantyl-terminated 8-arm PEG 
and a star-shaped PNIPAAm with a β−CD core has been designed which self-
aggregates into a 3D network that induces thermo-responsive hydrogel formation 
(Zhang et al., 2013). Liu et al., (2014) obtained supramolecular assemblies with a 
bottle-brush structure by utilizing β−CD modified chitosan as host. The 
supramolecular hydrogels were formed by the host-guest inclusion of the ADA-
modified methoxy-PEG into the β−CD cavity on the chitosan chain. The hydrogels 
can be used to realize the biomimetic structure of the articular cartilage proteoglycan. 
Supramolecular hydrogels, without using a cross-linker, were prepared by the 
polymerization of the inclusion complexes between β−CD acrylamide and ADA 
acrylamide (Kakuta et al., 2013). The hydrogels demonstrated high performance 
physical properties in terms of elasticity and toughness.    
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Besides ADA moieties, other molecules have also been utilized as guests for the 
formation of CD inclusion complexes. Self-assembling PEG hydrogel system based 
on the inclusion complexes of β−CD and cholesterol have been described by van de 
Manakker and colleagues (2013). The hydrogels were formed after the hydration of a 
mixture of star-shaped 8-arm PEG (PEG8) end-modified with β−CD groups and 
cholesterol. The hydrogels offered excellent biocompatibility and potential for various 
biomedical applications. The authors have reported the degradation and protein release 
behaviour from the β−CD and cholesterol-derivatized PEG8 hydrogels (van de 
Manakker et al., 2009). The high tunability, unique protein release mechanism and 
ease of preparation makes these useful as injectable drug delivery devices and 
scaffolds. In another approach, the PEG8 hydrogels were obtained by an alternate 
strategy (van de Manakker et al., 2010). In this system, the PEG8−cholesterol was 
combined with 0.5 to 4 equivalent of free β−CD which led to hydrogel formation that 
were 5-10 folds stronger than the gels composed of PEG8−β−CD and 
PEG8−cholesterol.  
In recent days, carbon nanotubes (CNTs), either single-walled (SWCNTs) or multi-
walled (MWCNTs), have invited much attention because of their unique thermal, 
electronic and mechanical properties. They have been invariably utilized as carriers 
for therapeutic molecules. Since the CNTs are entirely built of carbon, the major 
limitation, besides their non-degradability, is their solubility in aqueous solvents. To 
improve the aqueous solubility, CNTs have been modified with β−CD. PEG-g-
MWCNTs were synthesized and formed inclusion complexes after selective threading 
of the PEG segment of the PEG-g-MWCNT through α−CD cavities (Sui et al., 2010). 
A chemically responsive supramolecular SWCNT hydrogel has been constructed by 
using the host-guest interactions of hybrids of SWCNTs and β−CDs (Ogoshi et al., 
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2007). SWCNTs were incorporated into a Pluronic supramolecular hydrogel 
containing α−CD exploiting the inclusion efficacy of α−CDs with SWCNTs (Wang 
and Chen, 2007). 
Efforts are still being made to incorporate CDs into various polymer matrices in order 
to explore and improve current drug release systems. 
 
1.10 OBJECTIVES 
The present research work aims at employing a simple and easy strategy for 
incorporating CDs to hydrogel matrix by loading preformed drug−CD ICs directly 
into the hydrogel to design an array of controlled delivery systems and exploring this 
possibility in greater details. CDs have the potential to reduce the release rate of drug 
from hydrogels even without any covalent linking to the matrixes, for they diffuse in 
the gel much slower than small molecule drugs probably due to their higher excluded 
volumes, low water-solubility, and hydrogen bonding ability.  
 
Figure 1.25. Drug−CD inclusion complex incorporated hydrogels for controlled 
delivery of hydrophobic drugs. 
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The specific objectives are: 
 To explore the controlled drug releasing characteristics of PVA hydrogels 
containing drug-β-CD inclusion complexes. To investigate the role of CD, the 
effect of nature of drug (hydrophilic/ hydrophobic) and degree of cross-linking 
on the drug release process and to know the probable mechanism of drug 
release. 
 To examine the utility of pH-sensitive CS-PVA hydrogels containing drug-CD 
ICs for controlled delivery of non-steroidal anti-inflammatory drugs; naproxen 
(NX) and diclofenac sodium (DS), to the intestine. 
 To study the behaviour of PVA-PAA microspheres towards pH-responsive 
sustained release of dexamethasone (DX) and to further inspect the influence 
of method of preparation of the inclusion complexes on the drug release 
phenomenon.  
 To study the drug delivery behaviour from thermo-sensitive Guar 
gumPNIPAAm hydrogels containing 5-fluorouracil-CD solid inclusion 
complexes. 
 To evaluate and compare the efficacy of GG-PAA-CD hydrogels with CD as a 
part of their network structure and GG-PAA hydrogel containing the 
preformed DX-CD inclusion complexes, for the controlled delivery of DX. 
 
                                                                                                                    Chapter 2 
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2.1 MATERIALS 
2.1.1 Polymers and Monomers Employed for Hydrogel Preparation 
 
Poly (vinyl alcohol) (PVA) having molecular weight of 85,000 − 1, 24,000 and degree 
of hydrolysis 86−89% was purchased from S. D. Fine Chemicals, India and employed 
in the preparation of hydrogel films. Another grade of PVA (Mw = 89,000 − 98,000 
and 99.0% hydrolyzed) was received from Sigma-Aldrich, India and utilized in the 
synthesis of hydrogel microspheres. Chitosan (CS) (deacetylation degree > 75%, bulk 
density = 0.15−0.3 g/ cm3 and viscosity > 200 cP) was obtained from Sigma-Aldrich, 
India. Guar gum (GG) was purchased from Merck India Ltd.  
 N-isopropylacrylamide (NIPAAm), the monomer for poly (N-isopropylacrylamide) 
(PNIPAAm), was obtained from Sigma-Aldrich, India and Acrylic acid (AAc), the 
monomer for poly (acrylic acid) (PAA), was received from SRL, India.  
2.1.2 Medium Components  
β−cyclodextrin (CD), ammonium persulfate (APS), tetraethyl orthosilicate (TEOS), 
N,N,N',N'- tetramethylethylene diamine (TEMED) and analytical grade acetic acid 
were procured from Sigma-Aldrich, India and used as received. Glutaraldehyde (GA) 
was supplied as a 25% (w/w) aqueous solution by Spectrochem Pvt. Ltd., Mumbai, 
India. Ceric ammonium nitrate (CAN), light liquid paraffin oil and hydrochloric acid 
were obtained from S. D. Fine Chemicals, Mumbai, India. Tween-80 was received 
from Merck, India. Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine 
Serum (FBS), Penicillin–streptomycin antibiotic solutions, 0.25% Trypsin and 0.02% 
EDTA solutions, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide), RPMI-1640, Luria Bertani (LB) agar medium required for the biological 
studies were procured from Hi-Media, India. 
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2.1.3 Drugs   
Ibuprofen (IBF), Dexamethasone (DX) and Naproxen (NX) were obtained from 
Sigma-Aldrich, India. Analytical-reagent grade Salicylic acid (SA) was received from 
Merck India Ltd. 5-Fluorouracil (5FU) was acquired from Spectrochem Pvt. Ltd., 
Mumbai, India. All the drugs were used as received. 
2.1.4 Solvents and Buffers 
Triply distilled water was utilized for the hydrogel syntheses and drug−CD inclusion 
complex preparation processes. Hexane and ethanol were obtained from Merck, India. 
D2O, employed in the 
1
H NMR studies, was obtained from Sigma-Aldrich, India.  The 
phosphate buffers were prepared using sodium monohydrogen phosphate and sodium 
dihydrogen phosphate according to standard methods. Simulated gastric fluid (SGF) 
(pH 1.2, NaOH= 34.2 mM) containing pepsin (0.1 mg/ ml) and Simulated intestinal 
fluid (SIF) (pH 7.4, NaOH= 34.8 mM, NaCl= 68.62 mM) containing pancreatin were 
prepared according to standard methods reported in United States Pharmacopeia 
(Marques et al., 2011).  
2.2 INSTRUMENTS  
Following instruments were used for the studies: 
 Shimadzu UV−Vis spectrophotometer (UV−1800) for absorption studies. 
 Horiba Jobin-Yvon Fluoromax-4P spectrofluorimeter for fluorescence 
measurements. 
 Perkin Elmer RX I spectrophotometer for recording the Fourier Transformed 
Infrared (FTIR) spectra. 
 PANalytical X−Ray diffractometer for the X−Ray diffraction (XRD) studies. 
 Mettler Toledo DSC822 and Netzsch DSC200 instruments for carrying out 
Differential Scanning Calorimetry (DSC) studies. 
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  Microscopic observations were performed under an optical microscope 
(Olympus BX-51). 
 Morphological studies were carried out on a JEOL Scanning Electron 
Microscope (SEM), model JSM 6480LV and Nova Nano 450 Field Emission 
SEM (FESEM). 
 Bruker 400 MHz NMR Spectrometer for Nuclear Magnetic Resonance (1H 
NMR) studies. 
 LabTech and Scanvac Coolsafe Lyophilizers for freeze-drying purposes. 
 Temperature related experiments were carried out in a Heidolph temperature 
control instrument working in the temperature window of −10°C to 100°C 
with an accuracy of ±0.1°C. 
2.3 METHODS 
2.3.1 Studies on Inclusion Phenomenon in Solution Phase  
The inclusion phenomenon of drug in CD was studied in the solution phase by Phase 
solubility studies, UV−Vis, Fluorescence and 1H NMR spectroscopic techniques.   
2.3.1.1 Phase Solubility. Phase solubility studies were carried out in aqueous medium 
at room temperature according to the reported method by Higuchi and Connors 
(1965). An excess amount of drug (20 mg) was added to 5 ml of aqueous solution 
containing various concentrations of CD (0−10 mM) in sealed glass containers. The 
suspensions were shaken on a mechanical shaker for 7 days at room temperature to 
achieve equilibrium. After equilibrium was achieved, the samples were filtered 
through 0.22 µm syringe filters (Himedia, India) and properly diluted. The 
concentration of the drug was determined spectrophotometrically from the absorbance 
at appropriate λmax of the drug and comparing it with the calibration plot of the drug. 
The apparent stability constant Ks was calculated from the phase solubility diagram 
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(plot of solubility of drug against concentration of CD) according to the following 
equation: 
   
     
           
    (1) 
where S0 is the solubility of the drug in absence of CD. 
2.3.1.2. UV−Vis and Fluorescence Spectroscopy. For the UV-Vis and fluorescence 
studies appropriate concentration of the drug of interest was chosen. The CD 
concentration was varied from 0 to 20×10
3 
M. After preparation, the solutions were 
left undisturbed for at least 2 h to ensure equilibrium. The absorption and emission 
spectra were then recorded. For the emission spectra the excitation wavelength was set 
at the absorption maximum. 
The binding constant (Kb) for the drug and the CD complexation was calculated from 
the absorbance and fluorescence data using the modified Benesi-Hildebrand equation 
(Velaz et al., 1997; Li and Zhang, 2011): 
 
      
  
 
         
 
 
 
                                 
 
 
      
  
 
         
 
 
 
                                 
Here A0 and A represent the absorbance of drug in absence of CD and at each CD 
concentration respectively, F0 and F represent the fluorescence intensity of the drug in 
absence of CD and at each CD concentration respectively and α is a constant. From 
the double reciprocal plot of [1/ (A−Ao)] or [1/ (F−Fo)] against 1/ [CD], the ratio of 
the intercept to the slope was calculated which provided the value of Kb.  
2.3.1.3. 
1
H NMR. 
1
H NMR experiments of CD, drugs and the inclusion complexes 
were carried out in D2O at 298 K. Tetramethylsilane (TMS) was used as an internal 
reference. All data have been shown by fixing the D2O peak at 4.69 ppm.  
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In the present thesis work, drug-CD inclusion complexes have been prepared by using 
β−CD. Henceforth, CD represents β−CD in all the work chapters. 
2.3.2 Preparation of Solid Drug-CD Inclusion Complex (IC) 
All the drugs employed in this study are found to form 1:1 solid IC with CD. There 
are various methods of preparation of inclusion complexes of drug in CD; namely, 
physical mixing, kneading, co-precipitation, freeze-drying, spray-drying, microwave 
irradiation etc. The ICs employed in this thesis work have mostly been prepared by the 
co-precipitation and/or the freeze-drying/ lyophilization processes. 
2.3.2.1 Physical Mixture 
A physical mixture (PM) of drug and CD was obtained in 1:1 molar ratio by 
homogeneous blending of the components in a mortar for 15 min. 
2.3.2.2 Co-precipitation Method 
Briefly, calculated amount of CD was dissolved in distilled water at 50°C for 1 h. 
Desired amount of drug was solubilized in ethanol and slowly added to the CD 
solution with continuous stirring. The molar ratio of drug to CD was maintained at 
1:1. The final solution was left undisturbed at room temperature for 3 days. The 
precipitated complex (CP) was recovered by filtration and washed with ethanol to 
remove the uncomplexed drug. The residue was vacuum−dried and utilized for further 
studies. 
2.3.2.3 Freeze−drying/ Lyophilization Method 
Desired amount of drug was solubilized in ethanol and slowly added to the CD 
solution with continuous stirring. After agitation for 24 h, the solution was filtered 
through 0.22 µm syringe filter. The clear solution was frozen at −20°C for 6 h and 
then freeze−dried at −55°C for 48 h in a Freeze Dryer. The product was ground and 
stored in air tight bottles for further uses.    
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2.4 Characterization of Solid Drug−CD ICs 
2.4.1 FTIR Studies. The FTIR spectra were recorded in the scanning range of 4000 to 
400 cm
1
 using KBr as reference at room temperature. The samples were triturated 
with dry KBr, compressed to pellets and then scanned.  
2.4.2 XRD Studies. The XRD profiles were collected on an X-Ray diffractometer 
using Nickel-filtered Cu Kα radiation and scanned from 5° to 50° at room temperature 
at a scan rate of 3°/min. 
2.4.3 DSC Studies. DSC was performed on 5−10 mg of powdered samples under N2 
atmosphere (purging rate: 40 mL/ min) from 50°−300°C at a heating rate of 10°C/ 
min. 
2.4.4 Optical Microscopic Studies. Microscopic observations of the powdered 
samples were performed under an optical microscope.  The samples were mounted on 
glass slides and viewed under normal light. 
2.4.5 SEM Studies. The surface morphology of the samples was investigated by 
SEM. The powder samples were gold-coated and directly observed under SEM.  
2.5 Hydrogel Preparation  
The objective of the present thesis is to design pH-sensitive and thermo-sensitive 
smart hydrogels to be utilized as controlled delivery vehicles for different drugs. The 
detailed methodologies involved in the fabrication of the different hydrogel systems 
are given below. 
2.5.1 Synthesis of PVA Hydrogels 
10 wt% PVA was dissolved in water by heating at 80°C for 6 h. To the clear PVA 
solution, desired amount of GA as cross-linking agent and concentrated HCl as 
catalyst were added and the mixture was stirred at room temperature for an hour. To 
this mixture, desired amount of drug or preformed drug-CD IC was added and stirred 
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briefly at 200 rpm. The mixture was then poured onto a clean and dried glass petri 
dish of known surface area to obtain a film. The quantity of GA was varied so as to 
get a series of cross-linked hydrogels. GA cross-linked PVA and PVA-CD hydrogels 
without containing drug or ICs were also synthesized and used for characterization 
and swelling studies. 
2.5.2 Design of pH-sensitive Hydrogels 
pH-sensitive hydrogels were prepared by using two pH-responsive polymers: CS 
(natural) and PAA (synthetic). Individually both CS and PAA lack mechanical 
strength; therefore IPN hydrogels such as CS−PVA, GG−PAA and PVA−PAA were 
prepared. 
2.5.2.1 Synthesis of CS−PVA IPN Hydrogels 
2% (w/v) CS was dissolved in 0.1 M aqueous acetic acid solution under continuous 
stirring for 48 h. PVA was dissolved in distilled water for 6 h at 80°C to obtain the 
desired final concentration of PVA. The mixture of CS and PVA solutions was stirred 
for a brief period of time followed by drop-wise addition of the cross-linking reagent 
GA (1 wt %) and the solution was stirred for an hour. To this solution, desired amount 
of free drug or the preformed solid IC was added and stirred for 24 h.  Further, the 
solution was added to known area glass petri dishes and allowed to dry at room 
temperature in-vacuo. GA cross-linked CS−PVA and CS−PVA−CD hydrogels, in 
absence of drug or IC, were also synthesized and used for characterization and 
swelling studies. 
2.5.2.2 Synthesis of GG−PAA IPN Hydrogels 
A weighed amount of GG was allowed to hydrate by overnight stirring in a round-
bottomed flask at 40°C. The solution was cooled down to room temperature. An 
appropriate weight of AAc monomer was added into the GG solution according to the 
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desired ratio. The solution was purged with nitrogen to eliminate dissolved oxygen. 
APS as initiator and TEMED as activator (each at 1 wt% with respect to AAc 
monomer) were added into the reaction mixture under the nitrogen atmosphere. This 
was then followed by the addition of the cross-linking agent, TEOS (2 wt %) and CD 
(0.2 g). The reaction vessel was transferred to an oil bath maintained at 60°C and the 
reaction was carried out for 24 h. Subsequently, the resulting homogenous polymer 
solution was cooled to room temperature and was evenly cast on petri plates to form 
films. In a similar fashion, hydrogels without containing CD were also synthesized for 
comparison. For the drug containing hydrogels, drug (10 mg) was added to the 
polymer solution at room temperature and magnetically stirred for 30 min to ensure 
proper mixing and then the films were casted.  
2.5.2.3 Synthesis of PVA−PAA Hydrogel Microspheres 
Synthesis of PVA-PAA microspheres was carried out according to reported method by 
Kurkuri and Aminabhavi, (2004). CAN have been used as an initiator for the 
polymerization of AAc (Mino and Kaizerman, 1958; Jana, Maiti and Biswas, 2000). 
10 wt% PVA solution was prepared by dissolving in distilled water at 80°C for 6 h. 
Requisite amount of AAc monomer (10 wt%) was taken in distilled water and added 
drop-wise to the PVA solution maintained at 50°C with continuous stirring. Then 0.2 
g CAN was dissolved in 10 ml water and added to the above solution and stirred 
vigorously. The solution was cooled down to room temperature followed by the 
addition of free drug or the IC and stirred for 30 min to get a homogeneous mixture. 
The entire solution was emulsified to form water-in-oil (w/o) emulsion in 100 ml of 
light liquid paraffin oil containing 2% (w/v) Tween- 80, 1 ml of 0.1 M HCl and 1 ml 
of 0.1 M GA and stirred for 5 h. The microspheres formed were centrifuged and 
washed repeatedly with hexane and water to remove the excess of reactants. The 
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microspheres were dried under vacuum and stored in desiccator for further use. Blank 
microspheres without containing any drug were also synthesized. The schematic 
illustration for the formation of microspheres by the emulsion cross-linking method is 
presented in Scheme 2.1. 
 
Scheme 2.1. The preparation process of PVA−PAA microspheres by the emulsion 
cross-linking method. 
 
2.5.3 Design of GG−PNIPAAm Temperature-Sensitive Hydrogels 
An appropriate weight of NIPAAm monomer was added into GG solution according 
to the desired ratios. The solution was purged with nitrogen for 30 min to eliminate 
oxygen. APS as initiator and TEMED (30 µl) as activator were added into the reaction 
mixture under the nitrogen atmosphere. This was then followed by the addition of the 
cross-linking agent, TEOS (2 wt %) and stirred for 24 h. To this solution, desired 
amount of free drug or the preformed IC was added and stirred to get a homogeneous 
mixture.  Subsequently, the resulting polymer solution was evenly cast on petri plates 
to form a film. Hydrogels with different feed compositions were synthesized. Blank 
hydrogels without any free drug or IC were also synthesized for characterization 
purpose. 
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2.6 Characterization of Hydrogels 
2.6.1 FTIR Studies. The FTIR spectra of the hydrogels were recorded in the scanning 
range of 4000 to 400 cm
1
 using KBr as reference at room temperature. The hydrogels 
were properly ground with KBr so as to form a homogeneous mixture, pressed to form 
a pellet and then scanned.  
2.6.2 XRD Studies. The XRD profiles were collected on a X−Ray diffractometer 
scanned from 5° to 50° at room temperature at a scan rate of 3°/min.  
2.6.3 DSC Studies. Dried hydrogel samples weighing around 5 mg were taken in Al 
crucibles, sealed with Al-lid and then placed in DSC instrument. All the samples were 
first heated over the temperature range from 25°C to 200°C (first heating cycle); then 
cooled to 25°C followed by heating again up to 300°C (second heating cycle), all at a 
heating rate of 10°C/ min under nitrogen environment (purging rate: 40 ml/ min). The 
reported results were taken from the second heating runs of the experiments in order 
to avoid experimental effects arising from the previous thermal history, structural 
relaxation and incomplete chemical reactions. 
2.6.4 SEM Studies. The surface morphology of the samples was investigated by 
SEM. The hydrogels were either swollen in distilled water or in phosphate buffers of 
desired pH till equilibrium. They were frozen at −20°C for 6 h and lyophilized at 
−55°C for 48 h. The lyophilized samples were gold-coated and then observed under 
SEM directly.  
2.7 Drug Loading Efficiency and Drug Content 
To study the drug encapsulation efficacy of the hydrogels, dry hydrogel films were put 
inside vials containing the saturated drug solution in hydroalcoholic medium (1:1), 
which was subjected to mechanical shaking for 30 min and the films were left in the 
 Materials and Methods 
78 
 
drug solution for 24 h at room temperature. The drug concentration was determined 
spectrophotometrically by comparing with standard calibration curve.  
The drug content of the microspheres was performed in accordance with the procedure 
reported by Angadi et al., (2011). Microspheres of known weight (10 mg) were finely 
ground using a mortar, extracted with 50 ml of distilled water and sonicated for 30 
min (Electrosonic Industries, India). The solution was centrifuged (Remi Research 
Centrifuge, India) to remove the polymeric debris and the clear supernatant was 
analyzed spectrophotometrically. The percent drug content was calculated as: 
  drug content = 
weight of drug in microspheres 
weight of microspheres
  100              (4) 
The values reported are the mean of the three independent measurements. 
2.8 Equilibrium Swelling Measurement of Hydrogels 
The swelling characteristic of all the prepared hydrogels was studied. The dried and 
pre-weighed samples were immersed in distilled water or buffer solution of 
appropriate pH (for pH dependence studies) at 37°C till equilibrium swelling was 
achieved. They were taken out at regular intervals and their weight was measured after 
gentle wiping with tissue paper to remove excess surface water. The degree of 
swelling was calculated as:  
                      
     
  
                       (5) 
where Ws and Wd are the weights of the swollen and dried hydrogels, respectively. The 
pH- dependent and temperature-dependent swelling of the hydrogels was also studied. 
The pH-responsive swelling behavior of the hydrogels was investigated by immersing 
them in solutions of different pH (2.0−11.0). Samples were allowed to swell in the 
buffer solution of desired pH till equilibrium and weighed after gentle wiping with 
tissue paper. The swollen gel was then slowly dried to constant weight. The swelling 
percentage was calculated using the above formula (Eq. 5).   
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The swelling response of the hydrogel microspheres was also investigated as a 
function of time at pH 1.2 (dilute HCl) and pH 7.4 (phosphate buffer). The 
microspheres were allowed to swell and weighed at regular intervals of time till a 
constant weight was achieved. The percentage equilibrium swelling was then 
calculated. 
The temperature-responsive swelling characteristics of the hydrogels were evaluated 
by immersing in phosphate buffer (pH 7.4) solutions maintained at the desired 
temperature (15°C – 50°C). At regular time intervals, samples were taken out, gently 
wiped with filter paper to remove the excess surface water and weighed and their 
swelling parameters were evaluated. 
The data have been expressed as the mean value of three independent experiments and 
the standard deviations are presented as error bars. 
2.9 In vitro Drug Release Studies 
Calibration plots were constructed spectrophotometrically by monitoring the 
absorbance of the drug solutions at the respective λmax of the drugs as a function of 
concentration. In vitro release studies of the drug was carried out by placing the drug 
loaded hydrogels in 50 ml of the releasing medium at 37°C and taking out aliquots of 
3 ml at particular time intervals. The withdrawn aliquots were replenished with equal 
volumes of fresh buffer solution to simulate physiological conditions. For the pH-
responsive hydrogels release studies have been carried out at pH 1.2 (dilute HCl) and 
pH 7.4 (phosphate buffer). In order to imitate the conditions of the human 
gastrointestinal tract (GIT), the drug loaded hydrogels were immersed in SGF for 2 h 
and then transferred to SIF and the drug release was monitored. The concentration of 
the drug released was estimated from the calibration plots. Drug release experiments 
have also been conducted at 25°C in order to test the thermo-sensitivity of 
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GGPNIPAAm hydrogels. The release data shown are expressed as the mean value of 
three independent experiments and the standard deviations are represented as error 
bars.  
2.10 Drug Release Kinetics 
Accurate prediction of the mechanism of drug release from swellable hydrogel 
matrices is very complicated. Several factors such as hydrogel swelling (water 
diffusion into the polymer matrix), polymer relaxation, diffusion of drug inside and 
from the swollen matrix, drug-polymer interaction and its effect on the drug diffusion, 
changes in the geometry and/or dimensions of the hydrogel, and many more such 
factors influence the drug release kinetics from a hydrogel matrix. In the present study 
the drug−CD interaction and its effect on the drug diffusion from the hydrogels 
containing drug−CD ICs also needs to be considered in order to have a clear 
understanding of the release mechanism. However to garner an approximate idea 
about the probable mechanism of the drug release from the hydrogels, the release data 
were analyzed according to four basic kinetic models. These models are valid for the 
initial 60% of drug release (Serra et al., 2006). All data were analyzed using OriginPro 
7 (OriginLab Corporation). 
Model 1 is based on the Higuchi equation that describes the Fickian diffusion of a 
drug (Higuchi, 1963): 
Mt/M = k. t
0.5
   (6) 
where Mt/M is the fractional drug release at time t and k is the kinetic constant. 
Model 2 is described by the Ritger–Peppas equation (Ritger & Peppas, 1987):  
Mt/M = k’. t
n
   (7) 
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where k’ is the kinetic constant, t is the release time and n is the diffusional exponent 
that explains the drug transport mechanism. Table 2.1 summarizes the different values 
of n for drug delivery systems of different geometries and their significance. 
Table 2.1. Diffusion exponent and solute release mechanism. 
Diffusion exponent (n) 
Mechanism 
Film Cylinder Sphere 
0.50 0.45 0.43 Fickian diffusion 
0.50 < n < 1.00 0.45 < n < 0.89 0.43 < n < 0.85 Anomalous transport 
1.00 0.89 0.85 Case II transport 
 
For hydrogel films, when n = 0.5, the drug release mechanism is Fickian diffusion 
which occurs due to the molecular diffusion of the drug. When n = 1, Case II transport 
occurs, which is associated with the relaxational release of drug leading to zero-order 
kinetics. When n lies between 0.5 and 1, anomalous transport is observed where both 
Fickian and relaxational phenomena contribute to the drug release. And n > 1 implies 
super Case II transport mechanism which is due to a large increase in osmotic pressure 
driving forces, followed by relaxation and swelling of polymers. 
Model 3 is based on the Peppas–Sahlin equation, accounting for the coupled effects of 
Fickian diffusion and Case II transport (Peppas & Sahlin, 1987): 
 
Mt/M = k1. t
m
 + k2. t
2m
  (8) 
The first term on the right hand side of Eq. 8 represents the contribution of Fickian 
diffusion and the second term refers to the macromolecular relaxation contribution on 
the overall release mechanism. k1 is the diffusion and k2 is the relaxation rate constant. 
The coefficient m is the Fickian diffusional exponent which also depends on the 
geometry of the device. The values of m for different types of drug delivery devices 
are known to be 0.5 (film), 0.45 (cylinder) and 0.43 (sphere). 
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Using the estimated values of k1 and k2 obtained from fitting the experimental data to 
Eq. (8), the ratio of relaxation (R) and Fickian (F) contributions was calculated using 
Eq. (9) as: 
R/F = (k2/k1) t
m
  (9) 
The release time is related to the fraction of drug release; thus R/F is represented as a 
function of fraction of drug released.  
Model 4 is the zero−order drug delivery kinetics equation given as: 
Mt/M = k”. t   (10) 
Where k” represents the zero-order kinetic rate constant. 
2.11 Antimicrobial Assay  
Antimicrobial activity of the synthesized hydrogels obtained directly after synthesis 
(without drying) was evaluated against E. coli (Gram−negative) and S. aureus 
(Gram−positive) by the disc diffusion method (Vimala et al., 2009). The nutrient agar 
medium was prepared by using peptone (5.0 g), yeast extract (3.0 g) and NaCl (5.0 g) 
in 1000 ml distilled water. The pH was adjusted to 7 and agar (15.0 g) was added to 
this solution. The agar medium was sterilized in a conical flask at a pressure of 15 lbs 
for 15 min. This nutrient agar medium was transferred into sterilized petri dishes. 
After the medium was solidified, 9 mm wells were bored using a cork borer.  The 
bacterial culture was swabbed on the solid surface of the medium to obtain a lawn 
culture.  To the inoculated petri dishes, one drop of gel particle solution was added 
and incubated for 48 h at 37°C in the incubation chamber. After incubation, the zone 
of inhibition was measured in mm.  
2.12 Cytotoxicity Assay   
Cytotoxicity of the hydrogels was studied by the direct contact method and the 
indirect MTT colorimetric assay technique. Cytotoxicity was tested on mouse 
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fibroblast L−929 cells procured from National Centre for Cell Science, Pune, India. 
Cultures were maintained at 37°C under 5% CO2 in RPMI-1640 medium. Prior to the 
cytotoxicity evaluation, the hydrogel samples were sterilized at 15 lb/ in
2
 steam 
pressure, 121°C for 1 h in an autoclave. 
2.12.1 Direct Contact Method 
The fibroblast cells, 1 x 10
5
 cells/ ml, were seeded in RPMI-1640 medium and directly 
incubated with the hydrogel samples at 37°C. After 48 h of incubation, the number of 
cells was counted and their physical appearance was observed. 
2.12.2 Indirect Method: MTT Colorimetric Assay 
Cell viability was measured by the MTT colorimetric assay. For this test, reference 
fibroblast cells and cells containing the hydrogel samples dispersed in phosphate 
buffer were added to RPMI-1640 medium and incubated at 37°C in 5% CO2 
atmosphere for 24 h. The absorbance was monitored at 575 nm. The untreated cells 
were considered as control (100% viability). The percentage cell viability of the 
samples was calculated as [O.D.]sample/ [O.D.]control x 100. All experiments have been 
performed in triplicate. 
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CHAPTER   3 
 
EXPLORING POLY(VINYL ALCOHOL) HYDROGELS 
CONTAINING DRUG−CYCLODEXTRIN 
INCLUSION COMPLEXES AS CONTROLLED 
DRUG DELIVERY SYSTEMS 
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3.1 INTRODUCTION 
Poly(vinyl alcohol) (PVA) is a neutral, synthetic and water soluble hydrogel forming 
polymer produced by the partial or full hydrolysis of poly(vinyl acetate) (Scheme 3.1). 
The primary raw material used for the synthesis of PVA is vinyl acetate monomer 
instead of vinyl alcohol because the latter is unstable in nature. The degree of 
hydrolysis or the content of the acetate groups in the polymer determines the physical 
characteristics, chemical properties and the mechanical behaviour of the resulting 
PVA polymer. The resistance of PVA against organic solvents and its high aqueous 
solubility makes it suitable for various applications (Tubbs, 1966).  FDA has approved 
PVA to be applicable in food packaging industries because of its excellent barrier 
properties. In pharmaceutical fields, PVA is used as a biomaterial due to its 
biocompatible, non-toxic, non-carcinogenic and swelling characteristics. Moreover, its 
low protein adsorption properties results in low cell adhesion which makes it highly 
attractive for pharmaceutical purposes (Hassan and Peppas, 2000). 
 
Scheme 3.1. Synthetic scheme of PVA by hydrolysis of poly(vinyl acetate) 
The versatility of PVA is paramount in the fabrication of a variety of architectures 
including films, microgels, microspheres, microbubbles
 
and microcapsules. Owing to 
their good film forming ability, long-term temperature and pH stability and excellent 
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biocompatibility, PVA hydrogels are much in demand in the areas pertaining to 
biomedical research. The pharmaceutical and biomedical utilities of PVA hydrogels 
has been well documented in the review article by Kobayashi and Hyu (2010). PVA 
hydrogels and membranes have been developed for numerous biomedical applications 
such as contact lenses, artificial pancreases, hemodialysis, synthetic vitreous humor 
and implantable medical materials to replace cartilage and meniscus tissues (Peppas, 
1986). PVA shows higher elongation than conventional HEMA hydrogels when 
employed in contact lens fabrication, thus extending the wearing time without 
inducing hypoxia to cornea (Peppas, 1986). It has been used to treat vascular 
embolisms in the particulate form and as hydrophilic coatings to improve neurologic 
regeneration and tissue adhesion barriers (Baker et al., 2012). On the drug delivery 
front, PVA has been exploited as a preferred material for the fabrication of ocular 
inserts and films, nanoparticles, microspheres, floating microspheres, mucoadhesive 
and targeted drug delivery systems like rectal, colonic, transdermal, buccal, etc. The 
review article by Gajra and co-authors (2010) briefly summarizes the relevance and 
importance of PVA in DDS. 
Despite all the meritorious effects, pure PVA films are known to be very fragile in 
nature. They possess lower mechanical strength and dissolute totally upon swelling in 
aqueous medium or any other biological fluids because of their high hydrophilic 
characteristics. Thus their applicability is greatly hindered. Chemical or physical 
cross-linking methods are common strategies employed to impart tougher mechanical 
properties to the conventional PVA hydrogel. In the chemical cross-linking method, 
certain chemical agents such as GA, EPI, acetaldehyde and other monoaldehydes are 
usually employed (Xiao and Zhou, 2003). Cross-linking can also be achieved by the 
use of UV radiation, electron beam and -radiation (Hassan and Peppas, 2000). PVA 
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hydrogels can also be physically cross-linked by the freeze/ thaw process (Hassan and 
Peppas, 2000). The molecular weight of PVA, its concentration, the time of freezing 
and thawing and the number of freeze/ thaw cycles affect the properties of the 
generated PVA hydrogel. These cross-linking techniques generally improve the 
mechanical strength of the otherwise fragile pure PVA hydrogel.  
As drug delivery carriers, the major drawback that is inevitably associated with PVA 
hydrogel is its inefficacy to control the initial burst release of drugs. For many 
medications, the burst release has been known to cause patient non-compliances. 
Further, the burst release is a wasteful process since too high a burst will reduce the 
efficacy of the delivery device, leading to loss in effectiveness both therapeutically 
and economically. Moreover, excessive initial release rates can result in drug levels 
close to or exceeding toxic threshold levels (Huang and Brazel, 2001). For this reason, 
one of the goals in drug delivery systems is to reduce the initial burst effect and to 
achieve a constant release rate. In order to substantiate PVA hydrogels as controlled 
drug delivery devices, "composite" hydrogels have been designed as useful tools. 
Nugent and Higginbotham (2007) have developed freeze-thawed composite 
PVA−AAc hydrogel and demonstrated the controlled delivery for theophylline. It was 
observed that the composite hydrogel released the drug in a sustained manner in 
comparison to the pure one. Bai and co-workers (2010) have synthesized graphene 
oxide−PVA composite hydrogel and utilized for controlled drug delivery at 
physiological pH. The recent review article by Gonzales and Alvarez (2013) 
summarizes the current developments in composite PVA hydrogels towards 
applications in biomedicine and drug delivery.  
Incorporation of particulate systems (liposomes, micelles, microparticles, etc.) into the 
PVA hydrogel matrix has also been utilized to achieve a sustained drug release 
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profile. DDS have been constructed from aspirin and DOX dispersed PVA hydrogels 
loaded with poly(L-glutamic acid)-b-poly(propylene oxide)-b-poly(glutamic acid) 
(GPG) micelles (Wei et al., 2009). Aspirin had short term release while the release of 
DOX was sustained. Wei and colleagues (2011) have also utilized GPG micelles for 
encapsulating paclitaxel and then loaded onto the PVA hydrogel. Controlled release of 
paclitaxel was observed from the composites. Assimilation of microparticles has also 
been recognized as another strategy to fabricate PVA hydrogels as controlled delivery 
vehicles. Uniform PLGA microparticles have been produced by PVA hydrogel 
template method for delivery of risperidone, methylprednisolone acetate and 
paclitaxel (Lu et al., 2014).  An enhanced drug loading was observed by this method 
in comparison to the microparticles prepared by the conventional emulsion method.  
For all the three drugs, release was sustained for weeks. Spiller and co-workers (2012) 
have encapsulated insulin-like growth factor-1 (IGF-1) in PLGA microparticles 
embedded in PVA hydrogels. The release of IGF-1 was found to be sustained for over 
6 weeks in vitro.  
Integration of β−cyclodextrin (CD) to PVA hydrogels has also been performed with 
an aim to improve the drug release characteristics of the hydrogels. CD has been 
blended with PVA hydrogels and it was found that the presence of CD in the matrix 
prolonged the release of salicylic acid (Sreenivasan, 1997).
 
Microspheres of 
PVA−cyclodextrin have been synthesized by Constantin and co-workers (2004) and 
estimated for the inclusion and separation of drugs. Chemically modified PVA 
hydrogels containing methacrylated-CD prepared by UV-induced polymerization have 
been studied for sustained release of the ocular therapeutics, puerarin and 
acetazolamide (Xu et al., 2010). The amount of drug loaded into the hydrogels 
increase with the increase in CD content. The incorporation of CD effectively reduced 
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the initial burst of acetazolamide and the release was sustained for 15 days. Efforts are 
still being made to incorporate CDs into various polymer matrices in order to explore 
and improve current drug-release systems.  
In the present chapter, GA cross-linked PVA hydrogels containing solid drug-CD ICs 
have been explored as potential controlled drug delivery systems. Salicylic acid (SA) 
and Ibuprofen (IBF) (Figure 3.1) are employed as two model drugs. SA and IBF are 
commonly used anti-inflammatory, antipyretic and analgesic drugs. SA is 
monohydroxybenzoic acid and is best known for being a key ingredient in topical skin 
care products for the treatment of acne, psoriasis, corns, calluses, warts, ichthyosis etc. 
IBF (α-methyl-4-[isobutyl] phenylacetic acid), on the other hand, is a non-steroidal 
anti-inflammatory drug (NSAID) that is available in a variety of preparations. It is 
commonly used for the treatment of pain and inflammation in rheumatoid arthritis and 
other musculoskeletal disorders. The formulation for IBF is quite problematic because 
of its poor solubility in water (Manzoori, and Amjadi, 2003). The strategies that are 
usually employed to increase drug solubility include salt formation, microenvironment 
pH control, solubilization with surfactants, complexation with cyclodextrins, solid 
dispersions, lipid based formulations and nanoparticles formulations (Salustio et al., 
2011). Belyakova and co-authors (2006) have studied the inclusion of SA in CD and 
observed that encapsulation of SA in CD cavity improves its thermal stability. 
However, an elaborate discussion on the inclusion phenomenon of SA with CD is still 
lacking. The inclusion of IBF in CD improves the drug loading (Salustio et al., 2009). 
Hladon et al., (2000) have demonstrated an increase in IBF solubility by complexation 
with CD.  
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Figure 3.1. Chemical structures of (A) Salicylic acid (SA) and (B) Ibuprofen (IBF). 
OBJECTIVES 
In this context, achieving controlled drug release from PVA hydrogels containing 
preformed solid drug-CD ICs becomes an important strategy to explore.  Investigation 
of the effect of nature of the drug, extent of cross-linking, influence of CD 
complexation on the drug release characteristic from PVA matrices becomes 
interesting. The inclusion studies of IBF, which is a relatively hydrophobic drug 
(solubility of IBF at 25°C  0.552 x 10−4 M) (Garzon and Martinez, 2004), in 
comparison to SA (solubility of SA at 25°C  2.2 x 10−3 M) (Shalmashi and Eliassi, 
2008) and their subsequent release from GA cross-linked PVA hydrogels necessitates 
an elaborate discussion.      
The specific objectives of the present work are to: 
 prepare solid inclusion complexes (ICs) of SA and IBF with CD and affirm the 
formation of ICs by various spectroscopic techniques, 
 synthesize various compositions of GA cross-linked PVA and PVA−CD 
hydrogels and their  characterization, 
 synthesize hydrogels containing free drug and the ICs and explore their 
release characteristics,  
 study the effect of nature of drug and the role of CD on the drug release 
phenomena, 
 address the preliminary kinetics of drug release from the hydrogels, 
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 assay the cytotoxicity of the synthesized hydrogels for biomedical 
applications. 
The feed compositions and designations of the hydrogels are given in Table 3.1. 
  Table 3.1. Compositions of synthesized hydrogels 
Sample 
Number 
PVA (wt %) CD (wt %) GA (v/v) Sample Designation 
1 10 0 0.01% P1 
2 10 0 0.02% P2 
3 10 0 0.05% P3 
4 10 0 0.10% P4 
5 10 1 0.01% P1-CD 
6 10 1 0.02% P2-CD 
7 10 1 0.05% P3-CD 
8 10 1 0.10% P4-CD 
 
The PVA hydrogels having free drug hydrogels are designated as P1-D, P2-D, P3-D 
and P4-D and the ones with the drug-CD ICs are labelled as P1-IC, P2-IC, P3-IC and 
P4-IC. Here ‘D’ can be either SA or IBF and has been indicated in parentheses 
whenever needed. The amounts of drug released from the hydrogels were determined 
spectrophotometrically by observing absorbance at λmax = 296 nm for SA and λmax = 
276 nm for IBF. 
3.2 RESULTS AND DISCUSSION 
3.2.1 Characterization of Solid Drug-CD ICs 
Solid inclusion complexes of SA and IBF with CD were prepared by co-precipitation 
method and characterized by different techniques. 
3.2.1.1 FTIR Analysis      
The FTIR spectrum of CD (Figure 3.2) shows the characteristic CD peaks which 
include the broad band with a maximum at 3377 cm
−1 
due to the stretching vibrations 
of the hydroxyl groups, an absorption band at 2917 cm
−1 
attributed to the C−H 
stretching, a band at 1647 cm
−1 
assigned to the bending vibrations of O−H bonds in 
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COH groups and/or in water molecules and a band at 1412 cm
−1
owing to the bending 
vibration of C−H bonds in CH2OH and CHOH groups (Gao and Zhao, 2005).  
 
 
Figure 3.2. FTIR spectra of (A) CD, SA, SA-CD physical mixture, SA-CD inclusion 
complex and (B) CD, IBF, IBF-CD physical mixture and IBF-CD 
inclusion complex. 
(A) Salicylic Acid: 
The FTIR spectrum of SA (Figure 3.2 A) presents the bands attributed to the phenyl 
O−H stretching vibrations at 3240 cm−1, C−H  bending vibrations of aromatic protons 
at 1295 cm
−1
, stretching of C=O bonds at 1647 cm
−1 
and C=C bonds of benzene rings 
(1607, 1439, 1495 cm
−1
). The FTIR spectrum of the SA-CD PM is superposition of 
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the spectra of CD and SA. However, major shifts occurred in the spectrum of SA-CD 
IC. The shift in the absorption of the hydroxyl group to 3347 cm
−1
and the carbonyl 
group to 1666 cm
−1 
was witnessed. These changes suggested the inclusion of the 
benzene ring of salicylic acid into CD cavity (Belyakova et al., 2007). 
(B) Ibuprofen: 
The FTIR spectrum of IBF (Figure 3.2 B) shows the presence of a band at 1724 cm
−1 
corresponding to the carbonyl stretching. Two bands arising from C=O stretching and 
O−H bending appear in the spectrum at 1427 and 1231 cm−1. The spectrum of IBF-CD 
PM shows the presence of the key peaks of both CD and SA. A shift in the 
characteristic acid carbonyl stretching in the IBF-CD IC to higher frequency (1729 
cm
−1
)
 
was indicates the inclusion of IBF into the CD cavity (Hussain et al., 2007; 
Mura et al., 1998).
 
 
3.2.1.2 XRD Analysis 
X−Ray diffraction has been employed as one of the useful tools to judge drug−CD 
complexation. The diffraction profile of the inclusion complex is generally different 
from those of the individual components (Zhou et al., 2013). The XRD profile of CD 
(Figure 3.3) include peaks at 9.1° (101), 12.54° (111), 21.2° (410) which suggests CD 
adopts a cage type structure (Harata, 1998). 
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Figure 3.3. XRD profiles of (A) CD, SA, SA-CD physical mixture, SA-CD inclusion 
complex and (B) CD, IBF, IBF-CD physical mixture and IBF-CD 
inclusion complex. 
(A) Salicylic Acid: 
The X-ray diffraction profile of SA (Figure 3.3A) comprises of two sharp peaks at 
10.9° and 17.2° that indicates its crystalline nature. The physical mixture (SA-CD 
PM) represents a superposition of the XRD patterns of individual components. 
However, in the XRD profile of SA-CD IC, the shift in peak positions to 10.1°, 12.2°, 
17.9° and 21.9° were observed, which suggests the formation of new phases probably 
due to the inclusion of SA into CD cavity (Belyakova et al., 2007).  
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(B) Ibuprofen:  
The XRD profile of IBF (Figure 3.3B) exhibited numerous distinct peaks at 6.2°, 
12.2°, 16.8°, 18.8°, 20.1°, 22.3° and 24. ° that clearly points towards the crystalline 
nature of the drug. Principal peaks from IBF and CD were present in the IBF-CD PM. 
The diffraction profile of IBF-CD IC presented a completely different pattern with 
new peaks at 6.4°, 10.1°, and 17.7° which indicated the formation of new entities of 
inclusion complex (Salústio et al., 2009).
 
 
 
3.2.1.3 DSC Analysis 
DSC has been established as an important criterion for the recognition and 
characterization of CD inclusion complexes. When guest molecules are embedded in 
CD cavities; their melting or sublimating points generally shift to different 
temperatures or disappear completely (Marques et al., 1990). Figure 3.4 A presents 
the DSC traces of CD, SA, SA-CD PM and SA-CD IC and Figure 3.4 B represents 
that for CD, IBF, IBF-CD PM and IBF-CD IC. 
The thermogram of CD exhibits a broad endotherm around 130°C due to the 
dehydration process.  
(A) Salicylic Acid: 
The thermogram of SA was typical of a crystalline anhydrous substance with a sharp 
endotherm at 153°C indicating its melting temperature (Rotich et al., 2003). In the 
endotherm of SA-CD PM, the dehydration endotherm from CD and the melting 
endotherm from free SA are both seen. On the contrary, the endotherm of SA-CD IC 
presents a shift in the CD endotherm and lacks the characteristic SA melting peak. 
Thus the DSC studies suggest the inclusion of SA in CD cavity.  
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Figure 3.4.  DSC thermograms of (A) CD, SA, SA-CD physical mixture, SA-CD 
inclusion complex and (B) CD, IBF, IBF-CD physical mixture and IBF-
CD inclusion complex. 
 (B) Ibuprofen:  
The melting of IBF was observed as a sharp endotherm at 77°C. The IBF-CD PM 
exhibits the endotherms of both CD and free IBF. The absence of free IBF melting 
endotherm in the IBF-CD IC and the shift of the CD endothermic transition to lower 
temperature range indicate the formation of the inclusion complex of IBF in CD 
(Salústio et al., 2009). 
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3.2.1.4 Optical Microscopic Analysis 
The morphology of CD, drugs, the physical mixtures and the ICs was visualized by 
optical microscopy. The images of CD (Figure 3.5A), SA (Figure 3.5B) and IBF 
(Figure 3.5E) indicate their crystalline nature. The photographs of the physical 
mixtures, SA-CD PM (Figure 3.5C) and IBF-CD PM (Figure 3.5F) show the presence 
of both the drug and CD crystals. However, the images of the ICs (Figures 3.5D & G) 
clearly demonstrate the formation of new entities possibly due to the inclusion 
complexation. 
 
Figure 3.5. Optical microscopic images of (A) CD, (B) SA, (C) SA-CD physical    
   mixture (D) SA-CD inclusion complex; and (E) IBF, (F) IBF-CD  
   physical mixture, (G) IBF-CD inclusion complex. 
 
3.2.1.5 
1
H NMR studies 
1
H NMR spectroscopy is one of the most useful techniques for investigating the CD 
complexes, particularly in the solution state. NMR spectra obtained from most of the 
CD complexes represent concentration weighted averages since proton exchange 
between the free and complexed guest molecule is usually fast in the NMR time scale. 
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The major advantage consists in the possibility to use several independent signals for 
the evolution of association constants, so being less prone to misinterpretations caused 
by minor impurities (Schneider et al., 1998).   
Direct evidence for the formation of drug-CD ICs can be obtained from 
1
H NMR 
studies. It is well known that CD has the topology of a hollow cone with H−3 and H−5 
being the inner protons. The hydrophobic guests get included in the toroidal cavity of 
CD thereby affecting the inner protons of the macrocycle (Figure 3.6). The change in 
chemical shifts of H−3 [Δ(δH−3)] and H−5 [Δ(δH−5)] between the protons of CD and 
IC suggest the inclusion process; when Δ(δH−3) > Δ(δH−5), the inclusion of the guest 
inside the cavity is partial, while Δ(δH−3) ≤ Δ(δH−5) indicates total inclusion of guest 
inside CD cavity (Greatbanks and Pickford, 1987). 
 
Figure 3.6. Truncated cone shape of CD cavity showing the positions of its protons. 
The 
1
H NMR spectra of CD, SA-CD IC and IBF-CD IC are shown in Figure 3.7 and 
the chemical shifts (δ) of the CD protons are listed in Table 3.2.  
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Figure 3.7. 
1
H NMR spectra of (A) CD, (B) SA-CD inclusion complex and (C) IBF-
CD inclusion complex in D2O at  298K. 
 
Table 3.2. δ and Δδ of protons in CD, SA-CD IC and IBF-CD IC 
 
Protons 
 
δCD 
SA−CD IC IBF−CD IC 
δ Δδ δ Δδ 
H−1 4.991 5.012 0.021 5.015 0.024 
H−2 3.561 3.532 0.029 3.563 0.002 
H−3 3.874 3.813 0.061 3.818 0.056 
H−4 3.496 3.471 0.025 3.522 0.026 
H−5 3.761 3.660 0.101 3.676 0.085 
H−6 3.790 3.760 0.030 3.744 0.046 
 
 
From Table 3.2, it is noteworthy that the H−3 and H−5 protons shifted ca. 0.061 ppm 
and 0.101 ppm in SA-CD IC and 0.056 ppm and 0.085 ppm in IBF-CD IC with 
respect to the native CD. Considering the changes in the chemical shifts of H−3 and 
H−5 of CD and the ICs, total inclusion of both SA and IBF in CD cavity are 
confirmed.  
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3.2.2 Characterization of Hydrogels 
The reaction scheme for cross-linking of PVA by GA in presence of HCl is 
represented in Scheme 3.2. The cross-linking occurs by the formation of acetal bridges 
between the pendant hydroxyl groups of PVA chains.  
 
Scheme 3.2. Cross-linking scheme of GA with PVA. 
 
3.2.2.1 FTIR Analysis  
Figure 3.8 A presents the FTIR spectra of P1 and P1-CD hydrogels. The FTIR 
spectrum of P1 hydrogel shows all the characteristic peaks of PVA. A large band at 
around 3400 cm
1
 is due to O-H stretching. The C-H stretching from alkyl group 
regions is observed at around 2935 cm
1
 and the peak at 1720 cm
1  
is attributed to the 
C=O stretching. The peak at 1140 cm
1 
is attributed to crystalline C=O stretching due 
to the semi-crystalline nature of PVA. The FTIR spectrum of P1C hydrogel showed 
the characteristic O-H and C-H peaks. However, the carbonyl stretching has been 
modified and the crystalline C=O peak is considerably reduced indicating the 
reduction in the crystallinity of the hydrogel upon incorporation of CD. Figures 3.8 B 
and C display the FTIR spectra of P1, P2, P3, P4 and P1-CD, P2-CD, P3-CD and P4-
CD hydrogels, respectively. It is evident that as cross-linking increases, there is a 
reduction in the crystalline nature of the hydrogels.    
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Figure 3.8. FTIR spectra of (A) P1 and P1-CD, (B) P1, P2, P3, P4 and (C) P1-CD, 
P2-CD, P3-CD, P4-CD hydrogels. 
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3.2.2.2 XRD Analysis   
Figure 3.9 A illustrates the wide-angle X-Ray diffraction traces of P1, P2, P3, P4 and 
Figure 3.9 B represents that of P1-CD, P2-CD, P3-CD, P4-CD hydrogels.  
 
 
Figure 3.9. XRD profiles of (A) P1, P2, P3, P4 and (B) P1-CD, P2-CD, P3-CD,       
P4-CD hydrogels. 
The PVA hydrogel with the lowest GA content (P1) shows a peak at around 
diffraction angle (2θ) of 19.8° similar to that of pure PVA, which is associated with 
the crystalline phase of PVA, PVA being a semi-crystalline polymer. With further 
increase in GA content, there is remarkable decrease of the crystalline reflection from 
PVA (Figure 3.9 A). It is well established that GA disrupts the crystalline phase of 
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PVA (Hari and Sreenivasan, 2001). Similar effect was also observed for CD 
containing hydrogels (Figure 3.9 B). These samples show a broad diffraction pattern. 
Hence it can be concluded from the FTIR and XRD data that higher content of GA 
and CD prevent the self-association of PVA chains rendering somewhat amorphous 
nature to the otherwise semi-crystalline PVA matrix. 
3.2.2.3 DSC Analysis  
Figures 3.10 A and B represent the DSC thermograms of P1, P2, P3, P4 and P1-CD, 
P2-CD, P3-CD, P4-CD hydrogels, respectively.  
 
 
Figure 3.10. DSC thermograms of (A) P1, P2, P3, P4 and (B) P1-CD, P2-CD, P3-CD, 
P4-CD hydrogels. 
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In the thermograms, the glass transition temperature (Tg) and melting temperature 
(Tm) are clearly seen. The glass transition temperature was found to decrease with 
increase in the GA content (Tg  68.7 
o
C for P1, Tg  67.5 
o
C for P2, Tg  67.2 
o
C for 
P3 and Tg  65.8 
o
C for P4), which implies that the increased cross-linking density 
results in a limited mobility of the polymer chains (Figueiredo et al., 2009). The 
melting enthalpy decreased with increasing GA content (Table 3.3). This property is 
related to the membrane crystallinity. The addition of GA to the polymer increases the 
distance between the chains, which makes the organization of PVA in crystalline 
lattices difficult resulting in the decrease in the melting enthalpy. This is also clear 
from the decreased degree of crystallinity with increasing cross-linking.  
The degree of crystallinity of the hydrogels has been calculated from the given 
equation: 
  
  
   
 
Where ΔH is the heat of melting of PVA hydrogels and ΔHc is the heat of melting of 
100% crystalline PVA which is 138.60 J/g (Peppas and Merrill, 1976; Hassan and 
Peppas, 2000).  
Table 3.3. Values of Tm, ΔH and X of hydrogels 
Sample Tm (°C)  ΔH  (J/g) X (%) 
P1 189.55 26.88 19.4 
P2 187.75 24.68 17.8  
P3 187.31 24.34 17.6 
P4 187.11 24.11 15.6 
P1-CD 181.00 25.77 18.6 
P2-CD 177.90 24.15 17.4 
P3-CD 177.79 22.17 16.0 
P4-CD 177.45 19.59 14.3 
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The P1-CD, P2-CD, P3-CD and P4-CD hydrogels show lower melting temperature as 
compared to the corresponding hydrogel without CD i.e. P1, P2, P3 and P4, 
respectively (Table 3.3). This can be due to the decreased crystallinity of the PVA 
matrix in presence of CD as evident from the degree of crystallinity values. For a 
given amount of GA; the degree of crystallinity of the PVA matrix without CD is 
relatively higher than that of the corresponding hydrogel with CD. The melting 
temperature (Tm) of these hydrogels was also found to decrease with increasing GA 
content, which can be attributed to the restricted mobility of chains due to combined 
effect of CD and increased matrix density due to cross-linking. 
3.2.2.4 SEM Analysis 
The SEM images of the lyophilized P1, P2, P3, P4, P1-CD, P2-CD, P3-CD and       
P4-CD hydrogels were captured under a voltage of 15 kV and 1000X magnification. 
The SEM images (Figure 3.11) revealed the morphological dependence of the 
synthesized hydrogels on the extent of cross-linking. As the concentration of GA was 
increased, a distinct difference in the morphology of the hydrogels was observed. The 
P1 and P2 hydrogels (Figure 3.11 A and B respectively) exhibited highly porous 
network structures with a spongy appearance. The morphology of P3 hydrogel (Figure 
3.11 C) was more of a fibrillar kind. However, the matrix structure tightened in 
presence of 0.1% of GA. As evident, the P4 hydrogel (Figure 3.11 D) is relatively 
denser and compact as compared to others. Similar morphological behaviour was 
observed for the P1-CD, P2-CD, P3-CD and P4-CD hydrogels. The P1-CD and       
P2-CD hydrogels (Figure 3.11 E and F respectively) appeared to be porous while the 
P3-CD hydrogel (Figure 3.11 G) was observed to be somewhat fibrillar. The P4-CD 
hydrogel (Figure 3.11 H) was found to be compact in nature, similar to that of P4 
hydrogel.  
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Figure 3.11. SEM images of (A) P1, (B) P2, (C) P3, (D) P4, (E) P1-CD, (F) P2-CD, 
(G) P3-CD and (H) P4-CD hydrogels. 
 
3.2.3 Equilibrium Swelling Studies 
The swelling characteristic of hydrogels has significant influence on the diffusion 
behaviour of small molecules and is an important parameter in deciphering the nature 
of hydrogels for drug delivery applications. Figure 3.12 A shows the equilibrium 
swelling of P1, P2, P3, P4 and Figure 3.12 B shows that of P1-CD, P2-CD, P3-CD 
and P4-CD hydrogels. With the increasing cross-linker percentage, there is a gradual 
decrease in the degree of swelling observed for both types of hydrogels. This can be 
rationalized by considering the morphological dependence of these hydrogels on the 
cross-linker concentration. As evident from the SEM studies, the hydrogels with lower 
degree of cross-linking are porous in nature and therefore can accommodate more 
water in their capillary pores resulting in higher swelling ability. The decrease in 
swelling with increased cross-linker concentration can be due to the increased matrix 
density, which restricted the inward flow of solvent molecules. 
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Figure 3.12. Swelling behaviour of hydrogels at pH=7.4 and 37°C, (A) P1, P2, P3, P4  
   and (B) P1-CD, P2-CD, P3-CD, P4-CD hydrogels. 
 
For a given cross-linker concentration, the swellability of pure PVA hydrogel is 
slightly higher than that of PVA hydrogels containing CD. This might be due to the 
formation of somewhat rigid hydrogel matrix upon incorporation of CD because of the 
hydrogen bonding interaction between the CD and PVA or the CDs getting cross-
linked to some extent in the presence of GA. 
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3.2.4 In Vitro Drug Release and Kinetics Studies 
3.2.4.1 Drug Release from Hydrogels 
Figure 3.13 shows the drug release profiles of SA from P4-D and P4-IC hydrogels. As 
evident, the release patterns differ significantly from the two hydrogel matrices.  
 
Figure 3.13. Release profiles of SA from P4-D and P4-IC hydrogels in pH 7.4 at  
   37°C. 
P4-D film shows almost a burst type release of drug and total drug release is observed 
in a short period. The presence of CD significantly prolonged the release of SA 
showing a sustained release pattern from P4-IC hydrogel. In the P4-D hydrogel, the 
drug is freely dispersed in the polymer matrix and the drug being a small molecule can 
easily diffuse to the releasing medium as the hydrogel swells. On the other hand, the 
P4-IC hydrogel contains the drug in the form of an inclusion complex with CD. For 
drug release process to be accomplished from P4-IC hydrogel, the bound SA must 
first be released to the polymer matrix followed by the diffusion of the free drug from 
the matrix. Thus the difference in release rates observed between the above two 
hydrogels can be attributed to the diffusion barrier imposed by CD in terms of 
inclusion process, resulting in a slow release of the drug from the CD containing 
hydrogel. However, it is known that even with simple blending of CD with PVA, it is 
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possible to achieve prolonged release of drug (Sreenivasan, 1997). In order to verify 
whether the inclusion property of CD is solely responsible for the slow release of drug 
from the hydrogels, drug release studies were carried out from PVA hydrogels 
keeping the CD and dug content same but varying the cross-linker concentration i.e. 
P1-IC, P2-IC, P3-IC and P4-IC hydrogels. The release studies from PVA hydrogels in 
absence of CD at varying cross-linker concentration (P1-D, P2-D, P3-D and P4-D 
hydrogels) were also carried out for comparison (Figure 3.14). 
 
 
Figure 3.14. SA release profiles from (A) P1-D, P2-D, P3-D, P4-D and (C) P1-IC, 
P2-IC, P3-IC, P4-IC hydrogels.  
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Figure 3.14 A depicts the SA release profiles from the P1-D, P2-D, P3-D and P4-D 
hydrogels and Figure 3.14 B from that of PVA hydrogels containing SA-CD IC     
(P1-IC, P2-IC, P3-IC and P4-IC hydrogels). As evident from the figures, there is a 
striking difference in the release patterns as the GA concentration is varied. The drug 
release profiles from the hydrogels containing SA-CD IC show a strong dependence 
on the degree of cross-linking. With increasing GA concentration the drug release is 
found to be considerably slower. On the other hand, for the hydrogels containing free 
drug, the effect of GA concentration on the release rate is almost insignificant and 
there is only a nominal decrease in the release rate with the increased GA 
concentration. Release of drug from any hydrogel is governed by various factors such 
as hydrogel swelling, diffusion of drug from the swollen matrix and polymer 
relaxation. Therefore any change in the hydrogel that affects the above factors can 
influence the drug release process. If hydrogel swelling and drug diffusion from the 
swollen matrix are the governing factors, then both types of hydrogels are expected to 
show similar release patterns with respect to varying cross-linker concentration since 
they exhibit similar swelling behaviour with increasing GA percentage. Thus the 
observed difference in the release patterns from these hydrogels with change in GA 
concentration can be rationalized only when the presence of CD is somehow 
influencing the polymer relaxation which in turn affects the drug release rate. Apart 
from cross-linking PVA, GA probably interacts with the hydroxyl groups of CDs and 
further cross-links the matrix. Thus, with increasing GA concentration more and more 
CDs get cross-linked, as a result the polymer matrix is modified and the drug release 
rate is reduced. Among all the hydrogels studied, P4-IC was found to show the 
slowest release of SA and hence can be utilized as a controlled delivery system. 
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In order to study the effect of the nature of drug on the release process, the release of 
IBF, a relatively hydrophobic drug (Garzon and Martinez, 2004) in comparison to SA 
(Shalmashi and Eliassi, 2008) was monitored from P4-D and P4-IC hydrogels. 
 
Figure 3.15. Comparison of release profiles of SA and IBF from P4-D and P4-IC  
    hydrogels. 
Figure 3.15 shows the release profiles of IBF from P4-D and P4-IC hydrogels; the 
release profiles of SA from the same hydrogels are also included for comparison.  As 
expected, a sustained release for IBF was obtained from the P4-IC hydrogel as 
opposed to burst release from the P4-D hydrogel similar to that of SA. When SA and 
IBF releases are compared from P4-D hydrogel, there is not much of difference but 
from the P4-IC hydrogel the release of IBF is further prolonged than that of SA. The 
difference in the rates of release of IBF and SA can be explained by taking into 
account the binding efficiencies of the two drugs with CD. The association constant 
for IBF with CD (KIBF- CD 10
3
 M
1
) is almost an order higher than that for SA (KSA- CD 
= 119 ± 6 M
1
) (Belyakova and Lyashenko, 2008; Hergert and Escandar, 2003; 
Manzoori and Amjadi, 2003). Stronger the binding efficiency between the CD and the 
drug, slower is the diffusion of drug from the CD resulting in the slower release of 
drug from the hydrogel matrix. Thus the nature of drug in terms of its binding 
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efficiency with CD plays an important role in the drug release process from these 
hydrogels.  
3.2.4.2 Drug Release Kinetics 
The fundamental kinetic analyses of the drug release data can reveal the probable 
mechanism of release from the hydrogels. The release data showed the best fit to 
Ritger-Peppas and Peppas-Sahlin models in all cases (Table 3.4). The values of the 
diffusional exponent (n) lie between 0.5 and 1 for all the hydrogels except for P4-IC. 
The value of n between 0.5 and 1 indicates the anomalous nature of drug release from 
these hydrogels, where both diffusion and relaxation processes contribute. From the 
Peppas-Sahlin equation, it was discovered that the diffusion kinetic constant (k1) 
dominates over the relaxation kinetic constant (k2) for P1-D, P2-D, P3-D and P4-D 
hydrogels.  
It is not possible to know exactly the contribution of the Fickian and Case II 
mechanism from the estimated values of k1 and k2 alone (Peppas and Sahlin, 1989), 
hence the ratio of the relaxational over Fickian contributions (R/F) was calculated for 
the hydrogels and plotted against the fraction of the drug released from these 
hydrogels (Figure 3.16).  
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Figure 3.16. Plot of ratio of relaxation to the Fickian contribution (R/F) with the 
   fraction of SA release for (A) P1-D, P2-D, P3-D P4-D and (B) P1-IC,  
   P2-IC, P3-IC, P4-IC hydrogels. 
 
The values of R/F for the P1-IC, P2-IC, P3-IC, P4-IC hydrogels were found to be 
higher than the corresponding P1-D, P2-D, P3-D, P4-D hydrogels. The fractional 
values of R/F clearly indicate the predominance of the diffusion process over the 
relaxation process and with the increased GA content, the R/F value also increases. 
The high value is suggestive of the greater polymer relaxation of the P4-IC hydrogel 
than others. For a given GA percentage the value of n is slightly higher for the 
hydrogels containing drug-CD IC as compared to those containing free drug. For P1-
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IC, P2-IC and P3-IC hydrogels the diffusion kinetic constant (k1) dominates over the 
relaxation kinetic constant (k2) very similar to that observed for P1-D, P2-D, P3-D and 
P4-D hydrogels. And with the increased GA concentration the R/F value was found to 
increase. The P4-IC hydrogel, however, showed Case II transport mechanism (n =1) 
associated with the dominant relaxational release of drug which is evident from the 
lower magnitude and negative values of diffusion rate constant k1 for both SA and IBF 
release. This is further supported by the fact that the release data from this film fit 
quite well to the zero-order kinetics. Thus the presence of CD at high cross-linker 
concentration influences the relaxation rate of the polymer chains, and further slows 
the release of the drug from the hydrogel matrix. This can be explained by taking into 
account that GA not only cross-links the PVA chains but also interacts with the 
hydroxyl groups of CDs thereby influencing the matrix structure (Bibby et al., 2000). 
Thus from the above studies it is clear that the role of CD in the drug release process 
is not only because of its inclusion ability but also its effect on the polymer relaxation. 
In other words, it is the combined effect of drug diffusion and polymer relaxation that 
controls the overall drug release process from the hydrogels containing IC. 
3.2.5 Cytotoxicity Assay  
While designing a material for drug delivery purposes, it is of utmost importance to 
characterize it in terms of cytotoxicity. In vitro cell culture studies are quite useful in 
assessing cytotoxicity. The effects of cells exposure to chemical agents at different 
concentrations and times can be determined by assessing cytotoxicity. In the 
biocompatibility evaluation of any biomaterial, in vitro tests should be conducted prior 
to in vivo tests in order to reduce animal suffering. Though the in vitro cytotoxicity 
assays reveal only the effects on cells during the initial 12−48 h after exposure to the 
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test substances, these assays provide a general idea about the biocompatibility and 
toxicity of the synthesized biomaterial.  
In order to test the biocompatibility of the prepared hydrogels, cytotoxicity assay was 
performed on P4-CD hydrogel. As shown in Figure 3.17, direct contact between       
L-929 cells and P4-CD hydrogel sample did not reveal any adverse effect. No cell 
death or effect on cell morphology was observed under the microscope. This 
suggested a high compatibility of the hydrogels with the living tissues thereby 
validating them as potential drug delivery systems. 
 
       
Figure 3.17. Optical Micrographs of L-929 cells cultured after 48 h incubation with  
   P4-CD hydrogel.  
3.3 CONCLUSIONS 
 PVA and PVA−CD hydrogels were synthesized with varying amounts of the 
cross-linker GA. Hydrogels were characterized by FTIR, XRD, DSC and 
SEM. 
 The solid ICs of SA and IBF in CD were prepared via co-precipitation method 
and affirmed from FTIR, XRD, DSC, Optical microscopy and 
1
H NMR 
studies.  
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 The swelling evaluation indicated the decreased swelling with the increasing 
cross-linker content for both PVA and PVA-CD hydrogels. For a given GA 
concentration, the swellability of PVA hydrogel is slightly higher than that of 
PVA-CD hydrogels.  
 The presence of IC in the hydrogel resulted in the sustained release of drug for 
a prolonged period of time. With increase in GA content, the rate of drug 
release was found to reduce. The influence of cross-linking was more 
pronounced in the hydrogels containing the ICs of the drug.  
 The rates of release of SA and IBF also varied greatly from the P4-IC hydrogel 
because of the difference in their binding efficiencies with CD. Higher is the 
binding of the drug with CD, slower is the release. 
 The preliminary kinetic analysis revealed the anomalous nature of drug release 
from the P1-D, P2-D, P3-D, P4-D, P1-IC, P2-IC and P3-IC hydrogels 
indicating the importance of drug diffusion over polymer relaxation. The     
P4-IC hydrogel, however, showed Case II transport mechanism indicating the 
dominant relaxational process.  
 GA, apart from cross-linking PVA, probably interacts with the hydroxyl 
groups of CDs thereby influencing the matrix structure.  
 The drug release is accomplished as a combination of the effects of drug 
diffusion, the hydrogel polymer relaxation, and the binding affinity of the 
drugs with CD.  
 The cytotoxicity tests performed on the hydrogels ensured the hydrogels as 
biocompatible hence can be utilised as controlled drug delivery systems. 
 Hence the strategy of incorporating pre-formed ICs into PVA hydrogels to 
achieve controlled delivery of drugs works quite well.  
                                                                                                                    Chapter 4 
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4.1 INTRODUCTION 
Oral route of drug administration accounts for about 80% of the available drugs 
worldwide. It is the most preferred form of drug formulation, because of the ease of 
administration. However, the conventional oral formulations lack the feature of 
controlled drug delivery and site-specificity. Thus, the oral drug delivery systems 
targeting the lower part of the GIT, including the intestine and colon, has attracted 
much interest for the local treatment of a variety of colonic diseases and the delivery 
of an array of therapeutic agents (Jose et al., 2009). The intestine as well as colon, are 
susceptible to various disorders such as Crohn's disease, irritable bowel syndrome 
(IBD), ulcerative colitis, colon cancer, polyps etc. that require localized drug therapy 
(Chourasia and Jain, 2003). Thus, proper site-specific delivery of drugs is beneficial in 
the effective treatment of such diseases. Additionally, the lower gut offers various 
therapeutic advantages as a site of drug delivery due to its near neutral pH and longer 
transit time as compared to stomach, where a harsh environment is experienced due to 
the low pH. Colon is often regarded as an ideal site for both systemic and local 
delivery of drugs. It is also favourable for systemic absorption of proteins and peptides 
because the proteolytic activity of the colonic mucosa is much less than that observed 
in the small intestine.  
For targeted delivery of drugs to the intestine or colon, the dosage must be formulated 
by taking into account the hindrances offered by the upper GIT. The successful 
delivery of a therapeutic to the lower part of the GIT lies not only in the protection of 
the drug from its premature degradation in the extreme conditions of the stomach but 
also ensuring its release in the proximal colon (Vats and Pathak, 2013). Various drug 
delivery systems are in the pipeline to deliver a drug quantitatively to the intestine and 
then trigger the release in therapeutic doses. The delivery systems targeting to the 
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intestine and colon mainly include (i) time-dependent delivery systems based on 
gastric emptying time and small intestine transit time, (ii) microbial-triggered delivery 
systems which make use of the fact that the degradability of the delivery device occurs 
by the microflora present in the colon and (iii) pH-sensitive delivery systems based on 
the changes in the pH of the GIT (Yin et al., 2001). 
Stimuli-sensitive polymers have become quite an important class of polymers and 
have received much attention in the areas of pharmaceutics and related research fields. 
Also termed as "smart" or "intelligent" or "environment-sensitive", these polymers 
exhibit dramatic conformational changes in response to small changes in the external 
factors such as pH, temperature, light, electric field, ionic strength, etc. In particular, 
such polymers have found great utility in the fields of controlled and self-regulated 
drug delivery. Thus stimuli-responsive polymers can be designed to produce specific 
and desired response according to the variations in the physiological environment of 
human body. Proton concentration (pH) is an imperative stimulus and has intrinsic 
variations depending on the differences in the pH of the human body. pH-responsive 
drug delivery systems are endowed with the unique ability to sense macro- or micro-
environments in organs, tissues, cells and subcellular compartments viz. blood (pH 
7.35 ~ 7.45), stomach (pH 1.0 ~ 3.0), duodenum (pH 4.8 ~ 8.2), colon (pH 7.0 ~ 7.5), 
early endosomal (pH 6.0 ~ 6.5), late endosomal (pH 5.0 ~ 6.0), lysosome (pH 4.0 ~ 
4.5), golgi (pH 6.4), extratumoral (pH 7. 2 ~ 6.5), etc. (Huh et al., 2012). Drug 
delivery studies with particular interests in the human GIT have been most 
pronounced due to pH fluctuations (pH 1 ~ 8) and have led to the development of an 
assortment of controlled delivery formulations. Prodrugs, liposomes, micelles, 
microchips etc. have been designed to respond to different pH environments and 
facilitate controlled delivery of therapeutics. Although new technologies have 
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evolved, pH-sensitive polymers still remain the most popular entities for drug delivery 
development. Due to their flexibility in terms of design, synthesis and cost 
effectiveness, these polymers are accountable for most of the drug delivery 
formulations. pH-responsive polymers can be sculpted into various architectures 
including tablets, capsules, microbeads, microspheres, nanoparticles, micelles, 
nanobeads, liposomes and hydrogels etc. The review article by Yoshida and co-
authors (2013) discusses about pH-responsive polymers and their specific properties 
that can be exploited for targeted delivery of drugs.  
In this context, pH-responsive smart hydrogel is both an outstanding innovation and 
contribution to pharmaceutical arenas in general, and drug delivery in particular. Over 
the past few decades, a great many research has been dedicated for the development of 
pH-sensitive hydrogels (Gupta et al., 2002; Gil and Hudson, 2004; Puoci and Curcio, 
2013). Many natural and synthetic polymers have been utilized in the fabrication of 
pH-sensitive hydrogels as controlled drug delivery systems. The pH-responsive 
polymers are either equipped with a pendent acidic group (carboxylic/ sulfonic acids) 
or basic group (e.g. ammonium salts) that accept or release protons in response to 
changes in the environmental pH. These pendant acidic or basic groups undergo 
ionization which ultimately affects the swellability of the hydrogel. Thus the pH-
responsiveness can be tailored by using different polymers as per requisites.  
Numerous pH-sensitive polymeric hydrogels containing linear polymers, grafted 
polymers, IPNs, semi-IPNs, etc. have been developed and investigated for 
pharmaceutical purposes. Some of the commonly used pH-responsive polymers 
employed in the design of pharmaceutical formulations are listed in Table 4.1. 
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Table 4.1. Commonly employed pH-sensitive polymers 
Charge Type Polymer Name 
 
Anionic 
Natural: Hyaluronic acid, Alginic acid, CMC, poly(aspartic 
acid), carboxymethyl dextran etc. 
Synthetic: poly(acrylic acid), PHEMA, polystyrene sulfonate, 
sulfoxyethyl methacrylate, etc. 
 
Cationic 
Natural: Chitosan, Polylysine, Polyhistidine etc. 
Synthetic: poly(N, N'− diethylaminoethyl methacrylate), 
PAAm, diallyldimethyl ammonium chloride, poly (N, N'− 
dimethylaminoethyl methacrylate) etc. 
  
Among all the polymers listed above, the natural polymer chitosan has been 
extensively employed in the design of pH-sensitive hydrogels while poly(acrylic acid)  
finds greater demand as a pH-responsive synthetic polymer.  
4.1.1 CHITOSAN  
Chitosan (CS) is a well-known pH-responsive natural polymer. CS [α (1→4) 
2−amino−2−deoxy−β−D−glucan] is a cationic polymer obtained by the alkaline 
N−deacteylation of the naturally occurring polymer, chitin. Chitin, the supporting 
material of crustaceans, insects and fungal mycelia is comprised of 2−acetamido−2-
deoxy−β−D−glucose through a β (1→4) linkage. Chitin is a highly insoluble, hard and 
inelastic nitrogeneous polysaccharide resembling cellulose in its solubility and 
chemical reactivity. Chitin may be regarded as cellulose with the hydroxyl position at 
C−2 replaced by an acetamido group. Both chitin and CS are of commercial 
significance due to their high percentage of nitrogen as compared to synthetically 
substituted cellulose (Muzzarelli, 1973). The chemical structures of cellulose, chitin 
and CS are shown in Figure 4.1. 
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Figure 4.1. Chemical structures of cellulose, chitin and chitosan (CS). 
The degree of N−deacetylation of CS is the deciding factor for its properties. This 
N−deacetylation degree is the ratio of the 2−acetamido−2−deoxy−D−glucopyranose 
to the 2−amino−2−deoxy−D−glucopyranose structural units. This ratio has a 
remarkable effect on the solubility and the properties of CS. It is soluble in dilute 
acids such as formic acid, acetic acid and hydrochloric acid. The nitrogen content of 
CS in the form of primary aliphatic amino groups makes it a highly reactive polymer. 
It undergoes the typical reactions of amines such as N−acylation, Schiff base 
formation and chelation with metal ligands. On the biological front, CS has the 
advantages of being biodegradable, biocompatible, non-toxic, bioabsorbable, 
mucoadhesive and possessing antimicrobial and wound healing properties (Bhattarai 
et al., 2010).  
The principal relevance of CS in pharmaceutical fields is in surgical sutures, dental 
implants, artificial skin, bone regeneration and contact lenses (Ravi Kumar, 2000). 
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Apart from these, CS shows promising features as an auxiliary agent in drug delivery. 
In contrast to all other biodegradable polymers having a monograph in a 
pharmacopeia, CS is the only one exhibiting a cationic character that makes it unique 
among others. This cationic character is due to its primary amino groups that are 
responsible for its various properties. These amino groups can easily be protonated in 
acidic medium thus making it soluble. This property therefore renders pH-
sensitiveness to CS. The mucoadhesive properties, permeation enhancing effect and in 
situ gelling nature of CS are based on its cationic character. The mucoadhesive nature 
of CS has proven beneficial for the absorption of drugs, especially at neutral pH. CS 
has recently been explored for tissue engineering applications including cartilage, 
bone, liver and nerve tissues (Croisier and Jerome, 2013). Tissue engineering is aimed 
at developing biocompatible substitutes to restore, maintain or improve biofunction of 
dysfunctional human tissues or organs. Since CS is biodegradable and non-toxic, it 
has been formulated into films, gels or powders to improve the cell seeding (Dash et 
al., 2011). In bone tissue engineering, CS has been shown to promote cell growth and 
mineral rich matrix deposition. In cartilage tissue engineering, glycosamine glycans 
(GAGs) play a vital role in modulating chondrocytes morphology, differentiation and 
function (Grande et al., 1997). CS, bearing structural similarity to GAGs, is chosen as 
the preferred scaffold material for cartilage tissue engineering. In liver tissue 
engineering, the bio-artificial liver requires an extracellular matrix for surrounding the 
liver stem cells (Wang et al., 2005). CS serves as the scaffold material for the 
hepatocytes culture due to its resemblance to the extracellular matrix. In nerve tissue 
engineering, artificial tubes are the effective means to repair injured nerves. CS is 
suitable for nerve regeneration because of its biocompatible, biodegradable and 
bioadhesive properties (Dash et al., 2011).         
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In the areas of wound-healing, an ideal dressing should protect the wound from 
bacterial infection, provide a moist and healing environment, and be biocompatible 
(Wu et al., 2003). CS, as a wound-healing agent, induces wound-healing on its own 
and produces less scarring. It enhances the vascularisation and the supply of chito-
oligomers at the lesion site. CS hydrogels can also deliver drugs to the local wound 
and facilitate the healing process. While acute wound-healing can be enhanced by CS 
alone, due to its attractive properties for neutrophils, chronic wounds have also been 
healed by CS. Here the slow release of growth factors can produce more effective 
results. A CS hydrogel scaffold impregnated with β−fibroblast growth factor-loaded 
microspheres has been developed by Park et al., (2009) that accelerates wound closure 
in the treatment of chronic ulcers.  
CS has effectively been utilized in drug delivery as a hydrogel system, drug conjugate, 
biodegradable release system and polyelectrolyte complex for many systems. CS 
based hydrogel systems are used for the delivery of proteins/ peptides, growth factors, 
antibiotics, anti-inflammatory drugs, as well as in gene therapy and bio-imaging 
applications. CS is degraded by the normal microflora of the colon and is not digested 
in the upper gastrointestinal tract (Cheng et al., 1994). By making use of this 
colon−specific degradation, CS has been discovered as a useful tool in order to 
guarantee a site specific delivery. CS hydrogels are favoured in the development of 
numerous drug delivery systems for various application sites which include oral, 
ocular, nasal, buccal, parenteral, transdermal, vaginal, rectal, intravesical and colonic 
areas (Ravi Kumar, 2000; Bhattarai et al., 2010; Hu et al., 2013; Uchegbu et al., 
2014).  
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4.1.2 POLY(ACRYLIC ACID) 
Poly(acrylic acid) (PAA) has been widely employed as a synthetic pH-sensitive 
polymer for drug delivery applications. Acrylic based hydrogels are generally 
regarded as safe excipients. Moreover the mucoadhesive properties of these polymers 
make them suitable for increasing the drug residence time of the delivery device at the 
absorbing tissue thereby increasing the drug bioavailability (Cheddadi et al., 2011). 
The pH-sensitivity of PAA is attributed to the ionization of the carboxylic acid groups 
in its backbone. Such polymers that consist of a large number of ionizable groups in 
their backbone are called as polyelectrolytes. Figure 4.2 shows the pH-dependent 
ionization behaviour of PAA which is ionized in higher pH. This ionization behaviour 
tend to make the apparent dissociation constant different from that of the 
corresponding monoacid or the monobase. The presence of ionizable groups also 
affects the swellability of the hydrogels. Since the swelling of these hydrogels is 
greatly influenced by the electrostatic repulsions among the charges present in the 
polymer chain, any change in the pH of the medium affects the extent of swelling. 
 
Figure 4.2. pH-dependent ionization of PAA.  
However, the application of pure PAA is limited because of the fast release of the 
drug due to its extensive swelling in water. Moreover, PAA tend to dissolve at high 
pH solution. The most commonly used strategy to alleviate these problems is to 
prepare three-dimensional polymeric network by physical or chemical cross-linking or 
incorporation of PAA in an IPN (Abd El-Rehim et al., 2007). PAA has been blended 
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with many polymers to fabricate IPN hydrogels with improved mechanical and 
chemical characteristics. Polymers such as CS (Wang et al., 2009), PVA (Ray et al., 
2010), PEG (Doulabi et al., 2013), PNIPAAm (Li and Liu, 2008) and others have 
been successfully employed to design such hydrogels.  
Hydrogels composed of PAA can be used for formulations that can deliver drugs at 
neutral pH. To render colon specificity to such hydrogels, PAA has been cross-linked 
with azoaromatic cross-linkers. The magnificence of these hydrogels lies in the fact 
that there occurs minimal swelling in the gastric region thereby restricting the drug 
release. As it moves down the intestinal region, the swelling increases which releases 
the drug. Moreover, the azo cross-links can only be degraded by the azoreductase 
enzymes synthesized by the colonic microflora. Thus, PAA hydrogels can be tailored 
into a variety of formulations to ensure optimal drug release.  
Hydrogels comprised of 2-vinyl pyridine and AAc were developed by Maziad and co-
workers (2009) to study the release of water-soluble chloramphenicol drug.  Recently, 
in a novel approach by Jiang et al., (2013), pH-sensitive organic-inorganic copolymers 
based on polyhedral oligomeric silsesquioxane (POSS) and PAA were developed as 
DDS for theophylline. Low amount of drug was released in SGF and the addition of 
POSS prolonged the drug release time significantly. Poly[(NVP-AAc)-PEG] 
hydrogels were prepared by free radical polymerization and employed for the delivery 
of 5-Fluorouracil (Ravichandran et al., 1997). The hydrogels swelled extensively in 
SIF than SGF suggesting possible applications of localized drug delivery. 
Biodegradable thermo- and pH-sensitive hydrogels based on hydroxypropyl cellulose-
g-AAc have been developed for controlled delivery applications of the protein BSA 
(Zhang et al., 2011). Hosseinzadeh and coworkers (Hosseinzadeh, 2010) have 
investigated the controlled release of diclofenac sodium from carrageenan-g-PAA 
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superabsorbent hydrogel and found favourable release profiles in SIF. Singh and 
Sharma (2010) have exploited the potential of psyllium-PVA-AAc based hydrogels 
for the delivery of the antibiotic drug tetracycline HCl. CD cross-linked microspheres 
of PAA have been constructed for controlled delivery of dyes (Bibby et al., 1999) and 
drugs (Kutyla et al., 2013). Microsphere of copolymers containing PAA and CD have 
also been studied for sorption studies (Guo and Wilson, 2012).   
OBJECTIVES 
The objective of this chapter is to design pH-responsive smart hydrogels based on CS 
and PAA for controlled drug delivery. This chapter consists of two parts;  
 Part I: To explore the potential of GA cross-linked CS−PVA hydrogels 
towards the controlled delivery of NSAIDS, Naproxen and Diclofenac 
sodium, to the intestine. 
 Part II: To inspect the utility of PAA hydrogel microspheres towards 
controlled delivery of Dexamethasone and investigate the influence of method 
of preparation of IC on the drug release phenomenon from the microspheres. 
    
  
                                                                                                                    Chapter 4 
 
 
 
 
 
 
 
         PART−I 
 
CHITOSAN−POLY(VINYL ALCOHOL) 
INTERPENETRATING POLYMERIC NETWORK 
HYDROGELS FOR SUSTAINED RELEASE OF NON-
STEROIDAL ANTI-INFLAMMATORY DRUGS  
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4.2 INTRODUCTION 
The potential applications of CS as drug carriers have been quite well acknowledged. 
The principal uses of CS in oral formulations and also in parenteral drug delivery 
devices are also well listed. The relevance of CS hydrogels in nasal, ophthalmological, 
renal, rectal and colon drug delivery has been aptly justified (Bhattarai et al., 2010). 
However, the inherent shortcomings associated with pure CS hydrogels cannot be 
ignored. They are highly porous, lack mechanical strength and tend to absorb moisture 
(Don et al., 2002). Moreover as CS precipitates at pH > 6.5; it loses its mucoadhesive 
and permeation enhancing properties in the distal segments of the intestine. This effect 
reduces its applicability for drugs having their absorption window in the proximal 
segment of the GIT.   
Incorporation of CS in an IPN hydrogel improves the mechanical strength of the 
conventional hydrogel. In the IPNs, CS is incorporated with either hydrophilic 
polymers or with hydrophilic monomer(s) treated to bring about in situ 
copolymerization in the presence of a suitable cross-linking agent. The formation of 
IPN produces an advanced multi-component polymeric system with superior physico-
chemical properties.  
PVA, because of its ease of film formation, long-term temperature and pH stability, 
has established itself as a potential supporting material in IPN fabrication. Hydrogels 
based on PVA and CS have emerged as one of the promising biodegradable materials 
due to their highly controllable and other advantages of non-toxic, non-carcinogenic 
and bioadhesive properties. Huge efforts have been made to prepare CS−PVA 
hydrogels and their potential in drug delivery systems is being extensively studied. 
CS−PVA hydrogels cross-linked by tetraethyl orthosilicate (TEOS) have been 
developed by Islam and co-workers (2013) and their structural and visco-elastic 
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properties were evaluated. The potential of the developed hydrogels in drug delivery 
was also investigated from the in vitro release studies of progesterone. The 
cytotoxicity evaluation on human fibroblast cells demonstrated the hydrogels to be 
nontoxic and biocompatible in nature. Khan and Ranjha (2014) have recently prepared 
low viscous CS−PVA hydrogels cross-linked by GA and inspected the effect of cross-
linking on the swelling and drug release behaviour of the hydrogels. Diphenhydramine 
HCl was chosen as the model drug and its release characteristics were observed in 
buffer solutions of pH 1.2, 5.5 and 7.5. The developed hydrogels were found to be 
suitable for the oral delivery of the chosen drug. In a very recent study by Lejardi et 
al. (2014), CS−PVA hydrogels were synthesized by cross-linking with glycolic acid. 
The hydrogels were found to possess enhanced rheological properties and their 
thixotropic behaviour can be utilized as injectable materials for biomedical 
applications. CS−PVA IPN hydrogels cross-linked by GA and also by −irradiation 
were tested for their delivery efficacy for 5FU (Abdelaal et al., 2007). The release of 
the drug from both types of hydrogels was found to be directly dependent on the PVA 
content indicating a slow release in neutral medium. Blend hydrogel microspheres of 
PVA and succinyl CS produced by water-in-oil emulsion cross-linked with GA were 
explored for delivery of nifedipine (Kajjari et al., 2013). The review article by Ranjha 
and Khan (2013) discusses the biomedical applicability of CS−PVA IPN hydrogel 
networks at length. 
The focus of this chapter is to design pH-sensitive CS−PVA hydrogels towards 
controlled and intestine-targeted delivery of NSAIDS, NX and DS. NSAID, as the 
name implies are compounds of non-steroidal origin, with the capability of inhibiting 
or reducing inflammatory responses associated with tissue injury due to physical 
trauma, noxious chemicals or microorganisms. NSAIDs are widely used for the 
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purpose of anti-inflammation, antipyretic and analgesia. They are also used for the 
alleviation of pain, fever, and inflammation associated with rheumatoid arthritis, 
gouts, fractures, sports injuries and musculoskeletal pain. Naproxen 
((S)−6−methoxy−β-methyl−2−napthalene acetic acid) (NX) (Figure 4.3A), a member 
of the family of the arylpropionic acids and  diclofenac sodium (sodium− (o− ((2,6− 
dichlorophenyl)− amino)− phenyl)− acetate) (DS) (Figure 4.3B), a phenylacetic acid 
derivative, are potent NSAIDs. NX and DS are commonly employed in everyday life 
as anti-inflammatory agents. 
 
Figure 4.3. Chemical structure of (A) Naproxen (NX) and (B) Diclofenac Sodium 
(DS). 
 
However, the use of NSAIDs is usually associated with the deleterious effects on the 
epithelium of the GIT. Thus, targeting of the NSAIDs to the intestine reduces the risks 
of gastrointestinal irritation and also ensures the proximal delivery of the drug.  
OBJECTIVES 
 The specific objectives of the present study are:   
 Preparation of solid ICs of NX and DS with CD and affirm the formation of 
ICs by various spectroscopic techniques 
 Synthesis of GA cross-linked CS−PVA and CS−PVA−CD hydrogels of 
varying composition and their characterization 
 Study of the antimicrobial properties of CS−PVA hydrogels 
 To evaluate the pH-responsive swelling characteristics of the hydrogels. 
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 To explore the drug release behaviour of the hydrogels containing free drug 
and the ICs. 
 To investigate the pH-responsive drug delivery behaviour in SGF and SIF for 
the oral delivery of the drugs. 
 To address the preliminary kinetics and the effect of CD on the drug release 
mechanism of the hydrogels. 
The compositions of various CS−PVA hydrogels are shown in Table 4.2.  
Table 4.2. Compositions of synthesized hydrogels 
 
Sample 
 
CS: PVA 
(wt%) 
Sample Designation 
CS−PVA CS−PVA−CD CS−PVA−Drug CS−PVA−IC 
1 1:0 CS CS-CD CS-D CS-IC 
2 1:1 CP11 CP11-CD CP11-D CP11-IC 
3 1:3 CP13 CP13-CD CP13-D CP13-IC 
4 1:5 CP15 CP15-CD CP15-D CP15-IC 
 
The CS-PVA hydrogels containing free NX are represented as CP11-NX, CP13-NX 
and CP15-NX while the hydrogels containing the free DS are labelled as CP11-DS, 
CP13-DS and CP15-DS. For the NX release studies IC represents the NX-CD IC and 
for the DS release studies IC represents the DS-CD IC. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Characterization of CS−PVA Hydrogels 
 
In the present study, GA has been employed as the cross-linking agent. It reacts with 
the hydroxyl groups of PVA and amino groups of CS producing a cross-linked 
network. The cross-linking reaction between CS and GA, which is a typical Schiff 
base reaction, is dominant to form the three-dimensional cross-linked network of 
CS−PVA hydrogel. The reaction scheme for the cross-linking of CS and PVA with 
GA is shown in Scheme 4.1.  
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Scheme 4.1. Cross-linking reaction scheme of CS and PVA with GA. 
4.3.1.1 FTIR Analysis  
The FTIR spectra of pure CS, pure PVA, CP11, CP13 and CP15 hydrogels are 
presented in Figure 4.4. 
 
Figure 4.4. FTIR spectra of pure CS, PVA, CP11, CP13 and CP15 hydrogels.  
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The characteristic CS peaks include the peaks at 893 cm
−1
 and 1155 cm
−1
 due to the 
pyranose ring and saccharin structure of CS.  The broad band around 3300−3000 cm−1 
is due to the N–H stretching. The bands at 2922 and 2810 cm−1 represent the C−H 
aliphatic stretching vibrations. The three bands appearing at 1657, 1560 and 1254 
cm
−1 are assigned to amide−I, amide−II and amide−III of chitosan (Angadi et al., 
2010). The typical PVA peaks include a large band at 3400 cm
−1
 (O−H stretch), the 
peaks at 2395 cm
−1
 (C−H stretch from alkyl groups), 1720 cm−1 (C=O stretch) and 
1140 cm
−1
 (crystalline C=O stretch of semi-crystalline PVA). In the FTIR spectra of 
the IPN hydrogels, the amide groups of CS are still evident and the key PVA peaks are 
also seen but with a small shift in their positions. A peak at 1654 cm
−1
 is observed in 
all the IPN samples which is associated with the imine group formed by the 
nucleophilic reaction of the amine of CS with GA. The characteristics carbonyl peak 
of PVA is visibly modified in the IPN hydrogels which can be due to the cross-linking 
reaction. The peak at 1140 cm
−1 
of PVA has reduced significantly indicating the loss 
in the regularity of PVA polymer chains due to inter-polymer interaction. 
4.3.1.2 XRD Analysis 
Figure 4.5 A projects the diffraction profiles of PVA and CS. PVA shows a broad 
peak centred at 2θ value of 19.8° due to its semicrystalline nature. Pure CS shows a 
typical strong diffraction around 20° and a relatively weak diffraction peak at around 
9.5° (Kolhe and Kannan, 2003). The XRD profiles of CP11, CP13 and CP15 
hydrogels are depicted in Figure 4.5 B. The IPN hydrogels showed single broad peak 
of relatively lower intensity as compared to pure CS and PVA hydrogels. This 
indicates that the IPN hydrogels exhibit somewhat reduced crystallinity. The weak 
diffraction peak of CS around 9.5° is completely missing in the IPN hydrogels 
indicating the proper blending of the two polymers in the IPN. The relative shifts in 
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the 2θ positions in the IPN hydrogels with respect to the pure components suggested 
that the intermolecular interaction disturbed the regularity of the component polymers 
(Tang et al., 2009). 
 
 
 
 
Figure 4.5.  XRD profiles of (A) CS, PVA and (B) CP11, CP13, CP15 hydrogels. 
 
4.3.1.3 DSC Analysis 
DSC analysis is an important criterion to determine the miscibility of two polymers. 
The DSC thermograms of neat PVA, CP11, CP13 and CP15 hydrogels are shown in 
Figure 4.6. CS crystallinity could not be detected by DSC analysis, though it presents 
some crystallinity when analysed by certain other techniques. As reported by Lee and 
 Chitosan−PVA IPN Hydrogels................ NSAIDs 
134 
 
co-workers (2000), CS has a rigid-rod backbone having strong inter- and/ or intra-
molecular hydrogen bonding and its thermal transitions could not be detected by DSC. 
 
Figure 4.6. DSC thermograms of pure PVA, CP11, CP13 and CP15 hydrogels. 
Neat PVA exhibited a melting temperature (Tm) at around 190°C. From the DSC 
traces of CP11, CP13 and CP15 IPN hydrogels; it was evident that the Tm shifted to 
slightly lower temperatures as compared to pure PVA. This indicates that the ordered 
association of the PVA chains was somewhat perturbed in presence of chitosan in the 
IPNs. Moreover, the presence of cross-linking is also known to cause a decrease in the 
polymer chain mobility that results in lowering of Tm. For the IPN hydrogels the Tm 
was found to increase with increase in PVA content i.e. CP15  CP13  CP11.  From 
the DSC thermograms, it is clear that in the IPN hydrogels the two polymers have 
good miscibility. 
4.3.1.4 Morphological analysis 
The morphology of the freeze-dried CS and the IPN hydrogels were observed under 
SEM. The hydrogels were freeze-dried so as to maintain their bulk structure and 
prevent the collapse of the matrix networks. The SEM images of the hydrogels are 
presented in Figure 4.7. Pure CS exhibits a highly porous structure (Figure 4.7 A). The 
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effect of PVA content on the hydrogel morphology was examined. The photographs 
clearly illustrate the dependence of hydrogel morphology on the PVA content. 
 
 
 
Figure 4.7. SEM micrographs of (A) CS, (B) CP11, (C) CP13, (D) CP15,                  
   (E) CP15-CD and after release (F) CP15, (G) CP15-CD hydrogels. 
With increasing PVA content, (Figure 4.7 B−D); the porosity diminishes making the 
hydrogel relatively compact. This can be explained by the enhanced entanglement 
between CS and PVA with increased PVA content (Tang et al., 2007). CP15-CD 
exhibits more or less a similar morphology as that of CP15, which indicates that 
presence of CD did not induce any significant alteration in the hydrogel morphology 
(Figure 4.7 E). The morphology of the CP15 and CP15-CD hydrogels after drug 
release was also visualized (Figures 4.7 F & G). Interestingly the CP15-CD film was 
intact and eroded less even after prolonged exposure to the releasing medium; whereas 
the CP15 film had some wear and tear. Thus, it could be inferred that the CP15-CD 
hydrogel possessed the most dense and rigid matrix network structure in comparison 
to the other hydrogels.  
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4.3.2 Swelling Response of Hydrogels 
4.3.2.1 Swelling in Water 
Time dependent swelling behaviour of the hydrogels in deionized water was studied. 
The CS film was very brittle in nature and exhibited less mechanical strength; upon 
swelling it disintegrated and resulted in a gel-like mass (Figure 4.8). With increasing 
amount of PVA, the stability of the hydrogels was found to increase indicating 
increased mechanical strength. The CP15 and CP15-CD hydrogels were found to be 
the most stable ones and were intact even after prolonged exposure to swelling.  
 
 
Figure 4.8. Photographs depicting the physical stability of hydrogels after swelling in 
water for 24 h. 
 
The swelling profiles of CP11, CP13 and CP15 hydrogels in pH 7.4 and 37°C over a 
prolonged time period are shown in Figure 4.9 A. The swelling ability of the 
hydrogels was found to decease in the order CP11  CP13  CP15, which can be due 
to the increased compactness and rigid network structure of the hydrogels with 
increasing PVA content. This feature has previously been revealed by the SEM 
studies. 
The swelling profiles of both CP15 and CP15-CD hydrogels were found to be similar 
in nature (Figure 4.9 B). However the swelling capacity of the CP15-CD hydrogel was 
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found to be a little lower than that of CP15. This could be possibly explained by 
considering the slightly compact nature of CP15-CD as compared to CP15 due to the 
presence CD, which has also been seen from the SEM images of the respective 
hydrogels. Thus it could be concluded that the presence of CD did not reveal any 
drastic effect on the swelling abilities of the hydrogel. 
 
 
 
Figure 4.9. Time-dependent swelling profiles of (A) CP11, CP13, CP15 hydrogels  
  and (B) CP15, CP15-CD hydrogels in pH 7.4 at 37°C. 
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4.3.2.2 pH-responsive Swelling 
The swelling response of the hydrogels was also investigated at different pHs. The 
effect of pH on the swelling of the CP11, CP13, CP15 hydrogels and that of CP11-
CD, CP13-CD, CP15-CD hydrogels is shown in Figure 4.10 A and B, respectively. 
The hydrogels exhibited pH-sensitive swelling with maximum swelling at neutral pH 
and lower swelling at acidic and alkaline pHs. Due to protonation of amino groups 
(−NH2) in CS at lower pH, strong electrostatic repulsion occurs between the polymer 
chains. The flow of counter ions into the hydrogel matrix takes place to localize near 
the ammonium groups and the overall electrostatic potential is neutral. Thus, the 
increased osmotic pressure inside the hydrogel results in a reduced water uptake 
capacity. At neutral pH, the deprotonation of  –NH3
+
 occurs and intra-chain hydrogen 
bonding can take place in the polymer matrix as a result the hydrogel can 
accommodate more water around hydrogen bonded groups and capillary pores, 
resulting in maximum swelling. At basic pH, due to complete deprotonation of –NH3
+
 
groups, the degree of ionization of the hydrogels is lowered and there is a possiblity of 
stronger and extensive hydrogen bonding in the hydrogel matrix, which results in a 
more compact structure and swelling is hindered (Islam and Yasin, 2012; Islam et al., 
2012). 
The degree of swelling was found to decease in the order CP11  CP13  CP15. This 
can be explained considering the increased matrix density with increasing amount of 
PVA in the hydrogel. The overall swelling behaviour of CP11-CD, CP13-CD and 
CP15-CD hydrogels were found to be very similar to the corresponding hydrogels 
without CD but with a slight decrease in the degree of swelling. This indicates that the 
presence of CD did not have any significant effect on the pH-sensitivity of the 
hydrogels. This has been clearly illustrated in Figure 4.10 C. 
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Figure 4.10. pH dependent swelling of (A) CP11, CP13, CP15; (B) CP11-CD, CP13- 
  CD, CP15-CD  and (C) CP15 and CP15-CD hydrogels in buffer. 
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4.3.3 Antimicrobial Activity of Hydrogels 
CS has been studied in terms of its bacteriostatic/ bactericidal activity to control 
growth rate of algae and to inhibit viral multiplication. Three models have been 
proposed to describe the antibacterial mode of action of CS (Kong et al., 2009); the 
most acceptable being the interaction between the positively charged CS and the 
negatively charged bacterial cell wall. Another proposed mechanism is the binding of 
CS with microbial DNA which leads to inhibition of mRNA and protein synthesis via 
the penetration of CS into the nuclei of the microorganisms. However, Raafat and co-
workers (2008) found out that the probability of it occurring is rather low. The third 
mechanism is the chelation of ligands, suppression of spore elements and binding to 
essential nutrients to contribute to cell death. There are certain controversies regarding 
the bacterial effectiveness of CS on Gram−positive and Gram−negative bacteria. It has 
been demonstrated that the high hydrophilic characteristics in Gram-negative bacteria 
make them more sensitive to CS (Chung et al., 2004).  Although the exact mechanism 
of antimicrobial activity of CS is yet to be established, however the growth of E. coli 
is known to be inhibited in the presence of CS (Abdel-Mohsen et al., 2011). In the 
present study, the synthesized CS−PVA hydrogels were tested for their antibacterial 
activity against E. coli in absence and in presence of CD. Figure 4.11 shows the 
antibacterial effects of CS and the IPN hydrogels against E. coli. The results indicated 
that the hydrogels are not compromised in their antimicrobial characteristics even after 
addition of PVA and/or CD in the matrix. The antimicrobial assay on the hydrogels 
also demonstrated the probable applicability of the synthesized CS−PVA IPN 
hydrogels as wound-healing agents. 
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Figure 4.11. Antibacterial activity of pure CS (Control(C)), (1) CP11, (2) CP13, (3) 
CP15, (4) CP11-CD, (5) CP13-CD and (6) CP15-CD hydrogels against 
E. coli. 
 
Controlled Delivery of Naproxen from CS−PVA IPN Hydrogels 
 
4.4 CS−PVA IPN Hydrogels as Controlled Release Platforms for Delivery of NX 
Naproxen, marketed under the trade names Anaprox and Naprosyn, finds wide 
employment for the treatment of osteoarthritis. NX is typically used in the treatment 
of rheumatoid and gouty arthritis that require prolonged supply of the drug for cure. 
The chronic exposure of the patient to the drug raises the concerns of side effects 
which include dizziness, drowsiness and nausea. NX has also been known to induce 
photosensitivity in some patients and is capable of causing photo-cleavage of DNA. 
Moreover, the bioavailability of NX is also limited because of its extremely low 
aqueous solubility (about 27 mg L
−1
 at 25°C) and causes undesirable effects on the 
gastric mucosa when orally administered, thereby leading to patient non-compliances 
(Mura et al., 2005). Additionally, gastrointestinal ulcerative damages are common 
adverse reactions of NX. Thus, delivery of NX generally demands lower doses over 
prolonged period and targeted to the intestine. Cyclodextrins, in this context, play a 
vital role as drug delivery media in enhancing the aqueous solubility, stability and 
bioavailability of NX (Mura et al., 2005). Complexation of NX with CD also has the 
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advantages of reduction in ulcerogenicity (Otero-Espinar et al., 1991),
 
improved anti-
inflammatory properties (Ramı´rez et al., 2006) and decreased photoreactivity of the 
drug (Valero et al., 2004).  
Thus, in order to reduce the adverse effects of free NX in the GIT, ICs of NX with CD 
were first prepared. The ICs were then added to the CS−PVA hydrogels and their 
delivery potential was explored. By taking advantage of the pH-responsive swelling 
characteristics of the CSPVA hydrogels the delivery of NX could be directed to the 
intestine.   
4.4.1 Inclusion Studies of NX in CD   
The interaction of NX with CD in solution state was studied by UV-Vis and 
Fluorescence techniques. The solid ICs of NX with CD were prepared by the co-
precipitation method and characterized by various analytical techniques.  
4.4.1.1 UV−Vis Study 
 
Figure 4.12. Absorption spectra of NX at varying concentrations of CD, [NX] =    
    5×10
5 
M, [CD] = 0−20 ×103 M, pH=7.4. 
The solution phase NX−CD inclusion complexation behaviour was studied using 
spectrophotometric titration method. As illustrated in Figure 4.12, the absorbance of 
NX gradually increased with the addition of CD, which can be attributed to the 
increased solubility of NX in presence of CD due to formation of inclusion complex.  
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However, this increase is not that significant to estimate the binding constant (Kb) 
therefore fluorescence study was carried out.  
4.4.1.2 Fluorescence Analysis 
Fluorescence studies provide a better scope for understanding the formation of CD 
inclusion complexes because of the higher sensitivity of the technique. The solution 
phase inclusion efficiency of NX with CD was evaluated by fluorescence 
measurements using the intrinsic fluorescence of the drug. The emission spectra were 
recorded with excitation at 280 nm and scanned between 300 and 500 nm. Figure 4.13 
A displays the fluorescence emission spectrum of NX as a function of [CD] in 
aqueous medium (pH=7.4). The fluorescence intensity of NX was very sensitive to the 
addition of CD; the addition of CD produced an increase in the fluorescence intensity. 
Once the drug is incorporated in the cavity of CD, it is protected from solvent induced 
quenching of fluorescence, which results in an increased quantum yield. Thus the 
fluorescence study suggests that a stable complex is formed between NX and CD. 
It is important to know the binding constant of the drug−CD complex because the 
process of drug incorporation within a CD will be effective in reducing the 
concentration of free drug only if the binding constant (Kb) of the drug in the IC is 
sufficiently large, which is essential to minimize the undesired side effects of the free 
drug in the GIT. The Kb for the IC was found to be 1.67(8)   10
3
 M
1
 from the double 
reciprocal plot of [1/ (F−Fo)] against 1/ [CD] (Figure 4.13 B).  
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Figure 4.13. (A) Emission spectra of NX at varying concentrations of CD,                   
[NX] = 5×10
5
M, [CD] = 0−20 ×103 M, pH=7.4, (ex = 280 nm); and 
(B) Benesi-Hildebrand plot for NX-CD interaction. 
4.4.1.3 FTIR Analysis 
The FTIR spectra of CD, NX, PM and IC are represented in Figure 4.14. The key NX 
peaks include 856 cm
1
(C−O−C bonds), 1728 cm1 (C=O stretch), 1392 cm1(C=C 
stretch) and 1228 cm
1
(−O− stretch). The characteristic CD peaks include the 
asymmetric R−O−R stretch at 1158 cm1, C−OH stretch at 1025 cm1, broad band at 
3377 cm
1 
(OH stretch). The FTIR spectrum of the PM is superposition of both CD 
and NX spectra. The characteristic aromatic C=C stretching band of NX at 1392 cm
1
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shifted to 1402 cm
1 
in the inclusion complex (IC). The shift of the O−H band to 
higher frequency region (3396 cm
1
) in the IC indicated the cleavage of hydrogen 
bonding, probably due to inclusion phenomenon (Mura et al., 2005). 
 
Figure 4.14. FTIR spectra of CD, NX, PM and IC. 
4.4.1.4 XRD Analysis 
The X-ray diffraction profiles of CD, NX, PM and IC were collected and illustrated in 
Figure 4.15.  
 
 
 
 
 
 
 
 
Figure 4.15. XRD profiles of CD, NX, PM and IC. 
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NX showed sharp diffraction peaks at 2θ values 16.5°, 18.7°, 20.1°, 22.2° and 27.2° 
indicating a highly crystalline nature. Crystalline nature of CD was also indicated by 
sharp diffraction peaks. PM showed almost all the peaks of NX and CD. In contrast, 
the characteristics peaks of NX and CD disappeared for the IC and new diffraction 
peaks appeared around 2θ values 9.5°, 24.7° and 26°, which indicate formation of new 
phases and confirm the inclusion of NX in the CD cavity. 
4.4.1.5 DSC Analysis 
The DSC curves of CD, NX, PM and IC were collected and shown in Figure 4.16. The 
DSC traces of CD exhibited a broad endothermic effect around 130°C due to the 
dehydration process. The thermal curve of NX was typical of a crystalline anhydrous 
substance, showing a sharp endothermic peak at 156°C due to the drug melting. The 
individual characteristic thermal profiles of CD and the drug were observed in the 
physical mixture. On the contrary, the complete disappearance of the drug thermal 
profile in the IC affirmed the encapsulation of NX in CD cavity (Mura et al., 2005). 
 
Figure 4.16. DSC thermograms CD, NX, PM and IC. 
4.4.1.6 Optical Microscopic Images 
Optical microscopic images were collected for the CD, NX, PM and IC to visualize 
their morphology. The images of CD (Figure 4.17 A) and NX (Figure 4.17 B) indicate 
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their crystalline nature. The photograph of PM (Figure 4.17 C) shows presence of both 
NX and CD crystals. However, the image of the IC clearly point towards the 
formation of a new crystals of ICs (Figure 4.17 D). 
 
Figure 4.17. Optical microscopic images of (A) CD, (B) NX, (C) PM and (D) IC. 
 
4.4.1.7 
1
H NMR Analysis  
The 
1
H NMR spectra of CD and NX-CD IC are shown in Figure 4.18. The values of 
chemical shifts δ, for different protons in CD and NX-CD IC are listed in Table 4.3.  
 
Figure 4.18. 
1
H NMR spectra of CD and NX-CD inclusion complex in D2O at 298 K. 
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Table 4.3. A.  δ and Δδ of protons in CD and NX-CD IC 
Protons δ CD δ IC Δ (δ CD and δ IC) 
H−1 4.991 4.880 0.111 
H−2 3.561 3.504 0.027 
H−3 3.874 3.832 0.042 
H−4 3.496 3.441 0.035 
H−5 3.761 3.709 0.052 
H−6 3.790 3.756 0.034 
 
 
Table 4.3. B. Chemical shift δ and Δδ of protons of NX in free NX and IC 
 Ar-H    
NX 7.125−7.737 
 
IC 7.144−7.825 
Δδ 0.019−0.088 
Comment Down field 
 
The values of chemical shifts, δ for the aromatic protons in NX and IC complex are 
listed in Table 4.3 B. The shift in aromatic protons (7.125−7.737 to 7.144−7.825) of 
NX indicates the inclusion of the naphthalene ring in the CD cavity. From Table 4.3. 
A, by comparing the differences in the chemical shifts of the H−3 and H−5 protons of 
CD and IC the total inclusion of NX in CD cavity is clearly indicated (Banik et al., 
2012). 
4.4.2 NX Release Studies  
Figure 4.19 shows the release profiles of NX from CS-NX, CS-IC, CP15-NX and 
CP15-IC hydrogels at pH 7.4 and 37°C. NX release from CS films (CS-NX and CS-
IC) was found to be very fast and complete drug release takes place in a short period 
of time. This can be explained by considering the high porosity and extensive swelling 
of CS hydrogel that leads to the fast release of the encapsulated drug. Moreover, it is 
known that CS precipitates at pH above 6.5.  Since the CS matrix itself is undergoing 
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such drastic changes, the presence of CD did not have any significant effect on the 
drug releasing behaviour of CS-IC hydrogel. 
 
Figure 4.19. Drug release profiles of CS-NX, CS-IC, CP15-NX and CP15-IC 
 hydrogels in pH 7.4 and at 37°C. 
 
The drug release from the IPN hydrogels (CP15-NX and CP15-IC) was much 
prolonged as compared to the pure CS-NX and CS-IC hydrogels. The CP15-IC 
hydrogel released the drug at a much slower rate as compared to the CP15-NX 
hydrogel. The release of drug from a hydrogel is essentially because of swelling, 
polymer relaxation and diffusion of drug from the swollen matrix. However, for the 
CP15-IC hydrogel another important factor that needs to be considered is the strong 
binding (Kb = 1.67(8)   10
3
 M
1
) of the drug with CD. Thus for drug release process 
to be accomplished from CP15-IC hydrogel, the bound NX must first be released to 
the polymer matrix followed by the diffusion of the free drug. Again the presence of 
CD also influences the polymer relaxation, which in turn can affect the drug release 
rate. It is quite evident that at any given time the free drug concentration is 
considerably lower when CP15-IC is employed than CP15-NX.  
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The effect of PVA content on the rate of NX release from the hydrogels was also 
investigated. Figures 4.20 A and B illustrate that the rate of drug release from the 
hydrogels show significant dependence on the PVA content. 
 
 
Figure 4.20. Drug release profiles of (A) CP11-NX, CP13-NX, CP15-NX and (B)   
   CP11-IC, CP13-IC, CP15-IC hydrogels in pH 7.4 at 37°C. 
As the PVA content increases, the rate of drug release decreases. This can be 
explained by considering the dependence of rate of release of drug from the swollen 
hydrogels on the nature of the hydrogel matrix. Due to increased PVA content the 
hydrogel changes from a porous to a denser matrix and the swelling rate decreases, 
which inhibit the faster release of the drug. Similar results were also obtained for the 
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IC incorporated hydrogels. The effect of PVA content is more pronounced in the IC 
containing hydrogels. This can be due to the synergistic effect of the added CD and 
increased PVA content on the hydrogel matrix density, hence reducing the free 
volume available for the drug diffusion, which in turn decreases the release rate. The 
CP15-IC hydrogel was found to be the best among all the synthesized hydrogels for 
controlled delivery of NX. 
The drug release behaviour of the hydrogels was also studied in different pH 
conditions owing to their pH-responsive nature. Figure 4.21 depicts the drug release 
pattern from CP15-IC hydrogel in pH 7.4 and pH 1.2 media at 37°C 
 
Figure 4.21. Drug release profiles CP15-IC hydrogels in pH 7.4 and pH 1.2 media at  
   37°C. 
The maximum amount of NX released in pH 1.2 is much lower than that in pH 7.4 
even after prolonged exposure of the CP15-IC hydrogel to the releasing medium. This 
indicated the pH sensitivity of the hydrogels which can be utilized to emulate the 
conditions of the GIT for the delivery of NX. 
For further simulating the GIT conditions; CP15-NX and CP15-IC hydrogels were 
immersed in the SGF for 2 hours, then they were transferred to the SIF and the drug 
release was monitored. Figure 4.22 depicts the release pattern of NX from CP15-NX 
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and CP15-IC hydrogels in SGF and SIF conditions. Less than 5% of NX is released 
from CP15-NX and CP15-IC hydrogels during the initial 2h in SGF. However, when 
the hydrogels were transferred to the SIF the amount of NX release increased 
gradually. This release profile fulfils the requirements of USP XXIV, according to 
which, maximum 10% release in SGF is acceptable for the oral delivery of drug. 
 
Figure 4.22. Drug release profiles of CP15-NX and CP15-IC hydrogels in SGF and  
   SIF at 37°C.  
Comparing all the release data, it is found that NX release is much more controlled 
from CP15-IC than any other hydrogel and at any given time the free drug 
concentration is considerably lower when CP15-IC is employed. Thus, it can be 
proposed that the deleterious effects of NX on the epithelium of the GIT could be 
minimized by using the CP15-IC as a DDS given that it provides a controlled release 
resulting in a reduced concentration of free NX. Again the pH-specific release of NX 
from these hydrogels can be utilized for the intestinal-targeted delivery of NX. 
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Controlled Delivery of Diclofenac Sodium from CS−PVA IPN 
Hydrogels 
 
4.5 CS−PVA IPN Hydrogels as Controlled Release Platforms for Delivery of DS 
DS is another important NSAID advocated for its use in rheumatoid arthritis, 
degenerative joint disease, ankylosing spondylitis and allied conditions, and in the 
treatment of pain resulting from minor surgery, trauma and dysmenorrhoea. DS has 
been demonstrated to have antipyretic activity and to be an effective analgesic in 
patients with rheumatoid arthritis or pains of varying origin. DS is also known to be 
quite an effective antibacterial agent (Mazumdar et al., 2009). It exhibits remarkable 
inhibitory action against both drug-sensitive and drug-resistant clinical isolates of 
various Gram-positive and Gram-negative bacteria. The antibacterial action of DS has 
been attributed to its inhibition towards bacterial DNA synthesis (Dutta et al., 2007).  
Though DS has better tolerability than moderate doses of NX, gastrointestinal side 
effects such as peptic ulceration, bleeding etc. are the most frequently reported 
adverse effects. Also, the very low aqueous solubility of DS, especially in gastric juice 
(about 15µg/ ml) causes deleterious effects on the gastric mucosa when orally 
administered. Its biological half-life is very short, about 1−2 h.  Thus controlled 
delivery of DS to the intestine is generally warranted to reduce its adverse side-effects 
and improve its properties for better therapeutic outcome. Complexation of DS with 
CD has been reported to enhance the various physico-chemical properties of the drug 
(Manca et al., 2005). The excellent performance of CSPVA hydrogels towards the 
delivery of NX encouraged us to examine the hydrogels for the controlled delivery of 
DS to the intestine. For this the DSCD ICs were prepared and loaded to the CSPVA 
hydrogels and their drug releasing profiles were studied. 
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 4.5.1 Inclusion Studies of DS in CD 
Prior to the preparation of the solid ICs of DS and CD, the interaction of DS with CD 
was first studied by UV-Vis spectroscopy. 
4.5.1.1 UV−Vis Study   
Figure 4.23 illustrates the absorption spectrum of DS as a function of CD. DS exhibits 
a characteristic absorption peak at 272 nm (Figure 4.24 A).  
 
 
Figure 4.23. (A) Absorption spectra of DS at varying concentrations of CD, [DS] =    
   5×10
5 
M, [CD] = 0−20×103 M, pH=7.4 and (B) Benesi-Hildebrand        
   plot for DS-CD interaction. 
The absorbance was found to increase gradually with the step-wise addition of CD. A 
slight blue shift was observed in the spectra upon the increase in CD content. This 
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could be due to the inclusion of the drug into the hydrophobic CD cavity. From this 
study, the interaction of DS with CD was established. The Kb was calculated from the 
absorption data and found to be around 185 M
−1 
(Figure 4.24 B). 
In order to know the stoichiometry of interaction of DS with CD, phase solubility 
studies were further carried out. 
4.5.1.2 Phase Solubility Studies 
The phase solubility plot of DS−CD binary system is shown in Figure 4.24. As clearly 
evident, the aqueous solubility of the drug increased linearly as a function of CD. This 
type of phase solubility profile can be considered as AL type, thereby suggesting a 1:1 
stoichiometry according to Higuchi and Connors (1965). The value of the stability 
constant was found to be 172 ± 4 M
−1
. The value of the stability constant obtained in 
the range of 100 and 1000 M
−1
 is considered an ideal value, since smaller values are 
indicative of poor interaction between drug and CD while larger values suggest 
incomplete drug release from the IC (Mohit et al., 2010). 
 
Figure 4.24. Phase solubility profile of DS−CD in water. 
The solid ICs of DS with CD were prepared in 1:1 molar ratio by freeze drying 
method and the formation of IC was affirmed from various analytical techniques.  
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4.5.1.3 FTIR Analysis 
Figure 4.25 represents the FTIR spectra of CD, DS, PM and IC. The most important 
peak of DS was observed at 1600 cm
−1
 which is attributed to the carbonyl stretching. 
The FTIR spectrum of the PM exhibited both the characteristics features of CD and 
DS.The spectrum was found to be the superposition of the parent components. 
However, in the FTIR spectrum of IC, the characteristic peak of DS was totally 
absent. Even the C−H stretching band was shifted in the IC (2921 cm−1 in CD; 2942 
cm
−1
 in IC). These modifications in the IC are indicative of the entrapment of the drug 
inside the CD cavity (Manca et al., 2005). 
 
Figure 4.25. FTIR spectra of CD, DS, PM and IC.  
4.5.1.4 XRD Analysis 
Figure 4.26 presents the wide-angle XRD profiles of CD, DS, PM and IC. The CD and 
DS diffractograms display a series of sharp intense which reveal their crystalline 
nature. The diffraction profile of the PM revealed the features of both CD and DS 
which suggests that no new crystal has been formed. The diffraction profile of IC 
revealed a somewhat amorphous nature due to the freeze drying method of 
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preparation. The diffraction profile of the IC is completely different from the parent 
compounds. Thus the formation of an IC is also supported by the XRD data. 
 
Figure 4.26. XRD profiles of CD, DS, PM and IC. 
4.5.1.5 DSC Analysis 
The DSC curves of CD, DS, PM and IC are illustrated in Figure 4.27. The 
thermogram of DS showed a sharp peak at 280°C indicating its melting point. The PM 
exhibited both the melting traces of CD and DS. The thermogram of IC revealed the 
total disappearance of the drug melting peak and a shift in the CD peak. The absence 
of drug peak in the IC signified the inclusion of DS in CD cavity. 
 
Figure 4.27. DSC thermograms of CD, DS, PM and IC.  
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4.5.1.6 SEM Analysis 
SEM is a qualitative method to study the morphological aspects of CD and drugs and 
inclusion products The SEM images of CD, DS, PM and the IC are displayed in 
Figure 4.28. 
 
Figure 4.28. SEM images of (A) CD, (B) DS, (C) PM and (D) IC.  
The particles of CD (Figure 4.28 A) and DS (Figure 4.28 B) were found to be highly 
crystalline in nature. The SEM image of PM (Figure 4.28 C) reveals that it is 
composed of both the particles of CD and DS. The SEM image of IC (Figure 4.28 D) 
however was found to be very different from the parent compounds and the sample 
appeared flaky in nature. Thus the formation of a new entity is also verified from the 
SEM images. 
4.5.1.7 
1
H NMR analysis 
The 
1
H NMR spectra of CD, DS and the IC collected in D2O at 25°C, are illustrated in 
Figure 4.29 A. Figure 4.29 B clearly demonstrates the differences in the positions of 
the protons in CD and IC while Figure 4.29 C displays the differences in the positions 
of protons of DS and IC. The values of chemical shifts δ, for the protons of CD and 
those of the IC were calculated and listed in Table 4.4.  
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Figure 4.29.  
1
H NMR spectra of  (A) CD, DS and IC; Partial 
1
H NMR spectra of (B)   
CD and IC; (C) DS and IC in D2O at 298 K; * and ** represent the 
phenylacetic and dichlorophenyl protons of DS, respectively. 
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Table 4.4. δ and Δδ of protons in CD and DS-CD IC 
Proton δ CD δ IC Δ(δ CD and δ IC) 
H−1  4.991 4.881 0.110 
H−2 3.561 3.447 0.114 
H−3 3.874 3.696 0.178 
H−4 3.496 3.389 0.107 
H−5 3.761 3.529 0.232 
H−6 3.790 3.658 0.132 
 
By comparing the differences in the chemical shifts of the H−3 and H−5 protons of 
CD and IC; total inclusion of drug in CD cavity was evident. Molecular simulation 
studies by Abdoh and authors (2007) have also revealed similar possibility of total 
inclusion of DS in CD cavity. 
The inclusion phenomenon was also confirmed by comparing the chemical shifts of 
the protons of DS and that of IC (Figure 4.29 C). The phenylacetic protons of DS ( 
7.298 ppm) exhibit downfield shifts upon inclusion with CD ( 7.373 ppm in IC). This 
indicates the effective encapsulation of this moiety into the CD cavity. Also, the 
dichlorophenyl protons of DS (6.985−6.912 ppm) show downfield shifts in the 1H 
NMR spectrum of IC suggesting the inclusion of this group. Thus the 
1
H NMR 
spectral studies confirms the formation of an IC.  
4.5.2 DS Release Studies  
Figures 4.30 A and B illustrate the drug release profiles of CP11, CP13 and CP15 
hydrogels containing DS and the IC, respectively. The drug release from the CP11-
DS, CP13-DS and CP15-DS hydrogels were found to be very rapid in comparison to 
CP11-IC, CP13-IC and CP15-IC hydrogels. For the CP11-DS hydrogel, almost 80% 
of the drug has been released in the initial 5 h. On the other hand, the drug release 
amounted to a mere 40% from the CP11-IC hydrogel in the same time span. Similar 
type of slow drug release was also observed from CP13-IC and CP15-IC hydrogels 
with respect to CP13-DS and CP15-DS hydrogels. Since DS is in the bound state in 
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the IC (Kb =172
 
M
−1
), it offers an additional diffusional barrier for the drug release to 
be accomplished from CP11-IC, CP13-IC and CP15-IC hydrogels, which delays the 
release time, and a slow release is witnessed from these hydrogels containing the ICs. 
 
Figure 4.30. Drug release profiles of (A) CP11-DS, CP13-DS, CP15-DS; (B) CP11- 
IC, CP13-IC, CP15-IC hydrogels in phosphate buffer (pH 7.4) at 37°C. 
 
The dependence of the rate of drug release on the PVA content in the hydrogels is also 
demonstrated from Figures 4.30 A and B. As the PVA content was gradually 
increased, the rate of drug release was found to decrease accordingly. Similar effect of 
PVA was also observed in case of NX release from these hydrogels. The rate of drug 
release from the hydrogels containing either the free DS or the IC was found to 
decrease in the order of CP11 > CP13 > CP15. However, at any time, the amount of 
 Chitosan−PVA IPN Hydrogels................ NSAIDs 
162 
 
DS released was always less in case of the hydrogels containing the ICs. The CP15-IC 
hydrogel was found the best of the lot with the slowest drug releasing characteristics. 
In order to study the effect of pH on the drug release phenomenon, experiments were 
carried at two different pHs of 1.2 and 7.4. 
 
Figure 4.31. Drug release profiles of CP15-DS, CP15-IC at pH 1.2 and pH 7.4 and 
 37°C.  
 
Figure 4.31 shows the drug release profiles from CP15-DS and CP15-IC hydrogels at 
pH 7.4 (phosphate buffer) and pH 1.2 (dilute HCl) and 37°C. At pH 1.2, the amount of 
DS released was much lower than the release amount at pH 7.4, even upon prolonged 
exposure to the releasing medium. This can be attributed to the difference in extent of 
swelling of these hydrogels in the above two pH conditions. The evaluation of the 
swelling parameter had revealed the higher swellability of the hydrogels in pH 7.4 
medium and a relatively lower swelling in acidic (pH 1.2) medium. Since normal 
gastric emptying time is about 2 h, it is desirable for negligible or very low drug 
release during this period for targeting the drug release in the intestine. The drug 
release profile of the CP15-IC hydrogel in pH 1.2 clearly displays negligible drug 
release occurring here in the initial time period. Thus, the pH-sensitive release 
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characteristics of the CP15-IC hydrogels indicate its potential for controlled delivery 
of DS to the intestine.  
To further confirm this, the drug release study was carried out in simulated fluids 
mimicking the GIT condition. Figure 4.32 depicts the release pattern of DS from 
CP15-DS and CP15-IC hydrogels in SGF and SIF conditions. Less than 5% DS is 
released from both the hydrogels during the initial 2h in SGF. But the amount of DS 
release increased significantly when the hydrogels were transferred to the SIF. This 
release profile fulfils the requisites of USP XXIV for the oral delivery of drug. It was 
also observed that the amount of DS released from CP15-IC hydrogel was always 
lower than CP15-DS hydrogel at any given time. Thus the potential of the CP15-IC 
hydrogel as an oral controlled delivery vehicle for delivery of DS to the intestine is 
well supported from the above studies. 
 
Figure 4.32. Drug release profiles of CP15-DS and CP15-IC in SGF and SIF at 37°C. 
4.6 Drug Release Kinetics 
Table 4.5 summarises the kinetic parameters for NX release data from the hydrogels. 
From the data analysis it was found that the naproxen release data showed the best fit 
to the Ritger−Peppas and Peppas−Sahlin equations in almost all the cases. For the CS-
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NX and CS-IC hydrogels, the diffusional exponent (n) value was found to be 1.065 
and 1.191 respectively, suggesting the super case II transport mechanism for the 
release of naproxen from these hydrogels. The relative contribution from the diffusion 
and relaxation processes calculated from the Peppas−Sahlin equation shows the 
predominant effect of the relaxation kinetic constant (k2). The lower magnitude and 
negative values of k1 indicate the non-significant diffusion process as compared to the 
relaxation mechanism. From the swelling studies it was observed that these hydrogels 
undergo extensive hydration and swelling in a very short period of time, which can be 
due to the rapid polymer relaxation followed by water diffusion. Thus, the drug 
release from these hydrogels is controlled mostly by relaxation rate of the polymer 
chains. Since Higuchi model is applicable to a purely diffusion controlled mechanism, 
the release data did not show good fit to this equation whereas they fitted reasonably 
well to zero-order kinetic equation. As the PVA content increased the value of the 
diffusional exponent (n) also increased for the hydrogels. For CP13-NX, CP15-NX, 
CP13-IC and CP15-IC the n values lie between 0.5 and 1 indicating the anomalous 
nature of drug release, where both diffusion and relaxation processes contribute. From 
the Peppas-Sahlin analysis it is found that for the CP11-NX and CP11-IC hydrogels 
the relaxation kinetic constant (k2) values are negative indicating the non-significance 
of the relaxation process and the dominant effect of the Fickian diffusion mechanism 
in the drug release process. For the CP11-NX film, the release data fit well to the 
Higuchi model, which complies with the above observation. With increased PVA 
content both diffusion kinetic constant (k1) and relaxation kinetic constant (k2) become 
equally important. The release data from the CP15-NX and CP15-IC films in the SIF 
were also analyzed and the fitting parameters were found to be very similar to that of 
the respective films in the non-buffered solutions.     
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From Table 4.6, it was found that the DS release data showed the best fit to the Ritger-
Peppas and Peppas-Sahlin equations in almost all the cases. The values of the 
diffusional exponent (n) lie between 0.6 and 0.8 indicating the anomalous nature of 
drug release, where both diffusion and relaxation processes contribute. 
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The ratio of the relaxational to the Fickian contributions (R/F) was calculated for the 
samples and plotted against the fraction of the drug released from the hydrogels.                                                 
 
 
Figure 4.33. Plot of ratio of relaxation to the Fickian contribution (R/F) with the 
fraction of dug release for the hydrogels; (A) Naproxen and (B) 
Diclofenac sodium release. 
It is quite evident that as the PVA content is increased the relaxation process prevails 
over the diffusion process. For a given PVA concentration the relaxation contribution 
was found to be higher for the CD containing film as compared to the one without the 
CD. Thus it could be inferred that the presence of CD influences the relaxation rate of 
the polymer chains, leading to slow release of the drug from the hydrogel matrix as 
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observed earlier in PVA hydrogels in chapter 3. This can be explained by considering 
either the presence of hydrogen bonding interaction between the CDs and polymers 
and/or the CDs getting cross-linked to some extent in the presence GA (Bibby et al., 
2000). Among all the hydrogels, the relaxation contribution was found to be 
maximum for CP15-IC hydrogel leading to an almost Case II type of transport, which 
is further supported by the fact that the release data from this film fit fairly well to the 
zero-order kinetics.  
4.7 Cytotoxic Assay of Hydrogels  
From the above studies, the CP15 hydrogel was found to be the most suitable for 
controlled delivery of the drugs. Since all the studies have been carried out in vitro, it 
is important to know whether this hydrogel would be compatible in vivo. Thus 
cytotoxic analysis of this hydrogel was assayed by MTT colorimetric technique and 
shown in Figure 4.34. 
 
Figure 4.34. Optical micrographs of L-929 cells cultured after 48h incubation with  
   CP15 hydrogel. 
 
Direct contact between L-929 cells and the hydrogel did not reveal any adverse effect 
after 48 h incubation. This suggested the compatibility with the living tissues and non-
toxicity of the hydrogel thus validating these as possible drug delivery systems. 
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4.8 CONCLUSIONS 
 pH-Sensitive CS−PVA hydrogels, cross-linked with GA, with varying amount 
of PVA were synthesized and explored for the delivery of two NSAIDs.  
 Solid ICs of NX and DS in CD were prepared. The inclusion phenomenon of 
the drugs in CD was confirmed by various analytical techniques.  
 The hydrogels were characterized by FTIR, XRD, DSC and SEM analytical 
techniques.  
 The hydrogels exhibited pH-responsive swelling characteristics and exhibited 
maximum swelling at neutral pH. With increased amount of PVA in CS−PVA 
hydrogels, the degree of swelling decreased due to increased hydrogel density. 
The presence of CD did not have any drastic effect on the swellability of the 
hydrogels.  
 The antimicrobial activity of CS was not compromised in the presence of PVA 
and/or CD in the hydrogel.  
 A remarkable controlled delivery of the drugs could be achieved from the 
hydrogels by incorporating preformed solid ICs.  
 The hydrogels loaded with ICs showed less than 5% of drug release over a 
period of 2 h in SGF and upon transfer to SIF, the amount of drug released 
increased significantly.  
 The preliminary kinetic analyses revealed that the presence of CD influences 
the relaxation rate of the polymer chains, leading to slower release of the drug.  
 The pH-specific release from these hydrogels can be utilised for the intestinal 
delivery of NX and DS.  
 The cytotoxic assay performed on the hydrogels ensured them to be nontoxic 
and biocompatible.  
                                                                                                                    Chapter 4 
 
 
 
 
 
 
 
         PART−II 
 
CONTROLLED RELEASE OF DEXAMETHASONE 
FROM POLY(VINYL ALCOHOL)−           
POLY(ACRYLIC ACID) MICROSPHERES 
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4.9 INTRODUCTION 
With advances in genomics, combinatorial chemistry and biotechnology, a wide 
variety of potent therapeutics are being developed. Because of some common 
problems such as low solubility, poor stability and bioavailability of most of the drugs, 
new methods of drug delivery are constantly on the rise for their better administration 
(Vert et al., 2012). The method of drug delivery can greatly impact the efficacy and 
the potential of commercialization. Thus there is a higher need for safe and effective 
methods/ devices for drug delivery. Drug delivery systems designed to provide 
therapeutics in the right amount, at the right location with minimal side effects and 
increased patient compliances have gained much attention.  
While a myriad of formulations have been devised for controlled delivery of drugs, 
biodegradable polymeric microspheres are one of the most common types and hold 
various advantages. Microspheres are furnished with the exceptional property to 
encapsulate many types of drugs ranging from small molecules, proteins and nucleic 
acids. They can be ingested or injected and can be tailored for desired release profiles. 
They are usually biocompatible, provide high bioavailability and are capable of 
sustaining releases for longer periods of time (Freiberg and Zhu, 2004). Microspheres 
are characteristically free flowing powders and ideally having particle size less than 
200 µm. Size is very crucial in delivery of therapeutics to the targeted site in a 
sustained and regulated fashion (Ma, 2014). The many advantages of microspheres in 
drug delivery include protection of unstable drugs prior to their availability at the 
target, enabling slow release of drug, improving the cellular interaction of the drug 
and ensuring uniform distribution in the tissues (Yan et al., 2014). Polymeric 
microspheres can be made of either natural polymers such as CS, starch, GG, pectin, 
alginate, dextran, etc. or synthetic polymers like PVA, PAA, epoxy polymers, etc. 
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Several types of processes commonly used for the fabrication of microspheres include 
interfacial polymerization, solvent extraction/ evaporation, polymer extrusion, spray 
drying and coacervation or precipitation (Varde and Pack, 2004). The method of 
interfacial polymerization usually employs a mixture of monomer and an initiator 
which are polymerized in such a way that the growing polymer is constrained to form 
particles. This method involves suspension, emulsion and dispersion polymerizations. 
Emulsion-solvent extraction/ evaporation is one of the most extensively used methods 
to generate microspheres from preformed polymers. This method is widely accepted 
because of its relative ease. The extrusion method forms microspheres by forcing the 
raw components through an orifice or nozzle.   
Controlled release microspheres have been used for a wide range of applications such 
as in vaccines, encapsulated protein therapeutics, DNA encapsulation etc. More so, 
their applications in drug delivery have greatly improved in recent years. Since it is 
often desirable for target-specific delivery of therapeutic agents, it is also important to 
understand the basic mechanism of drug release from microspheres. A complicated 
array of factors affect the rate of drug release from the microspheres which include the 
nature of the polymer, the molecular weight of the polymer, the copolymer 
composition, the nature of excipients added (for stabilization of the therapeutics) and 
the size of the microspheres (Varde and Pack, 2004; Dasan and Rekha, 2012).   
 Polymer type: Depending on the rate of the hydrolysis, polymers can be 
classified as bulk-eroding and surface-eroding. Bulk-eroding polymers such 
as PLGA, readily allow the permeation of water into the matrix network.  
Thus, microspheres fabricated from bulk-eroding polymers degrade 
throughout the matrix and the drug is released to the surrounding medium 
from the spheres (Figure 4.35 A). Surface-eroding polymers are composed 
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of hydrophobic entities, e.g. polyanhydrides (Zhang et al., 2003). These 
polymers resist the entry of water into the polymer bulk while degrading at 
the polymer/ water interface (Figure 4.35 B).   
 
 
 
 
 
 
 
 
 
Figure 4.35. Polymer erosion and drug release from microspheres due to        
         (A) bulk-erosion and (B) surface-erosion.  
 Polymer molecular weight: Most of the studies agree that an increase in 
molecular weight decreases the rate of drug release from the microspheres 
(Le Corre et al., 1994). 
 Copolymer composition: Usually, in a copolymer, the relative ratio of each 
monomeric unit affects the relative release rate. Studies have indicated that 
increasing the content of the more rapidly degrading polymer enhances the 
release rate (Shen et al., 2002).  
 Drug-polymer interaction: Interactions between the encapsulated 
therapeutics and the polymeric microspheres may also influence the release 
rate. An attractive interaction will lead to slow release rate (Orienti et al., 
2001). 
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 Excipients: A range of excipients have been added to stabilise the emulsion 
during microsphere fabrication and also to stabilize the drug during the 
release (Jain et al., 2000).   
 Microsphere size: The effect of microsphere size on the release rate is 
significantly complicated. In general, as the size of the microsphere 
decreases, the surface area-to-volume ratio increases. Thus, the rate of flux 
of drug out of the sphere matrix will increase with decreasing particle size 
(Berkland et al., 2003).   
Hydrogels composed of natural polysaccharides such as CS or synthetic polymers like 
PAA and poly(methacrylic acid) have been employed in the fabrication of pH-
sensitive formulations for intestine targeted delivery (Qiu and Park, 2001). Literature 
suggests overwhelming researches devoted to microsphere formulations and 
subsequent applications in drug delivery. IPN microspheres of locust bean gum and 
PVA have been developed by Kaity et al., (2013) by the emulsion cross-linking 
method using GA as cross-linker and explored for the controlled delivery of the drug 
buflomedil hydrochloride. Semi-IPN microspheres of dextran-g-acrylamide and PVA 
have been synthesized and utilized for delivery of abacavir sulphate (Sullad et al., 
2011). The utility of microspheres in controlled drug delivery has been briefly 
reviewed by Dasan and Rekha (2012).  
PAA finds great applications as a synthetic pH-sensitive polymer for drug delivery 
purposes because of its strong mucoadhesive and biocompatible properties. The 
mucoadhesive properties of PAA make it quite suitable for increasing the residence 
time of the device at the absorbing tissue thereby increasing the drug bioavailability 
(Cheddadi et al., 2011). However, the application of pure PAA is limited because of 
the fast release of the drug due to its extensive swelling in water. Moreover, PAA tend 
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to dissolve at high pH solution. The most commonly used strategy to alleviate the 
inherent drawbacks of PAA is to prepare three-dimensional polymeric network by 
physical or chemical cross-linking or incorporation of PAA in an IPN with other 
polymers such as PVA, PEG, CS etc. (Abd El-Rehim et al., 2007). Hydrogels based 
on PVA and PAA have emerged as promising materials in biomedical applications 
due to their highly tunable chemical and physical properties. pH-responsive hydrogel 
microspheres from the blends of PVA with AAc-g-guar gum matrices were 
synthesized for the controlled delivery of isoniazid (Sullad et al., 2010). Higher drug 
release was evidenced in pH 7.4 than pH 1.2 media and the hydrogels were found to 
be suitable for the oral delivery of the drug. Park and others (2003) studied the release 
behaviour of insulin from pH-sensitive poly(vinyl alcohol-g-methacrylic acid) and 
poly(vinyl alcohol-g-acrylic acid) hydrogels prepared by gamma irradiation. The 
hydrogels sustained insulin release in SIF thus affirmed the oral delivery of insulin. 
PVA-PAA IPN hydrogels and microspheres have been prepared by Ray et al., (2010) 
and compared for the controlled delivery of diltiazem HCl. The results demonstrated 
that the hydrogel microspheres had better potential than the normal hydrogel to be 
employed as drug carrier.  
In this regard, evaluation of PVA-PAA microspheres containing drug-CD ICs towards 
controlled delivery of DX appears exciting. DX is one of the most preferred 
corticosteroid to treat inflammatory bowel disease, Crohn's disease and ulcerative 
colitis, which need its topical administration and often administered as enema. But in 
this method the drug gains access only to the rectum and the descending colon. 
Therefore, a number of approaches are being developed to deliver steroids to the 
intestine and colon via the oral route (McLeod et al., 1994; Fedorak et al., 1995). 
While DX is highly active in the treatment of virtually every type of B-cell 
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malignancy, significant side-effects such as immunosuppression, hyperlipidemia, 
proximal muscle wasting and osteoporosis are invariably associated with it (Mao et 
al., 2013; Lasa et al., 2001).  In addition, it is a lipophilic drug (log P = 1.9) with 
extremely low aqueous solubility (0.16 mg/ml).
 
As a result the bioavailability of DX is 
lowered and its efficiency is hindered (Cavalli et al., 2006). Thus the formulation for 
this drug particularly is more challenging and warrants a delivery system that can 
deliver DX at a controlled rate to the specific site.  
OBJECTIVES 
With this rationale, we aimed at designing a delivery system for controlled delivery of 
DX to the intestine. To achieve specific delivery to the intestine, pH-sensitive 
hydrogel microspheres comprising of PVA and PAA were synthesized using GA as 
cross-linker by free radical polymerization and sequential IPN technology. The solid 
ICs of DX with CD were added to the hydrogel matrix in order to get a controlled 
release. The physico-chemical properties of the drug-CD ICs have been found to be 
strongly dependent on the method of preparation (Priya et al., 2013; Chadha et al., 
2011; Mohit et al., 2010; Manca et al., 2005). Therefore, in this regard, it would be 
interesting to find out the influence of the method of preparation of IC on the drug 
release process from the synthesized PVA-PAA hydrogel microspheres.       
The specific objectives of the present study comprise: 
 Preparation of DX-CD solid ICs by co-precipitation and freeze-drying 
methods.  
 Characterization of the solid ICs and the PM by FTIR, XRD, DSC, SEM and 
1
H NMR spectroscopic techniques. 
 Synthesis of pH-sensitive sequential IPN hydrogel microspheres comprising of 
PVA and PAA using GA as cross-linker and their characterization. 
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 Exploring the drug delivery efficacy of the microspheres containing the ICs, 
free DX and PM, in phosphate buffers and also in simulated fluids. 
 Investigating the influence of the method of preparation of the inclusion 
complex on the drug release phenomenon from the microspheres. 
 A look at the preliminary kinetics of the drug release phenomenon from the 
microspheres and the mechanism of drug transport. 
 Assay of the cytotoxicity and biocompatibility of the synthesized microspheres 
on L−929 rat cells by MTT colorimetric technique.   
The designation and compositions of the synthesized microspheres are listed in Table 
4.7. 
Table 4.7. Composition and designation of PVA−PAA microspheres 
Sample  Composition Designation 
1 PVA−PAA MS1 
2 PVA−PAA−DX MS2 
3 PVA−PAA−PM MS3 
4 PVA−PAA−CP MS4 
5 PVA−PAA−FD MS5 
 
The amount of DX released was estimated spectrophotometrically by observing 
absorbance value at λmax = 242 nm and comparing with the calibration plot.  
 
4.10 RESULTS AND DISCUSSION 
4.10.1 Characterization of Solid DX-CD ICs 
The solid ICs of DX with CD were prepared by co-precipitation and freeze-drying 
methods. The formation of ICs was confirmed from the analyses of various analytical 
techniques.    
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4.10.1.1 FTIR Analysis 
Figure 4.36 shows the FTIR spectra of CD, DX, PM, CP and FD. The key DX (Figure 
4.36 b) peaks are observed at 1662 cm
−1 
(C=O vibration) and 1610 cm
-1 
(C=C 
vibration). The PM (Figure 4.36 c) exhibited a spectrum corresponding to the 
superposition of parent components. However the FTIR spectrum of both the 
inclusion products (CP and FD) showed shifts in the characteristics hydroxyl and 
carbonyl absorption positions.  A shift in the hydroxyl absorption position from 3377 
cm
−1 
to 3392 cm
−1 
and 3348 cm
−1 
in the spectral profiles of CP (Figure 4.36 d) and FD 
(Figure 4.36 e), respectively was evident. Similarly the carbonyl stretching in CP and 
FD were observed at 1664 and 1658 cm
−1
, respectively. These spectral shifts in the CP 
and FD indicated the encapsulation of DX in CD cavity due to the formation of ICs 
(Vianna et al., 1997; Doile et al., 2008). 
 
Figure 4.36. FTIR spectra of (a) CD, (b) DX, (c) PM, (d) CP and (e) FD.  
4.10.1.2 XRD Analysis 
Figure 4.37 presents the wide-angle XRD profiles of CD, DX, PM and the CP and FD 
inclusion products. The CD (Figure 4.37 a) and DX (Figure 4.37 b) diffractograms 
display a series of intense peaks indicating their crystalline nature. DX exhibited sharp 
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peaks at 2θ of 13.66°, 15.5° and 17.81° which represent the highly crystalline nature 
of the drug. The diffraction profile of the PM (Figure 4.37 c) revealed the features of 
both CD and DX suggesting that no new crystal has been formed. On the contrary, the 
diffractograms of CP and FD exhibited completely different features relative to the 
parent components. CP (Figure 4.37 d) presented new and distinct peaks at 6.72°, 
13.42° and 20.13° which propose that highly crystalline particles of the inclusion 
complex have been formed in this method. The diffraction profile of FD (Figure 4.37 
e) showed a somewhat amorphous nature of these particles in comparison to CP 
particles. It has been seen that the freeze-drying method of preparation of IC generally 
results in the amorphization of drug (Riekes et al., 2007). 
 
Figure 4.37. XRD profiles of (a) CD, (b) DX, (c) PM, (d) CP and (e) FD.   
4.10.1.3 DSC Analysis 
The DSC thermograms of CD, DX, PM, CP and FD are shown in Figure 4.38.  The 
DSC curve of CD (Figure 4.38 a) showed a broad endothermic effect around 130°C 
which is associated with its dehydration process. The thermogram of DX            
(Figure 4.38 b) was typical of a crystalline anhydrous substance with a sharp 
endotherm around 270°C indicating its melting point. For the PM (Figure 4.38 c), the 
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endotherms corresponding to both the dehydration of CD and DX melting were 
observed. The DSC curves for CP and FD (Figure 4.38 d and e respectively) revealed 
the disappearance of the DX melting peak and only the peak from CD was observed. 
These results signified the inclusion of DX in CD cavity in the CP and FD. 
 
Figure 4.38. DSC thermograms of (a) CD, (b) DX, ((c) PM, (d) CP and (e) FD.  
 
4.10.1.4 SEM Analysis 
The SEM images of CD, DX, PM, CP and FD are shown in Figure 4.39. The 
photographs were taken under a voltage of 20 kV at 500X magnification. CD (Figure 
4.39 a) crystallizes in larger polyhedral shapes, while DX (Figure 4.39 b) appears as 
crystalline particles with smaller dimensions. The micrograph of PM (Figure 4.39 c) 
presents the crystals of both the parent components. However, the crystals of the CP 
(Figure 4.39 d) appear as larger blocks which are much different from the sizes and 
shapes of CD and DX. The FD (Figure 4.39 e) gave rise to particles with flaky 
appearance, unlike the morphologies of CD and DX. This agrees with the XRD 
studies which had shown the amorphous nature for the freeze dried product. Thus the 
SEM analyses clearly point towards the formation of new entities by the co-
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precipitation and freeze-drying processes due to the formation of the inclusion 
complex of DX with CD.  
 
Figure 4.39. SEM images of (a) CD, (b) DX, (c) PM, (d) CP and (e) FD.  
 
4.10.1.5 
1
H NMR Analysis 
The 
1
H NMR spectra for CD, freeze dried and co-precipitated inclusion products are 
shown in Figure 4.40.  
 
 
Figure 4.40.  
1
H NMR spectra of (A) CD, (B) FD and (C) CP in D2O at 298K. 
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The values of chemical shifts (δ) for the protons of CD and those of CP and FD are 
listed in Table 4.8. It is noteworthy that for both FD and CP, total inclusion of drug in 
CD cavity is indicated. 
Table 4.8. δ and Δδ of protons in CD, DX-CD FD and DX-CD CP 
 
Proton 
 
δCD 
FD CP 
δ Δδ δ Δδ 
H−1 4.982 4.880 0.102 4.891 0.091 
H−2 3.561 3.468 0.093 3.469 0.092 
H−3 3.874 3.737 0.137 3.782 0.092 
H−4 3.496 3.405 0.091 3.408 0.088 
H−5 3.761 3.604 0.157 3.669 0.092 
H−6 3.790 3.693 0.097 3.697 0.093 
 
The magnitudes of chemical shifts are relatively higher in case of FD as compared to 
that in CP, which points towards a somewhat stronger interaction between the drug 
and CD in FD than in CP complexes. Inclusion complexes prepared by freeze-dried 
method are often known to be physically more stable than co-precipitated products 
(Zingone and Rubessa, 2005). 
 
4.10.2 Characterization of Microspheres  
4.10.2.1 FTIR Analysis 
The FTIR spectra of pure PVA, MS1, MS2, MS3, MS4 and MS5 microspheres are 
displayed in Figure 4.41. The FTIR spectrum of pure PVA shows a large band at 
around 3400 cm
−1
 due to hydroxyl stretching. The C−H stretching from alkyl group 
regions is observed at around 2941 cm
−1
 and the peak at 1740 cm
−1 
is attributed to the 
C=O stretching. The peak at 1140 cm
−1 
is associated with the crystalline nature of 
PVA. 
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Figure 4.41. FTIR spectra of (a) pure PVA (b) MS1 (c) MS2 (d) MS3 (e) MS4 and (f)  
  MS5 microspheres. 
 
In the spectra of microspheres, the carbonyl stretching and the region between 
1020−1080 cm1 have been modified indicating the formation of acetal ring by the 
cross-linking reaction between the hydroxyl groups of PVA and aldehydic groups of 
PAA (Wang et al., 2007; Lu et al., 2009). The peak at 1252 cm
−1
 which is due to C−O 
stretching vibrations of PAA is enhanced in the spectra of microspheres. This 
evidenced the incorporation of PAA in the matrices of the synthesized microspheres. 
In addition, the decrease in intensity in the 1140 cm
-1 
peak in the microspheres 
indicates a decrease in crystallinity.  
4.10.2.2 XRD Analysis 
The X-ray diffraction profiles of pure PVA, MS1, MS2, MS3, MS4 and MS5 
microspheres are demonstrated in Figure 4.42. All samples show almost similar 
diffraction pattern, a broad peak around 19.8°. Pure PVA hydrogel shows a peak 
around diffraction angle (2θ) of 19.8°, which is associated with the crystalline phase 
of PVA. The relative broadness and decreased intensity observed in the diffraction 
profiles of the microspheres indicates a decrease in crystallinity in the samples, which 
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might be because of the interpolymer interaction and cross-linking of PVA that 
prevents the PVA chains from self-associating and crystallizing. 
 
Figure 4.42. XRD profiles of pure PVA and MS1, MS2, MS3, MS4 and MS5  
     microspheres. 
 
In MS2, the peaks for pure DX are absent and only the peaks for the polymer can be 
seen. This confirms the molecular dispersion of DX in the polymer matrix and the 
absence of drug crystallinity (Angadi et al., 2011). The diffraction profiles of MS3, 
MS4 and MS5 exhibited more or less similar features and did not show any 
characteristic CD or DX or inclusion complex peaks. This indicated that the physical 
mixture and the inclusion complexes are properly blended with the hydrogel matrix.    
4.10.2.3 Morphology Analysis 
Figures 4.43 A−E show the SEM images of MS1, MS2, MS3, MS4 and MS5 
microspheres. And Figures 4.43 F−J present the SEM images of a single MS1, MS2, 
MS3, MS4 and MS5 microspheres. The microspheres were found to be polydispersed 
in size. They are spherical in shape and formed without any agglomerations. The mean 
sizes of the microspheres were calculated by considering the average sizes of fifty 
microspheres of each sample. The mean sizes were found to be 131 ± 23 µm (MS1), 
139 ± 24 µm (MS2), 140 ± 22 µm (MS3), 139 ± 21 µm (MS4) and 140 ± 21 µm 
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(MS5). There was no significant difference observed in the morphology of the drug 
free and drug loaded microspheres. This indicates that the presence of DX or PM or 
inclusion complex did not have any remarkable effect on the morphology or the size 
of the microspheres. 
 
Figure 4.43. SEM images of (A) MS1, (B) MS2, (C) MS3, (D) MS4, (E) MS5  
    microspheres at 150X magnification and single (F) MS1, (G) MS2,        
    (H) MS3, (I) MS4, (J) MS5 microspheres at 2000X magnification. 
 
4.10.3 Drug Content of the Microspheres 
The percentage drug content of the MS2, MS3, MS4 and MS5 microspheres were 
found to be 11.5 ± 0.5, 12.1 ± 0.7, 15.3 ± 0.8 and 17.2 ± 0.7 %, respectively. The drug 
loading efficacies of the microspheres demonstrated an increase with the addition of 
the inclusion complexes of the drug in comparison to the free drug. The MS5 
microspheres exhibited highest drug loading capacity probably due to better inclusion 
complex formation by the freeze-drying method. 
4.10.4 Swelling Studies 
The swelling studies of the MS1 microspheres in gastric and intestinal pH conditions 
(pH 1.2 and pH 7.4 respectively) revealed the dependence of the swelling on the pH of 
external medium. The microspheres exhibited higher swelling at neutral pH as 
compared to that at acidic pH (Figure 4.44). The pH-sensitivity of these microspheres 
is mainly attributed to the presence of the carboxylic acid group in PAA which is a 
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weak acid with an intrinsic pKa of around 4.28. At pH 1.2, the ionization of carboxylic 
groups is suppressed and there can be hydrogen bond interaction between the two 
polymers which reduces the flexibility of the polymer chains. Thus the swelling 
capacity is lowered. As the pH of the external medium rises above 4.28 (at pH 7.4), 
the carboxylic groups within the network tend to ionize as a result the inter-polymeric 
repulsion increases thus increasing the free volume in the polymer matrix which in 
turn increases the swelling ratio. Additionally, the negative charge in the polymer 
matrix drives the flow of cations into the hydrogel as a result of which the ionic 
swelling pressure increases resulting in an increase in swelling (Byun et al., 1996; Fei 
et al., 2002; Quintero et al., 2010). 
 
Figure 4.44. Swelling profiles of MS1 microspheres at pH 7.4 and pH 1.2.  
 
4.10.5 In vitro DX Release Studies and Kinetics 
4.10.5.1 In vitro DX Release Studies 
Figure 4.45 demonstrates the release profiles of DX from MS2, MS3, MS4 and MS5 
microspheres at pH 7.4 and pH 1.2 and 37°C. As evident, a pronounced difference is 
observed in the release rates of DX at pH 1.2 and pH 7.4. At pH 1.2, the amounts of 
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DX released from all microspheres were much lower than the release amounts at pH 
7.4, even upon prolonged exposure to the releasing medium. This can be attributed to 
the difference in extent of swelling of these hydrogels in the above two pH conditions. 
Thus, the pH sensitive release characteristics of these hydrogels make them suitable 
candidates for intestine specific drug delivery systems.  
 
Figure 4.45. Drug release profiles of MS2, MS3, MS4 and MS5 microspheres in       
    pH 7.4 and pH 1.2 at 37°C. 
 
At pH 7.4 the rate of release of DX from these hydrogels follows the order: MS2 > 
MS3 > MS4 > MS5. DX release from the MS2 microspheres was found to be very 
rapid and almost 80% of the drug has been released in the initial 3 h. However, the 
release was much prolonged from the MS4 and MS5 microspheres. As discussed 
earlier, the release of a drug from a polymer matrix is generally governed by the 
combined effects of network swelling, polymer relaxation and diffusion of drug from 
the hydrogel matrix. The observed differences in the release patterns of these 
microspheres can be rationalized by taking into consideration the physical state of the 
drug in the hydrogel matrices. The MS2 microspheres contain the uncomplexed drug 
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which is dispersed freely in the hydrogel. But the drug is present in the form of 
inclusion complex in MS4 and MS5 microspheres. And, in MS3 microspheres, the 
drug is dispersed along with a blend of CD. The drug release from MS2 microspheres 
is expected to occur due to the simple diffusion of drug from the hydrogel network to 
the releasing medium as the hydrogel swells. Whereas in the other three microspheres, 
the presence of CD in the hydrogel network greatly directs the drug release profiles. 
For the MS3 microspheres, though the drug release is driven by diffusion, the 
presence of CD in the hydrogel matrix plays a pivotal role in the achievement of 
relatively slower drug release rate as compared to that from MS2 containing the free 
drug. Similar decrease in release rate has also been seen for the release of salicylic 
acid from CD blended PVA hydrogel as compared to pure PVA hydrogel 
(Sreenivasan, 1997). This can be explained by considering the following possibilities 
that can influence the drug release rate: (i) a few of the drug molecules getting 
complexed with the CD during the hydrogel synthesis and/or (ii) presence of H-
bonding between CD and the polymer matrix influencing the polymer relaxation. For 
the drug release from MS4 and MS5 microspheres, apart from all the above mentioned 
factors, one major aspect that needs to be considered is the strong binding of DX with 
CD (Kb = 700 ± 40 M
1
) (Sadlej-Sosnowska, 1997).
 
Thus for the drug release process 
to be accomplished from these two microspheres, the bound DX must be released 
from the CD cavity to the hydrogel matrix followed by the diffusion of free drug. 
Additionally, the presence of CD in these microspheres can also influence the polymer 
relaxation rate which in turn affects the drug release rate. Thus a sustained release of 
DX is observed from these microspheres in contrast to the burst type release from 
MS2 microspheres.  
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A pronounced difference in the release rates from the microspheres containing the CP 
and FD, i.e. from MS4 and MS5 is observed. The drug release from MS5 was much 
more controlled and continued for longer time than MS4 microspheres. These two 
microspheres are very similar in all aspects except for the type of DX-CD inclusion 
complex. Thus, the observed difference in the drug release kinetics between MS4 and 
MS5 suggests towards a strong influence of the method of preparation of drug-CD IC 
on the drug release kinetics from the hydrogel matrix. In the present study, MS5, the 
microsphere containing the DX-CD FD, is found to be the best system for the slow 
release of dexamethasone. Thus, it can be proposed that the adverse side-effects of DX 
in the GIT could be minimized by using the MS5 microspheres as delivery vehicles 
since they provide controlled release of DX over a prolonged period.   
 
Figure 4.46. Drug release profiles of MS2, MS3, MS4 and MS5 microspheres in SGF  
   and SIF at 37°C. 
 
In order to imitate the conditions of the GIT, DX release from the microspheres was 
also studied in SGF and SIF. For further simulating the GIT conditions; the 
microspheres were immersed in SGF for 2 hours, and then transferred to SIF and the 
drug release was monitored. Figure 4.46 depicts the release pattern of DX from the 
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four microspheres in SGF and SIF environments. Approximately 5% of DX is 
released during the initial 2 h in SGF. However, when the microspheres were 
transferred to SIF, the rate of DX release increased significantly for all the four 
hydrogels. The release rate in the SIF was found to follow the same order as observed 
before i.e. MS2 > MS3 > MS4 > MS5. This release profile of dexamethasone fulfils 
the requirements of US Pharmacopeia XXIV for oral colon drug delivery. 
Thus the synthesized microspheres could be effectively employed for the oral delivery 
of dexamethasone and their pH sensitivity could be exploited for the intestine-specific 
delivery. However, in order to achieve a controlled release of drug, the MS4 and MS5 
microspheres are found to be more suitable. And MS5 was found to be the best of the 
lot for achieving sustained and intestinal delivery of DX.      
4.10.5.2 DX Release Kinetics 
The release data have been fitted to different empirical mathematical equations and 
shown in Table 4.9. The drug release data for MS2, MS3, MS4 and MS5 showed the 
best fit for the Ritger-Peppas equation with correlation coefficient values of 0.998, 
0.998, 0.992 and 0.996 respectively. The diffusion exponent value ‘n’ was found to be 
in the range of 0.76 to 0.85 for the microspheres indicating the anomalous nature of 
drug transport mechanism, which is the superimposition of diffusion-controlled and 
swelling controlled drug release.  
The R/F plot showed a higher value of R/F for MS3, MS4 and MS5 microspheres in 
comparison to MS2 microspheres. This suggested that polymer relaxation played a 
major role in the drug release where CD is present. The MS5 microsphere exhibited 
the highest value of R/F.  
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Figure 4.47. Plot of ratio of relaxation to the Fickian contribution (R/F) with the 
fraction of dug release for MS2, MS3, MS4 and MS5 microspheres. 
 
4.10.6 Cytotoxicity assay 
In order to ensure the biocompatibility of the synthesized microspheres, cytotoxicity 
assay was performed by MTT colorimetric technique. As shown in Figure 4.48, direct 
contact between L−929 cells and MS1 microspheres did not reveal any adverse effect. 
This suggested the compatibility of the synthesized microspheres with the living 
tissues thus validating these as possible delivery systems for the controlled delivery of 
DX. 
 
Figure 4.48. Optical Micrographs of L−929 cells cultured after 48 h incubation with  
   MS1 microspheres.  
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4.11 CONCLUSIONS 
 pH-Sensitive PVA-PAA microspheres cross-linked with GA were synthesized 
and studied for the delivery of the common anti-inflammatory and 
immunosuppressant drug DX.  
 To regulate the release rate of DX, preformed solid inclusion complex of DX 
with CD was added into the hydrogel microspheres.  
 In order to examine the effect of the method of preparation of inclusion 
complex on the release kinetics, the DX-CD inclusion complexes were 
prepared by two commonly used methods: the co-precipitation and freeze-
drying method.  
 The inclusion complexes were characterized by different spectroscopic 
techniques such as FTIR, XRD, DSC, SEM and 
1
H NMR.  
 Microspheres containing the free drug, the drug-CD physical mixture and the 
CD-complexed drug were synthesized and characterized by FTIR, XRD, DSC, 
SEM and their drug delivery efficacies were also investigated.  
 The swelling characteristics indicated higher swelling in neutral pH than in 
acidic pH therefore indicating their pH-responsiveness.  
 At pH 1.2, the amounts of DX released from all microspheres (MS2, MS3, 
MS4 and MS5) were much lower than the release amounts at pH 7.4. At pH 
7.4 the rate of release of DX from these hydrogels follows the order: MS2 > 
MS3 > MS4 > MS5.  
 Approximately 5% of DX released during the initial 2h in SGF but upon 
transfer to SIF, the rate of DX release increased significantly.  
   
Controlled Release............. PVA−PAA Microspheres 
 
194 
  
 The synthesized microspheres could be effectively employed for the controlled 
delivery of dexamethasone and their pH sensitivity could be exploited for the 
intestine-specific delivery.  
 Moreover, the compatibility of the synthesized microspheres with the living 
tissues further validates them as promising drug delivery systems.  
 MS5 containing the freeze-dried DX-CD inclusion complex was found to be 
the best of the lot for achieving a good control and intestine-specific delivery 
of DX.  
 Thus, it can be proposed that the adverse side-effects of DX in the GIT could 
be minimized by using these microspheres as delivery vehicles.   
                                                                                                                    Chapter 5 
 
 
 
 
 
 
 
CHAPTER   5 
 
REGULATING THE DELIVERY OF 5FLUOROURACIL 
FROM THERMO-RESPONSIVE                  
GUAR GUM−PNIPAAm HYDROGELS 
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5.1 INTRODUCTION 
Temperature-sensitive hydrogels are one of the most commonly studied classes of 
smart hydrogels in drug delivery research (Qiu and Park, 2001). Of the many 
temperature-sensitive polymers, poly(N-isopropylacrylamide) (PNIPAAm) is widely 
studied because of its lower critical solution temperature (LCST) around ~32°C, close 
to human body temperature. Block copolymers of PEO and PPO commercially 
available under the trade names of Pluronics® or Poloxamers® and Tetronics® have 
also been utilized in development of thermo-responsive drug delivery formulations. 
The excellent review article by Klouda and Mikos (2008) covers the developments in 
thermo-sensitive hydrogels for biomedical and pharmaceutical applications. 
      
Figure 5.1. Chemical structure of poly(N-isopropylacrylamide) (PNIPAAm).  
For hydrogels composed of thermo-sensitive polymers, the LCST is the deciding 
factor for their thermo-responsiveness. Polymeric materials that possess LCST-type 
phase diagram are composed of a mixture of hydrophilic and hydrophobic groups on 
their backbone and the LCST can be tailored as per requisites by adjusting the ratio of 
the hydrophilic and hydrophobic segments of the polymer (Qiu and Park, 2001). At 
temperatures below the LCST, the hydrogen bonding between the hydrophilic 
components of the polymer and the water is dominant and primarily responsible for 
the expansion of the hydrogel matrix. This leads to an increase in the water uptake 
capacity of the hydrogel thereby enhancing its swellability. At temperatures above the 
LCST, the intramolecular interactions become stronger while the polymer-water 
interaction (intermolecular) is weakened. Thus the hydrogel matrix is rendered 
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hydrophobic and the water is expelled out. This results in a contraction of the gel 
which directs to lower swelling characteristics and shrinking of the hydrogel 
(Wenceslau et al., 2012). The phase transition temperature of PNIPAAm is known to 
change by the incorporation of small amount of ionizable groups into the gel network 
or by changing the solvent composition. Even copolymerization of PNIPAAm with 
other polymers has led to the formation of hydrogels with versatile properties 
including faster rate of shrinking of the gel (Qiu and Park, 2001). In drug delivery, the 
swelling/ shrinking behaviour of the thermo-sensitive PNIPAAm hydrogels have been 
used to obtain an on-off drug release profile in response to changes in temperature 
(Figure 5.2).  
 
Figure 5.2. Schematic illustration of an on-off release for drug delivery. 
From the viewpoint of biomedical purposes, pure PNIPAAm hydrogels are not 
appropriate candidates due to their poor mechanical stability (Muniz and Geuskens, 
2001), low biocompatibility (Xiao et al., 2009) and low biodegradability (Zhang et al., 
2004). Another serious limitation associated with the PNIPAAm hydrogel as a 
potential drug carrier, is the lack of sustained drug releasing ability i.e. the 
impregnated drug is usually released within a very short span of time when the 
polymer matrix undergoes the phase transition. The poor mechanical strength and the 
fast drug release from the conventional PNIPAAm hydrogel could be attributed to its 
lower polymer mass per unit volume that leads to opening of many channels and pores 
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for the drug to diffuse out rapidly. More so, the intermolecular hydrogen bonds in the 
swollen state are quite weak and tend to facilitate the drug release (Zhang et al., 
2004).  
To overcome these deficiencies, copolymerization of PNIPAAm with hydrophobic co-
monomers is usually carried out. However, this method is not advisable as it almost 
eliminates the inherent thermo-responsive properties of PNIPAAm. Copolymerization 
of PNIPAAm with AAc monomers had been carried out to confer pH-sensitivity and 
improve the mechanical characteristics of the hydrogel (Jones, 1999).  It was observed 
that insertion of AAc units even in small amounts led to a disturbance of the 
continuous sequence of PNIPAAm and the cumulative hydrophobic interactions 
between the isopropyl groups were reduced. This eventually reduced the thermo-
sensitivity of the resulting copolymer hydrogel. In order to obtain biocompatible and 
biodegradable hydrogels that preserve the temperature-sensitivity of PNIPAAm, 
natural polysaccharides have been roped into this context (Wang et al., 2013). 
Recently, the research in the areas pertaining to hydrophilic natural polysaccharides 
for the design of oral controlled drug delivery formulations has brewed into a huge 
territory. More so, the utility of natural polysaccharides in the fabrication of hydrogels 
for controlled delivery of drugs has blossomed largely. Polysaccharides are polymeric 
carbohydrates composed of long chain monosaccharide units joined together by 
glycosidic linkages. Natural polysaccharides have various sources of origin; algal (e.g. 
alginate), plant (e.g. pectin, cellulose, gum Arabic, inulin, etc.), microbial (e.g. 
dextran, xanthan gum) and animal (e.g. chitosan, chondroitin). Polysaccharides are 
generally associated with a wide range of molecular weights, varying chemical 
composition and a large number of reactive groups. These features hugely contribute 
to the diversity in structure and properties of the polysaccharides (Prabaharan, 2008). 
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Polysaccharides are abundant in nature and their processing is also cost-effective. 
Additionally, they are safe, non-toxic, biocompatible and biodegradable (Prabaharan 
and Jayakumar, 2009). Also, the hydrophilic groups such as hydroxyl, carboxyl, etc. 
present in the polysaccharides are capable of forming non-covalent bonds with the 
biological tissues forming bio-adhesion (Lee et al., 2000).  The utilization of natural 
polysaccharides in drug delivery systems has been a subject of intense investigation 
lately because of their biodegradability and biocompatibility. 
IPNs of PNIPAAm with natural polymers were found to posses better mechanical 
properties in comparison to the parent homopolymer. Semi-IPNs of PNIPAAm and 
CS have been developed by Lee and Chen (2001) and it was found that the thermo-
sensitivity of PNIPAAm remained unhindered even after addition of CS. PNIPAAm 
and CS have also been grafted into hydrogels and their physico-chemical properties 
and drug release characteristics were examined (Fang et al., 2008). Hydrophilic and 
lipophilic drugs such as nalbuphine, indomethacin and nalbuphine prodrug were 
chosen as model drugs for the in vitro release experiments. The results suggested the 
controlled release of drugs from the hydrogels and the hydrogels were also found to be 
biocompatible in nature. Semi-IPN microspheres of PNIPAAm and NaAlg have been 
explored for the delivery of 5-Fluorouracil (Reddy et al., 2008). The hydrogels 
exhibited both pH- and temperature sensitivity and the controlled release of drug was 
achieved at the physiological temperature of 37°C. Biodegradable hydrogel 
formulations based on PNIPAAm and dextran targeted towards controlled delivery of 
DOX exhibited remarkable drug releasing properties and thermo-sensitivity 
(Namkung and Chu, 2007). Hydrogels comprising xanthan-maleic anhydride and 
PNIPAAm were synthesized by solution polymerization technique and found to have 
potential applications in biopharmaceutical and biotechnology fields as these 
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hydrogels were very sensitive to minute changes in temperature (Long et al., 2009). 
The LCST could be adjusted to be or near the body temperature by varying the 
precursor compositions. Pectin-g-PNIPAAm hydrogels have also been utilized for the 
colon-targeted delivery of theophylline (Assaf et al., 2011). A plethora of research is 
dedicated towards development of formulations comprising of PNIPAAm and natural 
polysaccharides for controlled drug delivery (Ward and Georgion, 2011; Jing et al., 
2013).  
Guar gum (GG), a galactomannan, is one such natural polysaccharide which is of 
particular interest in this regard. GG is a water soluble polysaccharide derived from 
the seeds of Cyamopsis tetragonolobus, family Leguminosae. It consists of linear 
chains of (1→4) β−D−mannopyranosyl units with α−D−galactopyranosyl units 
attached by (1→6) linkages. The non-toxic nature allows its usage in biomedical, 
pharmaceutical, food and cosmetic industries (Prabaharan, 2011). GG has been used 
as a binder, stiffener, disintegrant, thickening agent, suspending agent and as a 
stabilizer in various applications. GG hydrates in cold water producing a pseudo-
viscous plastic solution which has greater low-shear viscosity than other hydrocolloids 
(Cheetham and Mashimba, 1990). This gelling property retards the release of the drug 
thereby helping to attain a sustained drug release profile. 
 
 
 
Figure 5.3. Chemical structure of guar gum (GG). 
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GG, as a drug delivery agent, has gained considerable significance because of its 
biocompatibility, physico-chemical stability and compressibility features. The 
susceptibility of GG to microbial degradation in the large intestine has drawn much 
attention towards oral drug delivery purposes. The potential use of GG as colon-
specific, anti-hypertensive, protein and transdermal drug delivery systems has been 
well documented (Prabaharan, 2011). The flexibility of GG in drug delivery lies in 
tailoring its properties as per demand. Efforts in this direction have led to the 
development of a variety of dosage forms which include tablets, hydrogels, 
microspheres, beads, capsules, nanoparticles and others. Aminabhavi and co-authors 
(2014) have briefly summarized the advancement in the research endeavours on GG-
based polymeric formulations for controlled delivery of therapeutics. However, the 
major hindrance in using GG matrices as platforms for controlled drug delivery is 
their high hydrophilic characteristics which leads to extensive swelling and facilitates 
the premature release of loaded drugs (Li et al., 2008). GG has been often used in 
combination with a variety of other biodegradable polymers in the forms of 
copolymers, blends, grafts, IPNs, etc. Such polymers include PVA, PVP, 
polyacrylamide, NaAlg, HPMC, xanthan gum, PAA, CMC, NIPAAm, etc. (Ghosh 
and Wong, 2014). 
GG, in the form of matrix tablets, has been investigated for the delivery of 
indomethacin to the colon because of its ability to sustain the physiological 
environment of the stomach (Prasad et al., 1998).  Microspheres of carboxymethyl GG 
have been prepared and explored for their controlled delivery of the anti-asthmatic 
drug theophylline (Phadke et al., 2014). Recently, Bosio and co-workers (2014) 
observed sustained release of DOX from gel microbeads composed of alginate-
carboxymethyl GG for oral controlled delivery. GG is also known to be efficient 
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delivery carriers for protein-based drugs. Kono et al., (2014) developed GG hydrogels 
via esterification with 1, 2, 3, 4-butantetracarboxylic dianhydride as carrier materials 
for controlled protein delivery. The hydrogels adsorbed BSA and hen egg white 
lysozyme through electrostatic and hydrophobic interactions and exhibited slow and 
steady release of the proteins over a period of 24 h. Recently, Murali et al., (2014) 
developed an injectable hydrogel system comprising biocompatible aminated GG and 
Fe3O4-ZnS core-shell nanoparticles for the delivery of DOX hydrochloride. The 
hydrogels were stable over a wide range of pH and displayed excellent drug release 
properties where upto 90% of the drug release was achieved after 20 days of 
incubation. Literature is abound with the versatility and applicability of GG 
formulations in drug delivery (Aminabhavi et al., 2014). 
In this regard, there are only a few reports relevant to hydrogels based on PNIPAAm 
and GG. Thermo-responsive blend hydrogel microspheres of NaAlg and PNIPAAm-
g-GG were synthesized by emulsion cross-linking method using GA as cross-linker 
(Kajjari et al., 2012). The in vitro release experiments assayed the thermo-sensitivity 
of the microspheres for controlled delivery of isoniazid. Li and co-authors (2008) have 
synthesized GG-PNIPAAm IPN hydrogels cross-linked by MBA and their physico-
chemical properties have been investigated. The hydrogels possessed good thermo-
sensitivity and the introduction of GG into the matrix led to an improvement in the 
mechanical stability. Thus there is a current need for the development of GG-
PNIPAAm hydrogels and explore their drug releasing properties in greater details. 
5FU is a hydrophobic drug that has been used in the treatment of colorectal cancer for 
many years (Figure 5.4). It is a powerful cytotoxic drug that acts as an anti-metabolite 
and successfully utilized for treatment of genital, urethral and intravaginal 
condylomata. 
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Figure 5.4. Chemical structure of 5-Fluorouracil (5FU). 
However, it possesses moderate aqueous solubility, about 1g in 100 ml of water at 
room temperature (Bahaddi et al., 1997) and is poorly absorbed after oral 
administration with erratic bioavailability therefore it is usually administered 
intravenously. Following parenteral administration of 5FU, there is a rapid distribution 
of drug followed by its brisk elimination with an apparent terminal half-life of about 8 
to 20 min (Diasio and Harris, 1989). It has also been shown that when 5FU is applied 
topically to treat vaginal lesions; patient non-compliances occur due to 
chemoinflammation or epithelial erosion probably due to local high concentration of 
the drug (Syed et al., 2000). Also severe gastrointestinal, neural, cardiac and 
dermatological toxic effects due to 5FU cytotoxicity have been reported (Diasio and 
Harris, 1989; Jin et al., 2010). Thus lower doses of 5FU are generally warranted to 
reduce the side-effects and improve its bioavailability (Bilensoy et al., 2011). 
This work centres on the design of temperature sensitive GG−PNIPAAm IPN 
hydrogels cross-linked by tetraethyl orthoslilicate (TEOS), for the controlled release 
characteristics of 5FU. TEOS has been chosen as the cross-linker as alkoxysilanes and 
particularly TEOS are known to be nontoxic in nature and widely accepted for 
pharmaceutical purposes (Islam et al., 2012; Rasool et al., 2010). TEOS has been 
utilized to cross-link polyurethanes (Jena and Raju, 2008) and hydrogels of CS and 
PVA (Copello et al., 2014; Islam et al., 2013; Islam et al., 2012; Kulkarni et al., 
2006). Thermo-sensitive gels with different content of TEOS have been prepared from 
NIPAAm and MBA by emulsion polymerization technique and the effect of cross-
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linker on the hydrogels properties were investigated (Huang and Lee, 2009; Huang 
and Lee, 2010). 
OBJECTIVES 
The objectives of the present study constitute: 
 Preparation of solid ICs of 5FU with CD and the characterization of the ICs. 
 Synthesis of GG−PNIPAAm IPN hydrogels cross-linked by TEOS and their 
characterization. 
 Evaluation of the temperature-responsive swelling properties of the hydrogels. 
 To explore the drug releasing behaviour of the hydrogels containing the ICs 
for the controlled delivery of 5FU. 
 To address the preliminary kinetics of drug release from the hydrogels and 
understand the importance of the presence and effect of CD on the drug release 
phenomenon. 
 To asssay the cytotoxicity of the hydrogels on rat fibroblasts to ensure their 
biocompatibility with living tissues. 
Hydrogels with different feed compositions of GG and NIPAAm were synthesized. 
Blank hydrogels without any free drug or IC were also synthesized for 
characterization purposes. The compositions and designations of the synthesized 
hydrogels are provided in Table 5.1. 
Table 5.1. Composition and designation of synthesized GG−PNIPAAm hydrogels 
Sample 
 
GG: NIPAAm 
(wt%) 
Sample Designation 
GG−NIPAAm GG−NIPAAm−5FU GG−NIPAAm−IC 
1 1:0 GG GG-5FU GG-IC 
2 0:1 PNIPAAm PNIPAAm-5FU PNIPAAm-IC 
3 1:1 GN11 GN11-5FU GN11-IC 
4 2:1 GN21 GN21-5FU GN21-IC 
5 4:1 GN41 GN41-5FU GN41-IC 
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The concentration of 5FU released was estimated from the calibration plots obtained 
by observing the absorbance at λmax = 265 nm. 
5.2 RESULTS AND DISCUSSION 
5.2.1 Inclusion Studies of 5FU in CD 
5.2.1.1 UV−Vis Analysis 
As illustrated in Figure 5.5, the absorbance of 5FU was found to increase with the 
gradual addition of CD. A slight blue shift in the absorption maximum was observed 
in the spectra upon increasing the amount of CD.  This could be due to inclusion of 
the drug into the apolar cavity of CD indicating possible interactions between them. 
The increased absorbance of 5FU in presence of CD indicates the improved solubility 
of the hydrophobic drug in the aqueous medium due to 5FU-CD complexation. 
 
 
Figure 5.5. Absorption spectra of 5FU at varying concentrations of CD, [5FU] =  
5×10
5
 M, [CD] = 0−20 ×103 M, pH=7.4. 
 
5.2.1.2 FTIR Analysis 
The FTIR spectra of CD, 5FU, PM and IC are illustrated in Figure 5.6. 
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Figure 5.6. FTIR spectra of CD, 5FU, physical mixture (PM) and inclusion complex 
(IC). 
The characteristics FTIR peaks of 5FU include the aromatic ring regions around 
500−600 cm─1 and 2500−3000 cm─1 together with C=C stretching band at 1300−1500 
cm
─1 
(Bilensoy et al., 2007). The PM exhibited a spectrum corresponding to the 
superposition of the parent components. However the FTIR spectrum of the IC 
showed certain spectral shifts. A shift in the hydroxyl absorption position from 3377 
cm
─1
 to 3355 cm
─1
 in the spectral profile of IC was evident. In particular, the key drug 
peak at 1645 cm
─1
and 1251 cm
─1
 have shifted to 1667 cm
─1
and 1242 
cm
─1
respectively in the spectrum of IC. These spectral shifts and modifications in the 
IC indicated the encapsulation of drug in CD cavity due to the formation of an IC 
(Bilensoy et al., 2007). 
5.2.1.3 XRD Analysis 
Figure 5.7 shows the wide-angle XRD profiles of CD, 5FU, PM and IC. The 
crystalline nature of 5FU was established by its diffraction profile which shows a 
sharp peak at 2θ of 28.6°. The diffractogram of the PM revealed some new peaks 
along with the characteristic peaks of CD and 5FU, which could be attributed to some 
interaction of CD with 5FU in the PM. On the other hand, the diffractogram of IC was 
completely different as compared to the parent components. A somewhat amorphous 
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profile was observed for the IC, which might be due to the freeze-drying method of 
preparation. 
 
Figure 5.7. XRD profiles of CD, 5FU, physical mixture (PM) and inclusion complex 
(IC). 
5.2.1.4 DSC Analysis 
The DSC endotherms of CD, 5FU, PM and IC are displayed in Figure 5.8. 
 
Figure 5.8. DSC thermograms of CD, 5FU, physical mixture (PM) and inclusion 
complex (IC). 
The thermogram of 5FU was typical of a crystalline anhydrous substance showing an 
exothermic peak around 290°C indicating its melting point. For the PM, the 
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thermogram corresponding to both CD dehydration and DX melting was observed. 
The absence of the drug peak and the presence of the wide thermogram of CD in the 
DSC curve of the IC signified the inclusion of 5FU in CD cavity. 
5.2.1.5SEM Analysis 
The SEM images of CD, 5FU, PM and IC are presented in Figure 5.9. The images 
were taken at 5.00 kV and 500  magnification. The images demonstrate the typical 
crystals of CD (Figure 5.8 A) in polyhedral shapes while the particles of 5FU (Figure 
5.8 B) appear as crystalline particles with larger dimensions. The PM (Figure 5.8 C) 
was found to contain both the crystals of CD and 5FU. However the particles of the IC 
(Figure 5.8 D) were found to be quite flaky in nature, unlike the morphologies of CD 
and 5FU. This agrees with the XRD studies which had previously established the 
amorphous nature for the IC. Thus the SEM analyses are indicative of the formation of 
new entities due to the complexation between 5FU and CD. 
 
Figure 5.9. SEM images of (A) CD, (B) 5FU, (C) physical mixture (PM) and           
(D) inclusion complex (IC). 
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5.2.1.6 
1
H NMR studies 
The 
1
H NMR spectra for CD and IC obtained in D2O are shown in Figure 5.10. 
 
Figure 5.10. 
1
H NMR spectra of CD and inclusion complex (IC) in D2O at 298K. 
The values of chemical shifts for the H−3 and H−5 protons of CD and IC are 
compared and their differences are listed in Table 5.2. From the table, [Δ(δH−3)] = 
[Δ(δH−5)] is clearly indicated. Thus the formation of IC is verified from the 1H NMR 
spectral data and total inclusion of 5FU in CD cavity is confirmed. 
Table 5.2. δ and Δδ of protons in CD and 5FU-CD IC 
Protons δ CD δ IC Δ (δ CD and δ IC) 
H−1 4.991 5.011 0.020 
H−2 3.561 3.465 0.096 
H−3 3.874 3.822 0.052 
H−4 3.496 3.405 0.091 
H−5 3.761 3.709 0.052 
H−6 3.790 3.697 0.093 
 
5.2.2 Characterization of Hydrogels 
5.2.2.1 FTIR Analysis 
The FTIR spectra of the hydrogels are represented in Figure 5.11. A strong hydroxyl 
stretching absorption characteristic appears at around 3400 cm
─1
 in all the hydrogels. This 
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band corresponds to the hydroxyl stretching of GG. The amide I band at 1658 cm
─1
 (C=O 
stretching) and the amide II band at 1538 cm
─1
 (N−H bending) of the amide group of 
PNIPAAm are also observed in all the IPN hydrogels. The spectra of the hydrogels 
also exhibited peaks in the region of 1000−1200 cm─1 which are attributed to the 
absorption bands of secondary alcohol or cyclic ether of the six-member rings on GG 
backbone (Li et al., 2008).  
 
Figure 5.11.FTIR spectra of GG, GN11, GN21 and GN41 hydrogels. 
 
5.2.2.2 XRD Analysis 
 
The XRD profiles of the IPN hydrogels are displayed in Figure 5.12. GG presents a 
semi-crystalline nature with a broad diffraction pattern around 20
o
 and the crystalline 
regions are seen at 2θ of 29.6o and 36o which are the characteristics positions of the 
reflections from cellulose II (Zhang et al., 2012). The IPN hydrogels exhibited almost 
similar diffraction profiles as that of the GG hydrogel but a slight decrease in the 
intensities of the crystalline peaks was observed probably due to the interpolymer 
interaction. 
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Figure 5.12.XRD profiles of GG, GN11, GN21 and GN41 hydrogels. 
 
5.2.2.3 DSC Analysis 
The LCSTs of the GG−PNIPAAm hydrogels were determined from their DSC 
thermograms and shown in Figure 5.13. The PNIPAAm hydrogel showed the LCST 
around 33°C, which matches with that of the reported value (Zhang et al., 2004). The 
GN11, GN21 and GN41 hydrogels also exhibited LCST around 33°C. The invariance 
of the LCST with varying GG content implies that the arrangement of the PNIPAAm 
networks in the IPN hydrogels is more or less intact even after incorporation of GG. 
Previously it had been observed that copolymerization of a hydrophilic moiety into 
PNIPAAm hydrogel usually shifts the LCST to a higher temperature (Vernon et al., 
2007). Reversibly, the use of a hydrophobic moiety decreases the LCST (Koga et al., 
2001). In the present study, it could be inferred that no strong interactions were 
introduced into the PNIPAAm hydrogel by addition of GG and the thermo-sensitivity 
of the PNIPAAm was retained. It was also concluded that the incorporation of GG did 
not have a drastic impact on the LCST of the hydrogels. Similar results have also been 
observed earlier (Li et al., 2008; Zhang et al., 2005). 
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Figure 5.13. DSC thermograms of PNIPAAm, GN11, GN21 and GN41 hydrogels. 
5.2.2.4 SEM Analysis 
The morphology of the lyophilized hydrogels is represented in Figure 5.14. 
 
 
Figure 5.14. SEM images of GG, GN11, GN21 and GN41 hydrogels. 
The SEM images reveal the highly porous morphology of the pure GG hydrogel. A 
distinct difference in the morphology of the IPN hydrogels and the GG hydrogel was 
observed. Though the IPN hydrogels also exhibited a somewhat porous nature, the 
porosity was greatly reduced in comparison to the GG hydrogel.  An increase in the 
GG content led to the formation of a comparatively denser hydrogel network. This 
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increased network density could be attributed to the intermolecular hydrogen bonding 
between GG and PNIPAAm or intramolecular hydrogen bonding between the side-
chains of GG and its backbones (Li et al., 2008). Even the influence of cross-linking 
might be playing a role in the modification of the network structure. Thus the 
interplay of the above factors defines the morphology of the hydrogels. 
5.2.3 Swelling Studies 
5.2.3.1 Swelling in pH 7.4 buffer at 25°C and 37°C 
The time-dependent swelling profiles of GN11, GN21 and GN41 hydrogels in pH 7.4 
buffer at 25°C and 37°C, are illustrated in Figure 5.15 A and B, respectively. 
 
 
Figure 5.15. Time-dependent swelling profiles of GN11, GN21 and GN41 hydrogels 
in pH 7.4 buffer at (A) 25°C and (B) 37°C. 
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Higher swellability for the hydrogels was observed at 25°C than 37°C. The order of 
swelling of the hydrogels was found to be GN11 > GN21 > GN41. This implied that 
an increase in GG content in the matrix results in a decreased swelling capacity of the 
hydrogels. As evident from the SEM images, the GN41 hydrogel matrix structure was 
found to be relatively dense therefore it restricts the inflow of solvent molecules into 
the network which eventually leads to a lowering in its swelling ability. 
5.2.3.2 Temperature−dependent Swelling 
The equilibrium swelling ratios of the hydrogels in pH 7.4 buffer as a function of 
temperature is represented in Figure 5.16.  
 
 
Figure 5.16. Temperature-dependent equilibrium swelling profiles of (A) GG, 
PNIPAAm and (B) GN11, GN21, GN41 hydrogels in pH 7.4 buffer. 
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Figure 5.16 A illustrates the swelling profiles of pure GG and PNIPAAm hydrogels in 
pH 7.4 buffer as a function of temperature. As evident, the GG hydrogel did not show 
any thermo-responsive behaviour; only a small increase in swelling percentage was 
observed due to the increased diffusion of water with temperature. However, a clear 
phase transition around 32°C is observed for the PNIPAAm hydrogel. The phase 
transition of PNIPAAm is the result of the balance between the hydrophobic and 
hydrophilic segments in the polymer chain (Otake et al., 1990). PNIPAAm consists of 
the hydrophilic amido group (−CONH−) and a hydrophobic group (isopropyl−). 
Below LCST, the cooperative interaction (intermolecular hydrogen bonding) between 
the hydrophilic amide groups and the surrounding water molecules improve the 
hydrophilic characteristic of the hydrogel. Thus with decrease in temperature, the 
hydrophilic character is dominant and an enhanced swelling is observed (Zhang et al., 
2004). The water penetrating into the hydrogels is in a bound state at low 
temperatures. Upon increasing the temperature, the water molecules gain enthalpy and 
the intramolecular interaction becomes stronger while the intermolecular interactions 
between the polymer and water molecules weaken i.e. the hydrophobic force of the 
isopropyl group of the PNIPAAm chain increases. Thus the hydrophilic/ hydrophobic 
balance is disturbed in the PNIPAAm chains. The water present in the matrix is 
expelled out and the matrix experiences reduced swelling. In other words, the 
hydrogels showed contraction above the LCST, which is marked by the decrease in 
the swelling ratios. Both the hydrogels were found to be highly swelling matrices as 
indicated by their swelling values. 
The swelling patterns of the IPN hydrogels are depicted in Figure 5.16 B. A region of 
minimum in the plots of swelling values with temperature occurs around 32°C in the 
GN11, GN21 and GN41 hydrogels. This indicates that the gel transition temperature 
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of PNIPAAm was not affected by the added GG component in the hydrogels. Among 
the IPN hydrogels, GN41 showed the least amount of water uptake may be due to the 
increased matrix density.  
Photographs depicting the phase-transition of GN11 hydrogel is shown in Figure 5.17. 
 
Figure 5.17. Photographs depicting the phase-transition ofGN11 hydrogel at different  
   temperatures. 
The  photographs of the phase-transition of GN11 hydrogel swollen in pH 7.4 buffer 
at different temperatures of 15°C, 25°C, 32°C, 45°Cand 50°C are shown in Figure 
5.17. The hydrogel, below the LCST, appears translucent. However, the hydrogel has 
shrunk in dimensions and appeared opaque at temperatures above the LCST of 
PNIPAAm. Thus the phase-transition of GN11 hydrogel is clearly visualized from the 
above photographs. 
5.2.4 In vitro Drug Release Studies and Kinetics 
5.2.4.1 In vitro 5FU Release Studies 
The drug release patterns from GG-5FU, GG-IC, PNIPAAm-5FU and PNIPAAm-IC 
hydrogels and that from GN11-5FU and GN11-IC hydrogels in pH 7.4 buffer at the 
physiological temperature of 37°C are represented in Figures 5.18 A and Figures 5.18 
B, respectively.  
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The release of 5FU from GG and PNIPAAm hydrogels were found to be very rapid 
and almost over by 2 h. Even for the GG-IC and PNIPAAm-IC hydrogels, where the 
drug is present in the form of IC with CD, the rate of drug release was almost similar 
to that of GG-5FU and PNIPAAm-5FU hydrogels containing the free drug. Thus, for 
the GG-IC and PNIPAAm-IC hydrogels, the role of CD was insignificant in 
controlling the drug release.  
 
 
Figure 5.18. Drug release profiles of (A) GG-5FU, GG-IC, PNIPAAm-5FU, 
PNIPAAm-IC, and (B) GN11-5FU GN11-IC hydrogels in pH 7.4 
buffer at 37°C. 
As compared to the pure GG and PNIPAAm hydrogels the drug release was found to 
be significantly prolonged from the IPN hydrogels. Moreover, a remarkable difference 
was also observed in the release rates of 5FU from the GN11-5FU and GN11-IC 
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hydrogels. The GN11-IC hydrogel released the drug much slower than the GN11-5FU 
hydrogel containing the free drug. This could be attributed to the diffusion barrier 
imposed by CD on the drug diffusion from the GN11-IC hydrogel. From the above 
study it is clear that incorporation of IC into the hydrogel matrix is capable of 
controlling the drug release rate despite the fact that the matrix is undergoing a drastic 
morphological change above its LCST. 
 
 
Figure 5.19. Drug release profiles of (A) GN11-5FU, GN21-5FU, GN41-5FU and (B) 
GN11-IC, GN21-IC, GN41-IC hydrogels in pH 7.4 buffer at 25°C and  
(C) GN11-5FU, GN21-5FU, GN41-5FU and (D) GN11-IC, GN21-IC, 
GN41-IC hydrogels in pH 7.4 buffer at 37°C. 
To investigate the temperature-sensitivity of the synthesized hydrogels drug release 
experiments were performed at two different temperatures, below (25°C) and above 
(37°C) the LCST, in pH 7.4 buffer solutions. The release profiles of the drug from all 
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the synthesized GG−PNIPAAm IPN hydrogels in pH 7.4 buffer at 25°C and 37°C, are 
illustrated in Figure 5.19. The rate of drug release was found to be much slower at 
37°C than at 25°C from all the hydrogels irrespective of whether they contained free 
5FU or the IC. This could be explained by considering the temperature dependence in 
the swelling characteristics of the hydrogels. Since the hydrogels are in a contracted 
state at 37°C, the swellabilty is low and thus drug release is retarded. On the other 
hand, at 25
o
C the hydrogels are in a swollen state therefore exhibiting a rapid release 
characteristic. However, at any time, the amount of drug released from the hydrogel 
containing IC is always less than that of the corresponding hydrogel with the free 
5FU. This release profile signified the vital role of CD in the drug release 
phenomenon from the hydrogels and the temperature responsiveness of the hydrogels. 
Figure 5.19 also illustrates the effect of GG content on the rate of drug release. The 
order of drug release from the hydrogels was found to be GN11-5FU > GN21-5FU > 
GN41-5FU. Similarly the IC containing hydrogels followed the order GN11-IC > 
GN21-IC > GN41-IC. This suggested that an increase in GG content led to a decrease 
in the rate of the drug release from the hydrogels. The above observations hold true 
for the release data conducted at both the experimental temperatures. The GN41-IC 
hydrogel was found to exhibit the slowest drug releasing characteristics and 
considered as the optimum hydrogel for the controlled delivery of 5FU. Thus 
controlled delivery of 5FU from the thermo-responsive GG−PNIPAAm IPN 
hydrogels is accomplished as a result of the synergistic effects of drug complexation 
with CD and the nature of the hydrogel matrix.   
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5.2.4.2 5FU Release Kinetics  
The fitting parameters for the drug release data at 25°C and 37°C obtained by fitting 
to various mathematical models are tabulated in Tables 5.3 and 5.4, respectively. 
From Table 5.3, it is clear that the kinetics of drug release at 25°C mostly conform to 
Ritger-Peppas and Peppas-Sahlin models. The value of the diffusional exponent n 
lying between 0.77 and 0.89 specifies anomalous type of drug release from the 
hydrogels. 
It is also evident from Table 5.4 that the drug release at 37°C also points to Ritger-
Peppas and Peppas-Sahlin models. Anomalous type of drug release is indicated by the 
value of n lying between 0.74 and 0.96.  
 R
eg
u
la
tin
g
 th
e D
elivery o
f 5
F
U
......G
G
−
P
N
IP
A
A
m
 H
yd
ro
g
els 
2
2
0
 
 
T
a
b
le 5
.3
.5
F
U
 release p
aram
eters fittin
g
 to
 v
ario
u
s m
ath
em
atical m
o
d
els at 2
5
°C
 
             
S
a
m
p
le
 
H
ig
u
ch
i 
R
itg
er–
P
ep
p
a
s 
P
ep
p
a
s-S
a
h
lin
 
Z
ero
-O
rd
er
 
k
 (h
−
0
.5) 
R
2 
n
 
k
’ (h
−
n) 
R
2 
k
1  (h
−
0
.5) 
k
2  (h
−
1) 
R
2 
k
” (h
−
1) 
R
2 
G
N
1
1
-5
F
U
 
0
.2
7
4
 
0
.8
9
3
 
0
.7
7
 
0
.2
1
6
 
0
.9
8
8
 
0
.1
1
5
 
0
.1
0
2
 
0
.9
8
8
 
0
.1
7
3
 
0
.9
4
0
 
G
N
2
1
-5
F
U
 
0
.2
2
7
 
0
.8
6
0
 
0
.8
6
 
0
.1
4
9
 
0
.9
9
5
 
0
.0
5
4
 
0
.0
9
1
 
0
.9
9
4
 
0
.1
2
6
 
0
.9
8
2
 
G
N
4
1
-5
F
U
 
0
.1
5
1
 
0
.7
9
6
 
1
.0
8
 
0
.0
7
8
 
0
.9
9
6
 
0
.0
3
7
 
0
.0
6
2
 
0
.9
9
4
 
0
.0
8
5
 
0
.9
9
4
 
G
N
1
1
-IC
 
0
.1
9
3
 
0
.8
6
5
 
0
.8
6
 
0
.1
2
8
 
0
.9
9
5
 
0
.0
8
0
 
0
.0
5
0
 
0
.9
9
6
 
0
.1
0
7
 
0
.9
8
0
 
G
N
2
1
-IC
 
0
.1
5
9
 
0
.8
1
8
 
0
.8
9
 
0
.0
9
1
 
0
.9
8
7
 
0
.0
2
8
 
0
.0
6
3
 
0
.9
8
4
 
0
.0
7
6
 
0
.9
7
6
 
G
N
4
1
-IC
 
0
.1
2
9
 
0
.8
3
1
 
0
.8
6
 
0
.0
6
5
 
0
.9
8
7
 
0
.0
2
8
 
0
.0
3
9
 
0
.9
8
3
 
0
.0
4
9
 
0
.9
6
3
 
 R
eg
u
la
tin
g
 th
e D
elivery o
f 5
F
U
......G
G
−
P
N
IP
A
A
m
 H
yd
ro
g
els 
2
2
1
 
 
  
T
a
b
le 5
.4
.5
F
U
 release p
aram
eters fittin
g
 to
 v
ario
u
s m
ath
em
atical m
o
d
els at 3
7
°C
 
 
S
a
m
p
le
 
H
ig
u
ch
i 
R
itg
er–
P
ep
p
a
s 
P
ep
p
a
s-S
a
h
lin
 
Z
ero
-O
rd
er
 
k
 (h
−
0
.5) 
R
2 
n
 
k
’ (h
−
n) 
R
2 
k
1  (h
−
0
.5) 
k
2  (h
−
1) 
R
2 
k
” (h
−
1) 
R
2 
G
N
1
1
-5
F
U
 
0
.2
7
7
 
0
.8
9
9
 
0
.7
9
 
0
.2
1
6
 
0
.9
9
9
 
0
.1
0
6
 
0
.1
1
0
 
0
.9
9
7
 
0
.1
7
6
 
0
.9
6
1
 
G
N
2
1
-5
F
U
 
0
.1
8
5
 
0
.8
3
9
 
0
.8
6
 
0
.1
1
2
 
0
.9
9
2
 
0
.0
6
7
 
0
.0
4
7
 
0
.9
8
8
 
0
.0
8
8
 
0
.9
7
2
 
G
N
4
1
-5
F
U
 
0
.1
4
9
 
0
.8
9
2
 
0
.7
4
 
0
.0
9
3
 
0
.9
9
2
 
0
.0
7
3
 
0
.0
2
8
 
0
.9
9
0
 
0
.0
5
4
 
0
.9
0
5
 
G
N
1
1
-IC
 
0
.1
4
2
 
0
.7
8
1
 
0
.9
6
 
0
.0
8
6
 
0
.9
9
3
 
-0
.0
1
7
 
0
.0
9
1
 
0
.9
9
4
 
0
.0
7
3
 
0
.9
6
2
 
G
N
2
1
-IC
 
0
.1
3
0
 
0
.8
0
3
 
0
.9
1
 
0
.0
6
0
 
0
.9
9
0
 
0
.0
2
5
 
0
.0
4
0
 
0
.9
9
0
 
0
.0
4
9
 
0
.9
8
2
 
G
N
4
1
-IC
 
0
.1
0
6
 
0
.8
3
8
 
0
.8
9
 
0
.0
3
9
 
0
.9
9
0
 
0
.0
1
6
 
0
.0
2
5
 
0
.9
9
2
 
0
.0
2
9
 
0
.9
8
0
 
 Regulating the Delivery of 5FU......GG−PNIPAAm Hydrogels 
222 
 
In order to further demonstrate the importance of the polymer relaxation on the drug 
release mechanism from the hydrogels, plots of R/ F versus the fraction of drug 
released were constructed for the drug release data. Figure 5.20 presents the R/F plots 
for the drug release at 25°C and 37°C. 
 
Figure 5.20. Plots of ratio of relaxation to the Fickian contribution (R/F) with the  
fraction of dug released from hydrogels (A) GN11-5FU, GN21-5FU, 
GN41-5FU; (B) GN11-IC, GN21-IC, GN41-IC hydrogels at 25°C and 
(C) GN11-5FU, GN21-5FU, GN41-5FU and (D) GN11-IC, GN21-IC, 
GN41-IC hydrogels at 37°C in pH 7.4 buffer. 
In both the cases, the IC containing hydrogels were found to exhibit higher R/F values 
than the corresponding hydrogels containing the free drug.  This indicated that the 
presence of CD influences the relaxation rate of the polymers which in turn retards the 
drug release. This can be explained by considering either the presence of hydrogen 
bonding interaction between the CDs and polymers or the CDs getting cross-linked to 
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some extent in the presence of the cross-linker TEOS. The value of R/F was found to 
be the maximum for the GN41-IC hydrogels irrespective of the temperature.  
5.2.5 Cytotoxicity Assay 
Since PNIPAAm is known to have poor biocompatibility, it is inevitable to test the 
cytotoxicity of the GGPNIPAAm hydrogels before their use as drug delivery 
systems. The biocompatibility of GN41 hydrogel on L-929 rat fibroblasts was assayed 
by MTT colorimetric technique and the photograph obtained after 48 h incubation is 
shown in Figure 5.21. 
 
Figure 5.21. Optical micrographs of L−929 cells cultured after 48h incubation with  
   GN41 hydrogel. 
Direct contact between L-929 cells and the hydrogel did not reveal any adverse effect. 
This suggested the compatibility with the living tissues and non-toxicity of the 
hydrogel thus validating these as possible drug delivery systems. 
 
5.3 CONCLUSIONS 
 Solid ICs of 5FU in CD were prepared by the freeze drying/ lyophilization 
technique. The obtained ICs were characterized by FTIR, XRD, DSC, SEM 
and 
1
H NMR studies. The formation of ICs was affirmed from the above 
analyses.  
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 Temperature-responsive GG−PNIPAAm hydrogels cross-linked by TEOS 
were synthesized by solution casting technique. The hydrogels were also 
characterized by various spectroscopic techniques such as FTIR, XRD, DSC 
and SEM.  
 The FTIR analyses indicated the presence of amide-I and amide-II of 
PNIPAAm in the IPN hydrogels. An increase in GG content led to a decrease 
in the crystallinity of the hydrogels.  
 The DSC thermograms indicated that the incorporation of GG did not disturb 
the arrangement of PNIPAAm chains and the LCST remained invariant.  
 The hydrogels displayed temperature-dependent swelling characteristics. 
Higher swelling was observed at low temperatures (below the LCST of 
PNIPAAm) while a sudden drop in swelling ratio was observed around 32°C 
(LCST of PNIPAAm).  
 The swelling behaviour indicated that the PNIPAAm present in the hydrogel 
had retained its thermo-sensitivity.  
 The hydrogels also exhibited temperature dependence in their drug releasing 
characteristics. At higher temperature (above LCST) the release rate was 
considerably slower than that at lower temperature (below LCST). 
 The rate of drug release was always slow from the hydrogels containing the 
ICs as compared to the hydrogels containing the free drug.  
 Presence of IC in the hydrogel matrix is capable of significantly controlling the 
drug release rate despite the fact that the matrix is undergoing a drastic 
morphological change above its LCST. 
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 Higher amount of GG in the hydrogels led to a decrease in the release rate 
from the hydrogels. The order of drug release was found to be GN11 > GN21 
> GN41.  
 The GN41-IC hydrogel was found to be the optimum with slowest drug 
releasing characteristics.  
 The preliminary analyses of drug release indicated Case II type of mechanism 
from the hydrogels at both the temperatures of 25°C and 37°C.  
 Further analysis of R/ F values established the predominant effect of 
macromolecular relaxation on the drug release behaviour of the hydrogels.  
 The presence of CD in the hydrogels as ICs was vital in influencing the 
polymer relaxation and retarding the drug release rate from the hydrogels 
containing the ICs.  
 The cytotoxicity assay performed on rat fibroblasts certified the GG-
PNIPAAm hydrogels to be safe, nontoxic and biocompatible with living 
tissues thereby validating their potential as controlled drug delivery systems.    
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EVALUATING GUAR GUM−POLY(ACRYLIC ACID) 
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6.1 INTRODUCTION 
Introduction of cyclodextrins into hydrogels plays a vital role in deciding the drug 
release profiles (Concheiro and Alvarez-Lorenzo, 2013; Crini et al., 1998). 
Incorporation of cyclodextrins into polymeric drug release systems has been known to 
influence the mechanism by which the drug is released (Bibby et al., 2000). A range 
of strategies have been explored to modify cyclodextrin integrated hydrogels to meet 
desired drug delivery profiles. Hydrogels in which CDs form a part of the network 
structure, can be obtained by cross-linking of CDs with the polymer backbone or by 
copolymerization of CD with the hydrogel network (Alvarez-Lorenzo et al., 2011; 
Prabaharan and Gong, 2008; Prabaharan and Mano, 2005; Fulop et al., 2013; 
Kobayashi et al., 1989). Hydrogels bearing CDs as pendant groups have been 
constructed for modifying drug release rates (Liu et al., 2004; Liu et al., 2005; Szetjli 
et al., 1978). CS hydrogels bearing CDs as pendant groups have been used as carriers 
for controlled protein release (Zhang et al., 2009). Even hydrogels containing grafted 
CDs have been utilized in controlled drug delivery (Nielsen et al., 2009; Zhang et al., 
2008; Salmaso et al., 2007; Zhang et al., 2004; Prabaharan and Mano, 2005). 
Hydrogels where CD has been blended with the polymer matrix have also shown 
potential to prolong drug release (Sreenivasan, 1997). The details regarding the 
various strategies employed for the integration of CDs with different hydrogels and 
their applications have been discussed in Chapter 1. Efforts are still being directed 
towards integrating CDs with different hydrogels to design novel drug delivery 
systems.  
Mateen and Hoare (2014) have recently synthesized cyclodextrin-dextran hydrogels 
where CD is covalently attached to the polymer network through chemical cross-
linking and utilized for the controlled delivery of DX. Machin and co-workers (2012) 
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prepared discs of insoluble CD polymers by cross-linking with EPI. The potential of 
the synthesized discs against two anti-inflammatory (NX and nabumetone) and 
antifungal drugs (naftifine and terbinafine) was investigated. Drug release data 
evidenced the suitability of these hydrogel as sustained release systems. Pinho and co-
authors (2014) have recently illustrated the efficacy of CD-based hydrogels as wound 
dressing materials. A series of CD grafted carboxymethyl CS hydrogels have been 
constructed using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride as 
cross-linker in presence of N-hydroxysuccinimide (Kono and Teshirogi, 2015).  The 
CD grafted hydrogels prolonged the release of acetylsalicylic acid (ASA) in 
comparison to ASA release from pure carboxymethyl CS hydrogel.  Hydrogels based 
on the inclusion efficiency of CD have also been developed towards controlled 
delivery of drugs. Hybrid hydrogels based on host-guest interaction have been 
employed for the delivery of various anticancer drugs (Yu et al., 2014; Yu et al., 
2014; Wu et al., 2014). CD-based supramolecular assemblies for drug delivery 
purposes have been excellently reviewed by various research groups (Harada et al., 
2014; Tan et al., 2014; Zhang and Ma, 2013; Chen and Jiang, 2011; Li and Loh, 
2008). A plethora of literature is available regarding CD-integrated hydrogels towards 
controlled drug delivery applications. However, a comparative study of the drug 
delivery efficacy of hydrogels containing CD as a part of their network structure and 
hydrogels with preformed drug-CD ICs is yet to be explored. 
OBJECTIVES 
The focus of the present chapter is to evaluate GG-PAA-CD hydrogels, where CD is 
present as a part of the network structure, for the delivery of DX. Further, to compare 
the drug delivery efficacy of these hydrogels with that of the GG-PAA hydrogels 
containing preformed DX-CD ICs. GG matrices, as such are highly hydrophilic with 
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less mechanical strength (Li et al., 2008). To improve the mechanical integrity, GG 
has been usually employed in an IPN with other polymers. GG IPN hydrogels have 
been developed in combination with PAA which improves the mechanical strength of 
the hydrogel (Huang et al., 2007). Moreover, GG-PAA IPN hydrogels exhibit pH-
sensitivity; therefore can be utilized as pH-responsive drug delivery vehicles.  
The specific objectives of the present study are: 
 Synthesis and characterization of TEOS cross-linked GG-PAA IPN hydrogels 
containing CD moieties. 
 Synthesis of TEOS cross-linked GG-PAA hydrogels containing free DX as 
well as preformed DX-CD ICs. 
 Evaluation of the swelling capacities and antimicrobial activities of the 
hydrogels. 
 Estimation of the drug loading efficiencies of the hydrogels. 
 Comparison of the drug delivery characteristics of the GG-PAA hydrogels 
containing CD in their networks and the hydrogels containing DX-CD ICs. 
 Addressing the preliminary drug release kinetics. 
 Cytotoxic assay of the hydrogels on L-929 mice fibroblasts. 
The composition and designation of the synthesized hydrogels by varying the amounts 
of GG and PAA are listed in Table 6.1. 
Table 6.1. Composition and designation of synthesized GG−PAA hydrogels 
Sample 
 
GG: AAc 
(%) 
Sample Designation 
GG-PAA 
(GP) 
GG-PAA-CD 
(GP-CD) 
1 1:0 GP10 GP10-CD 
2 0:1 GP01 GP01-CD 
3 1:1 GP11 GP11-CD 
4 1:2 GP12 GP12-CD 
5 1:4 GP14 GP14-CD 
6 2:1 GP21 GP21-CD 
7 4:1 GP41 GP41-CD 
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Hydrogels comprising GG and PAA are represented as GP and those containing CD 
are represented as GP-CD, in general. The numerical values represent the molar ratio 
of the parent components. The hydrogels containing the ICs of DX with CD have been 
designated accordingly. For the characterization and swelling studies, GP and GP-CD 
designation indicate the respective hydrogels without any drug. For the drug release 
studies, the GP and GP-CD hydrogels were loaded with DX. The ICs were prepared 
by the freeze drying method and a detailed discussion regarding the formation of ICs 
has been presented in Chapter 4. 
6.2 RESULTS AND DISCUSSION 
6.2.1 Hydrogel Characterization 
6.2.1.1 FTIR Analysis 
The FTIR spectra of GP10, GP10-CD, GP01 and GP01-CD hydrogels are presented in 
Figure 6.1 A. For GP10 and GP10-CD hydrogels, the bands around 3400 cm
−1
, and 
30002800 cm1 are associated with the O−H and C−H stretching vibration modes, 
respectively and the peak at 1645 cm
−1
 is attributed to the ring stretching of the guar 
gum polymer backbone. The C−OH and the primary alcoholic CH2OH stretching are 
observed in the region of 1120 cm
−1
. The peak around 1400 cm
−1
 is due to the CH2 
deformation. The peaks observed in the 800−1200 cm−1 represent the highly coupled 
C−C−O, C−OH and the C−O−C stretching modes of the polymer (Mudgil et al., 
2012). The FTIR spectra of GP01 and GP01-CD show a broad band in the range 3500 
 3300 cm−1 owing to the hydroxyl stretching vibrations. The most important band is 
the 1640 cm
−1
 which is due to carbonyl stretching vibration, present in both the 
hydrogels. The band at 1417 cm
−1
 is associated with the bending vibrations of 
CH−CO groups. The bands at 1255 and 1192 cm−1 are attributed to the coupling 
between in-plane O−H bending and C−O stretching of the hydroxyl groups 
(Moharram and Khafagi, 2007). 
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Figure 6.1. FTIR spectra of (A) (a) GP10, (b) GP10-CD, (c) GP01, (d) GP01-CD; (B) 
GP and (C) GP-CD hydrogels; (a) GP11, (b) GP12, (c) GP14, (d) GP21, 
(e) GP41, (a') GP11-CD, (b') GP12-CD, (c') GP14-CD, (d') GP21-CD, (e') 
GP41-CD hydrogels. 
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In comparison with the pure samples, a shift in the carbonyl stretching peak to 1575 
cm
−1 
is observed in the spectra of the synthesized GP and GP-CD hydrogels (Figures 
6.1 B and C) which can be assigned to the symmetric deformation of COO
− 
(Huang et 
al., 2007). The characteristic 1417 cm
−1
 peak of PAA is also observed in the spectra of 
the hydrogels. This peak is most intense and sharp in GP14 and GP14-CD hydrogels 
but a decrease in the intensity of this particular peak is observed in the spectral 
profiles of GP21, GP21-CD, GP41 and GP41-CD hydrogels. This might be because of 
the dominant effect of GG in these hydrogels. Similar was the case observed with the 
peak at 1645 cm
−1
 due to the ring stretching of guar gum. The spectra of GP41 and 
GP41-CD hydrogels showed a more intense 1645 cm
−1
 peak than other hydrogels. 
Moreover, the peaks observed at 1020 and 1083 cm
−1
 in the spectra of all the 
synthesized hydrogels confirm the presence of the siloxane bond (Si−O−) resulting 
from the cross-linker TEOS (Islam and Yasin, 2012). 
6.2.1.2 XRD Analysis 
The X-ray diffraction profiles of the synthesized GP and GP-CD hydrogels are shown 
in Figures 6.2 A and B respectively. Results evidenced that all hydrogels except GP01 
and GP01-CD presented a semi-crystalline nature. GP01 and GP01-CD hydrogels 
show a broad diffraction around 22° indicating the amorphous nature of the hydrogels. 
GP10 and GP10-CD hydrogels show a broad diffraction pattern around 20.5° and 
several crystalline peaks are observed at diffraction angles (2θ) 29.6°, 36°, 39.4°, 
43.2° and 48.5°. Pure GG is known to present a broad diffraction pattern at 20.5° 
(Mudgil et al., 2012) and the characteristics crystalline regions of the reflections from 
cellulose II (Hu and Hsieh, 1996). The GP and GP-CD hydrogels showed similar 
diffraction patterns as that of GP10 and GP10-CD hydrogels. However, a decrease in 
the intensity of the crystalline peaks was observed in the IPN hydrogels. This could be 
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attributed to the interpolymer interaction. Thus the XRD profiles clearly demonstrate 
the proper mixing of both the polymer components as well as CD in the resulting 
hydrogels.  
 
 
Figure 6.2. XRD profiles of (A) GP hydrogels; (a) GP10, (b) GP01, (c) GP11, (d) 
GP12, (e) GP14, (f) GP21 and (g) GP41,(B) GP-CD hydrogels; (a') GP10-
CD, (b') GP01-CD, (c') GP11-CD, (d') GP12-CD, (e') GP14-CD, (f') 
GP21-CDand (g') GP41-CD. 
 
6.2.1.4 DSC Analysis 
The DSC thermograms of the synthesized hydrogels are shown in Figure 6.3.  
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Figure 6.3. DSC thermograms of (A) GP10, GP10-CD, GP01, GP01-CD; (B) GP11, 
GP21, GP41, and (C) GP11-CD, GP21-CD, GP41-CD hydrogels. 
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The DSC thermograms of GP10 and GP01 reveal strong endothermic peaks around 
83°C and 75°C respectively, which match with the reported Tg values for GG and 
PAA (Khutoryanskiy et al., 2004; Singh, 2013). For the GP10-CD and GP01-CD 
hydrogels, the endotherms shifted to slightly higher temperatures at 86°C and 79°C, 
respectively. This can be probably due to the increased rigidity of the network 
structure upon incorporation of CDs in the hydrogels, which restrict the polymer chain 
mobility. The GP11 hydrogel showed a strong endothermic effect around 89.5°C, 
which is considerably higher than that of GP10 and GP01. This proved that the matrix 
of the resulting IPN is rigid in nature and possess higher thermal stability. For the 
GP11, GP21 and GP41 hydrogels (Figure 6.3 B); the endotherms shifted to higher 
temperatures with an increase in the GG content. Similar was the case observed for 
GP11-CD, GP21-CD and GP41-CD hydrogels (Figure 6.3 C). However, the Tg of the 
GP-CD hydrogels were always slightly higher than that of GP hydrogels, indicating an 
improved stability of these hydrogels due to the presence of CD in their network 
structures. In all IPN hydrogels, a single Tg indicates that the component polymers 
(GG and PAA) have good miscibility (Huang et al., 2007). 
6.2.1.5 SEM Analysis 
Figure 6.4 displays the SEM images of the freeze-dried GP and GP-CD hydrogels. As 
evident, the GP10 (Figure 6.4 A) and GP01 (Figure 6.4 B) hydrogels exhibit highly 
porous matrix structures with spongy appearance. With an increase in PAA content in 
GP11 (Figure 6.4 C), GP12 (Figure 6.4 D) and GP14 (Figure 6.4 E) increase in the 
pore diameter of the hydrogels was observed although the matrix appeared relatively 
denser than the pure components. 
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Figure 6.4. SEM images of (A) GP10, (B) GP01, (C) GP11, (D) GP12, (E) GP14, (F) 
GP21, (G) GP41, (A') GP10-CD, (B') GP01-CD, (C') GP11-CD, (D') 
GP12-CD, (E') GP14-CD, (F') GP21-CD and (G') GP41-CD hydrogels. 
 
On the other hand, an increase in GG content led to the formation of a more compact 
and dense matrix for GP21 (Figure 6.4 F) and GP41 (Figure 6.4 G) hydrogels. For the 
hydrogels containing CD, almost similar morphological behaviour is observed as that 
of the corresponding hydrogels without CD, which indicates that the presence of CD 
did not have any significant effect on the morphology of the hydrogels.    
6.2.2 Swelling Response of Hydrogels 
6.2.2.1 Swelling in Water 
The swelling characteristic is suggestive of the diffusion behaviour of molecules to 
and from the hydrogels. The swelling profiles of GP10, GP10-CD, GP01 and GP01-
CD hydrogels are shown in Figure 6.5.   
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Figure 6.5. Time-dependent swelling behaviour of GP10, GP01, GP10-CD and    
GP01-CD hydrogels in water at 37°C. 
 
As evident, the hydrogels undergo rapid swelling and maximum swelling was 
achieved within 2 h. The high extent of swelling in these hydrogels signifies their 
highly porous nature which was also observed from the SEM images. The presence of 
CD does not have any significant effect on the swellability of the hydrogels. 
Time-dependent swelling of GP and GP-CD hydrogels in a buffer of pH 7.4 and at a 
temperature of 37°C were studied and illustrated in Figure 6.6 and Figure 6.7. As it is 
evident from the figures the swelling ability of the IPN hydrogels is significantly 
lower as compared to the hydrogels having single polymer component (i.e. GP10 and 
GP01). This can be explained considering the increased network rigidity induced by 
the IPN process, which was quite apparent from the SEM studies.   
Effect of PAA Content on Swelling  
Figures 6.6 A and B describe the effect of PAA content on the swelling behaviour of 
GP11, GP12, GP14 and GP11-CD, GP12-CD, GP14-CD hydrogels. Upon increase in 
PAA content, the swellability of the hydrogels increased, i.e. more the PAA content, 
more is the swelling. The increase in PAA amount results in increased number of 
ionizable groups in the polymer network; as a result of which the swelling ratio is also 
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enhanced. Similar increase in the swellability was also observed for GP11-CD, GP12-
CD and GP14-CD hydrogels.  
 
 
Figure 6.6. Time-dependent swelling behaviour of (A) GP11, GP12, GP14 and (B) 
GP11-CD, GP12-CD, GP14-CD hydrogels in water at 37°C. 
 
Effect of GG Content on Swelling  
The influence of GG on the swelling behaviour of GP and GP-CD hydrogels is 
demonstrated in Figure 6.7 A and B. With increased amount of GG in the hydrogels, 
the swelling ratio decreased. This might be attributed to formation of dense network 
structure due to inter-polymeric interaction between GG and PAA. More is the GG 
content, denser is the matrix which further leads to lower uptake of water and thus 
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swelling is reduced (Li et al., 2006). This observation of swelling behaviour of the 
hydrogels with variation in PAA or GG content is also supported by the SEM data. 
 
 
Figure 6.7. Time-dependent swelling behaviour of (A) GP11, GP21, GP41 and (B) 
GP11-CD, GP21-CD, GP41-CD hydrogels in water at 37°C. 
 
6.2.2.2 pH-Dependent Swelling  
The presence of ionic groups in the hydrogels is susceptible to changes in the 
environmental pH. Figure 6.8 A shows the swelling of GP11, GP12, GP14, GP21 and 
GP41 hydrogels at different pHs. As evident, the swelling ratios increased gradually 
from pH 2 to pH 7 and then a lowering is observed at alkaline pH. Again it is observed 
that more the PAA content higher is the swelling ratio irrespective of the pH. The pH-
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sensitivity of these hydrogels is attributed to the presence of the ionizable carboxylic 
groups in PAA, which is a weak acid with an intrinsic pKa of around 4.28. At low pH 
(pH  4.28) the ionization of carboxylic groups is suppressed and there can be strong 
hydrogen bond interaction between the polymer chains that reduces the flexibility of 
the chains as a result the swelling capacity is lowered. At pH  4.28, the water content 
of the hydrogels increases due to the ionization of the carboxylic groups. The 
increased ionic repulsion increases the free volume in the polymer matrix enhancing 
the water inflow. Additionally, the negative charge generated by the carboxylic groups 
drives the flow of cations into the hydrogel increasing the ionic swelling pressure and 
the degree of swelling. On further increase in pH ( 7), the effect of ionic strength 
surpasses the effect of electrostatic repulsion between the carboxylate groups by 
shielding the negative charges by high concentrations of counter ions thereby reducing 
the swelling (Huang et al., 2007). The overall swelling behaviour of GP11-CD, GP12-
CD, GP14-CD, GP21-CD and GP41-CD hydrogels were found to be very similar to 
the corresponding hydrogels without CD (Figure 4.50 B). This indicates that the 
presence of CD did not have any drastic effect on the swelling abilities of the 
hydrogels. For the IPN hydrogels the swelling ratio followed the order GP14 > GP12 
> GP11 > GP21 > GP41, which is the same for the CD containing hydrogels as well. 
The microstructures of the GP14 hydrogel swollen in solutions of different pHs were 
investigated by SEM. Figure 6.8 C displays the SEM images of the lyophilized GP14 
hydrogel swollen in solutions of three different pHs, 2, 7.4 and 9. Since maximum 
swelling occurs in neutral pH, the hydrogel becomes highly porous in nature at this 
pH.  As lower swelling takes place in pH 9, the hydrogel porosity is slightly decreased 
in comparison to pH 7.4. The hydrogel swells the lowest in acidic medium (pH 2), 
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thus a relatively compact morphology is evident. Similar morphological changes have 
been observed by Jin et al., (2006) for PAA-PVP hydrogels. 
 
 
 
Figure 6.8. pH dependent swelling of (A)GP11, GP12, GP14, GP21, GP41 hydrogels 
and (B) GP11-CD, GP12-CD, GP14-CD, GP21-CD, GP41-CD hydrogels, 
and (C) SEM images of GP14 hydrogel swollen in pHs 2, 7.4 and 9. 
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6.2.3 Drug Loading Efficiency  
The amount of drug that can be loaded when a hydrogel is immersed in a drug 
solution usually depends on both, the concentration of the soaking solution and the 
affinity of the drug for the hydrogel polymer network (Kim et al., 1992). The 
equilibrium drug loading capacity of the synthesized hydrogels, with and without CD, 
was determined and listed in Table 6.2. 
Table 6.2. Drug loading efficacies of GP and GP-CD hydrogels 
Sample DX Loading (%) 
GP11 59 ± 2 
GP11−CD 65 ± 3 
GP12 50 ± 2 
GP12−CD 58 ± 3 
GP14 49 ± 4 
GP14−CD 56 ± 2 
GP21 56 ± 2 
GP21−CD 58 ± 3 
GP41 55 ± 2 
GP41−CD 57 ± 3 
 
It was observed that the presence of CD in the polymer matrix improved the drug 
loading capacitates of the hydrogels. For a particular PAA or GG content, the CD-
containing hydrogel encapsulated more drug than the one without CD. This could be 
explained by taking into consideration the affinity of CD for hydrophobic guests 
(DX). It was also evident that the loading efficiency decreased with an increase in the 
PAA content. Since DX is mainly encapsulated in the hydrophobic cavity of CD, an 
increase in −COOH group implies an increase in the hydrophilic character of the 
hydrogel, which in turn, might decrease the loading efficiency of the hydrogel (Harada 
et al., 1981). An increase in GG content also led to a decrease in the drug loading 
ability of the hydrogels. This effect could be possibly explained by formation of 
denser network structure with addition of GG which restricts the chain mobility and 
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reduction in the swellability, thereby preventing the in-flow of drug molecules during 
equilibrium loading. 
6.2.4 In vitro Dexamethasone Release Studies and Kinetics 
6.2.4.1 In vitro Dexamethasone Release Studies 
Figure 6.9 shows the release profiles of DX from GP10, GP10-CD, GP01 and GP01-
CD hydrogels at pH 7.4 and 37°C. DX release from GP10 and GP01 hydrogels, 
containing either GG or PAA, was found to be very fast and complete drug release 
takes place in a short period of time (< 2 h). This can be explained by considering the 
highly porous nature of these hydrogels leading to extensive swelling that result in 
rapid release of the drug. The GP10-CD and GP01-CD hydrogels showed a slightly 
prolonged release characteristic as compared to the corresponding hydrogels without 
CD. However, the presence of CD in these extensively swelling matrices does not 
have any significant effect on the release characteristics and the total release is over by 
3 h.  
 
Figure 6.9. DX release profiles of GP10, GP01, GP10-CD, GP01-CD, hydrogels in 
pH 7.4 at 37°C. 
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Effect of PAA Content on DX Release from Hydrogels 
Figures 6.10 A and B demonstrate the effect of PAA content on the drug release 
phenomenon from GP11, GP12, GP14 and GP11-CD, GP12-CD, GP14-CD hydrogels 
in pH 7.4 buffer at 37°C.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10. DX release profiles from (A) GP11, GP12, GP14 and (B) GP11-CD, 
GP12-CD, GP14-CD hydrogels in pH 7.4 buffer at 37°C. 
 
Comparing the release profiles of GP11, GP12 and GP14 hydrogels, no significant 
difference is observed in the drug release rates with the increased PAA content. 
However, careful scrutiny of the release profiles indicate the drug release to follow the 
order GP14 > GP12 > GP11 i.e. with the increased PAA content a somewhat faster 
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release of DX is observed. This can be rationalized by considering the effect of PAA 
content on the swelling ratio. Since the increased amount of PAA leads to highly 
swellable matrix, the drug release also follows similar trend. The CD containing 
hydrogels show just a nominal increase in the release rate of DX as compared to the 
corresponding hydrogels without the CD. The DX release from these hydrogels also 
shows similar dependence on PAA content and follows the order: GP14-CD > GP12-
CD > GP11-CD. However, the presence of CD does not have much control on the 
release rate from these highly swelling matrices.  
Effect of GG Content on DX Release from Hydrogels 
The effect of GG content on DX release from GP11, GP21, GP41 and GP11-CD, 
GP21-CD, GP41-CD hydrogels is clearly depicted in Figure 6.11 A and B, 
respectively. The drug release profiles are found to show a strong dependence on the 
GG content in the hydrogels. As the GG content increases, the rate of drug release 
decreases and the drug release is significantly prolonged. This can be explained by 
considering the dependence of drug release rate on the nature of the hydrogel matrix. 
Due to increased GG content, the hydrogel becomes denser and the swelling ratio 
decreases, which eventually inhibits the faster release of the drug. The effect of GG is 
more pronounced in case of the CD containing hydrogels. DX release is significantly 
prolonged from the GP41-CD hydrogel than that from GP11-CD and GP12-CD 
hydrogels. Moreover, the CD containing hydrogels show a considerably slow release 
of DX as compared to the corresponding hydrogels without the CD. The synergistic 
effect of the increased GG content and the presence of CD on the drug release process 
can be due to the combined effect of the increased matrix density and the influence of 
CD on the polymer relaxation process, which reduce the free volume available for the 
drug diffusion thus decreasing the release rate. In addition, the possibility of DX-CD 
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complex formation in the CD containing hydrogels should also be considered. In 
GP11, GP21 and GP41 hydrogels DX is freely dispersed in the matrix and can diffuse 
out of the matrix as the matrix swells, while in GP11-CD, GP21-CD and GP41-CD 
hydrogels some of the DX are freely dispersed and some are likely to be in a bound 
state with CD therefore prolonging the release rate. The GP41-CD hydrogel was found 
to exhibit the best of all for obtaining controlled release of DX. 
  
 
 
Figure 6.11. DX release profiles from (A) GP11, GP21, GP41 and (B) GP11-CD, 
GP21-CD, GP41-CD hydrogels in pH 7.4 at 37°C. 
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DX Release in SGF and SIF 
In order to explore the drug release behaviour at pH conditions in the GIT, the release 
studies were carried out in the simulated fluids, SGF and SIF. For further imitating the 
GIT conditions; the GP41 and GP41-CD hydrogels were immersed in SGF for 2 
hours, then transferred to SIF and the drug release was monitored (Figure 6.12).  
 
Figure 6.12. Drug release profiles of GP41, GP41-CD hydrogels in SGF and SIF at 
37°C. 
 
 
For all the hydrogels, less than 5% of DX was released during the initial 2 h in SGF. 
However, when the hydrogels were transferred to SIF, the release of DX increased 
significantly. It could be observed that the amount of DX released from the CD-
containing hydrogels is considerably less than the hydrogels without CD at any given 
time. From the above study, it was proposed that GP41-CD could be employed as a 
controlled delivery vehicle for the delivery of dexamethasone to the intestine. 
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Drug Release from Hydrogels containing DX-CD ICs 
In order to compare the efficacy of GG-PAA-CD hydrogels and GG-PAA-IC 
hydrogels, release experiments were also carried out from the hydrogels containing 
DX-CD ICs. The release profiles of GP01 and GP10 hydrogels containing the ICs 
showed almost similar release profiles as that of GP01-CD and GP10-CD hydrogels 
and the drug release was over by 3 h, due to the extensive swelling of the hydrogels. 
Effect of PAA Content on DX Release from Hydrogels Containing DX-CD ICs 
Figure 6.13 A describes the influence of increasing PAA content on the drug release 
process from the IC containing hydrogels. Similar to that observed earlier for GP-CD 
hydrogels, with increased PAA content, no significant difference in the rate of drug 
release occurred even in the presence of IC. GP11-IC, GP12-IC, and GP14-IC all 
showed similar release rate.  
Effect of GG Content on DX Release from Hydrogels Containing DX-CD ICs 
Figure 6.13 B illustrates the influence of GG content on DX release from GP11-IC, 
GP21-IC and GP41-IC hydrogels. The presence of GG in higher amounts in the 
hydrogel matrix remarkably prolongs the drug release rate which is very similar to that 
observed in case of the GP-CD hydrogels. GP41-IC hydrogel was found to be the best 
of the lot for controlled delivery of DX.  
Therefore, it can be concluded that the hydrogel composition and the nature of the 
hydrogel matrix in terms of its network organization play vital roles in the drug 
release process, irrespective of whether CD is present as part of hydrogel network 
structure or added as an IC. 
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Figure 6.13. DX release profiles from (A) GP11-IC, GP12-IC, GP14-IC and (B) 
GP11-IC, GP21-IC, GP41-IC hydrogels in pH 7.4 at 37°C. 
 
Effect of Method of Drug Incorporation in Hydrogels  
To verify the influence of method of incorporation of drug into the hydrogel and the 
role of CD on the drug release characteristics, release studies were carried out from 
the following systems: (i) GP41-CD hydrogel where DX was added during the 
hydrogel synthesis, (ii) GP41 hydrogel containing the preformed solid DX-CD IC and 
(iii) GP41-CD (eq. loading) hydrogel where DX was loaded into the hydrogel through 
equilibrium loading process.   
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In the equilibrium loading method, the GP41-CD hydrogel was allowed to swell in the 
DX solution till equilibrium. Then the hydrogel was washed to remove the surface 
adhered drug. This hydrogel has been represented as GP41-CD (eq. loading); “eq. 
loading” in the parentheses indicates that the drug is loaded through equilibrium 
loading method.  
Figure 6.14 represents the DX release profiles of GP41-CD, GP41-IC and GP41-CD 
(eq. loading) hydrogels at pH 7.4 and 37°C.  
 
Figure 6.14. DX release profiles from GP41-IC, GP41-CD and GP41-CD                   
  (eq. loading) hydrogels at pH 7.4 and 37°C.  
 
The DX release rate was found to follow the order GP41-CD (eq. loading) > GP41-
CD > GP41-IC. The GP41-CD (eq. loading) hydrogel released the drug considerably 
faster in comparison to the other two hydrogels. The complete drug release from the 
equilibrium loaded hydrogel took around 12 h, from the GP41-CD hydrogel it took 
around 17 h whereas from the IC containing hydrogel the total drug release takes 
around 24 h.  This could be attributed to the fact that during equilibrium loading it is 
likely that major fraction of DX is distributed freely in the hydrogel matrix and a few 
are in the bound state with the CD. For GP41-CD hydrogel, since the drug was 
incorporated in situ i.e. during the hydrogel synthesis, therefore it is expected that the 
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fraction of CD-bound drug to be higher than that the freely dispersed drug. But in case 
of GP41-IC hydrogel, it contains the drug mostly in the bound state therefore showing 
the slowest release characteristic. Similar results were also obtained for other GP 
hydrogels i.e. for all hydrogels the IC containing hydrogel showed relatively 
prolonged release than the corresponding hydrogel with CD as a part of the network.  
Thus from the above studies it could be concluded that hydrogels containing ICs fare 
better in terms of controlled release characteristics than the hydrogels containing CD 
as a part of their matrix. Moreover the other benefits of loading drug in the form of IC 
are: (i) the drug can be protected from the harsh reaction conditions of hydrogel 
synthesis, (ii) it offers a control on the drug loading efficiency, and (ii) it can improve 
the solubility, stability and bioavailability of the drug.   
 6.2.4.2 In vitro DX Release Kinetics 
Table 6.3 summarizes the kinetic and the fitting parameters for the DX release data 
fitted to various mathematical equations. It was also found that DX release data 
showed the best fit to the Ritger-Peppas model for almost all the hydrogels. The 
kinetic fittings for GP10, GP01, GP10-CD and GP01-CD hydrogels also showed good 
fit to the zero-order equation. The relative contribution from the diffusion and 
relaxation processes calculated from the Peppas-Sahlin equation for these hydrogels 
shows the predominant effect of the relaxation kinetic constant (k2) over the diffusion 
kinetic constant (k1). It has been observed that these hydrogels undergo extensive 
swelling in a very short period of time which can be due to the rapid polymer 
relaxation followed by water diffusion. Thus, the drug release from these hydrogels is 
controlled mostly by relaxation rate of the polymer chains. The diffusional exponent 
(n) was found to be 0.96 and 0.97 for GP10 and GP10-CD hydrogels which implied 
the Case II drug transport mechanism from these hydrogels. For the GP and GP-CD 
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hydrogels the value of n lie between 0.5 and 0.9 indicating the anomalous nature of 
drug release, where both diffusion and relaxation processes contribute. 
Table 6.4 summarizes the kinetic and the fitting parameters for the DX release from 
GP-IC hydrogels which have been fit to various mathematical equations. The value of 
n lying between 0.87 and 0.95 indicate the drug transport mechanism to be of 
anomalous nature.    
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The R/ F plot for all the hydrogels has been drawn and shown in Figure 6.15. 
 
 
Figure 6.15. Plots of relaxation to the Fickian contribution (R/F) with the fraction of 
dug released for (A) GP11, GP12, GP14, GP21, GP41; (B) GP11-CD, 
GP21-CD, GP14-CD, GP21-CD, GP41-CD, (C) GP11-IC, GP12-IC, 
GP14-IC, GP21-IC, GP41-IC and (D) GP41-CD, GP41-IC, GP41-CD 
(eq. loading) hydrogels. 
 
Figure 6.15 A illustrates the R/F plots for the GP11, GP12, GP14, GP21 and GP41 
hydrogels, Figure 6.15 B that for GP11CD, GP12CD, GP14CD, GP21CD and 
GP41CD hydrogels and Figure 6.15 C presents the R/F plots for GP11-IC, GP12-IC, 
GP14-IC, GP21-IC and GP41-IC hydrogels. For the IC containing hydrogels, 
predominant effect of macromolecular relaxation over the diffusion on the drug 
release is clearly witnessed from the considerably high values of R/F as compared to 
the other two systems. The CD containing hydrogels (GP-CD) showed a slightly 
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higher value of R/F as compared the corresponding GP hydrogels without CD. 
Therefore, it could be concluded that the presence of CD in the hydrogel matrix plays 
a vital role in modifying the drug release process (Bibby et al., 2000). 
Figure 6.15 D demonstrates the R/F plots for GP41-CD, GP41-IC and GP41-CD (eq. 
loading) hydrogels. As observed the dominance of polymer relaxation over diffusion 
is clearly indicated for GP41-IC than GP41-CD hydrogel. The fractional values of R/F 
for GP41-CD(eq. loading) hydrogel were suggestive of the fact that drug release from 
this hydrogel was predominantly diffusion-controlled. This is further supported by the 
reasonably good fit of the release data from this hydrogel to Higuchi model (Table 
6.3).  
6.2.5 Antimicrobial Assay 
The design of complementary methods to inhibit the growth of pathogenic bacteria is 
an active area of research. Antimicrobial activity of GP-CD hydrogels against E. coli 
is shown in Figure 6.16. Hydrogel surface nanostructures and hydrophobic 
interactions are known to initiate bacterial cell phospholipids bilayer perforation. GG 
is known to exhibit antimicrobial activity due to hydrophobic interactions with the 
bacterial cell membrane (Das and Mukherjee, 2012; Qian et al., 2011).  Water has 
been used as negative control in this study. The hydrogels exhibited good bactericidal 
activity against E. coli and it was observed that the antimicrobial property of the 
hydrogels was not compromised by the introduction of PAA or CD in the matrix. 
Therefore the microbiocidal property of these hydrogels could be attributed to the 
surface hydrophobic interactions induced by GG and membrane perforation due to 
structural interactions. Thus these hydrogels could also be utilized as probable wound-
dressing agents.  
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Figure 6.16. Antimicrobial activity of GP-CD hydrogels against E. coli. 
 
6.2.6 Cytotoxicity Assay 
The MTT colorimetric technique has been employed to evaluate the in vitro 
cytotoxicity of the hydrogels. In the direct contact method, optical microscopy 
revealed that the cells possess normal morphology even after 48 h incubation with the 
hydrogel samples. Figure 6.17 A represents the optical photomicrograph obtained 
after 48 h incubation of mouse fibroblasts cells in direct contact with GP41-CD 
hydrogel. Fibroblast cell viability assayed by MTT colorimetric technique (indirect 
method) after 24 h incubation with the GP14-CD and GP41-CD hydrogels is shown in 
Figure 6.17 C. It can be seen that the cell viabilities of the two hydrogels are all 
greater than 95% after incubation. According to GB/T 16886.5-2003 (ISO 10993-
5:1999), samples with cell viability larger than 75% can be considered as showing no 
cytotoxicity (Yang et al., 2009). Therefore these hydrogels can be considered as non-
toxic in nature and thus biocompatible with living tissues therefore can be utilized as 
promising drug delivery systems. 
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Figure 6.17. (A) Optical photomicrograph obtained after 48 h incubation of mouse 
fibroblasts cells in direct contact with GP41-CD and (B) Effects of 
GP14-CD and GP41-CD hydrogels on the cell viability of the fibroblasts 
after 24 h incubation determined by MTT assay. 
 
6.3 CONCLUSIONS  
 pH-Sensitive hydrogels composed of GG and PAA containing CD were 
synthesized using a non-toxic cross-linker, TEOS and explored for the delivery 
of DX.  
 The hydrogels were characterized by various spectroscopic techniques.  
 Hydrogels containing preformed DX-CD ICs were also synthesized and 
investigated for delivery of DX. 
 The swelling studies revealed the pH-dependence and maximum swelling was 
observed at neutral pH. The incorporation of CD did not affect the swelling 
capacity of the hydrogels.  
 Controlled release of DX was obtained from CD-incorporated hydrogels as 
opposed to the fast release from the hydrogels without CD. The GP41-CD 
hydrogel was found to be most suitable for the controlled delivery for DX.  
 From the pH-responsive release studies it is concluded that these hydrogels 
could be employed as controlled delivery vehicles for the delivery of 
dexamethasone to the intestine. 
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 The incorporation of DX by equilibrium loading into GP41-CD hydrogel 
released the drug faster. 
 The hydrogels containing the ICs fared better in terms of controlled delivery 
characteristics. Moreover, the utilization of IC is beneficial as it protects the 
drug without altering its properties. 
 The preliminary kinetic analyses of the drug release presented the Case II type 
of drug release from the hydrogels. Moreover, the prevalence of the polymer 
relaxation process in the release phenomena was also established by the kinetic 
data.  
 The MTT colorimetric assay indicated that the hydrogels are biocompatible 
and non-cytotoxic in nature certifying them as promising drug delivery 
systems. 
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7.1 Summary 
Hydrogels are cross-linked hydrophilic polymers which retain their three-dimensional 
structure even after absorbing large amounts of water or biological fluids. In their 
fully swollen state, hydrogels are soft and have a rubbery consistency, therefore mimic 
the natural structure of the body’s cellular makeup, rendering them importance for a 
wide variety of biomedical applications e.g. tissue engineering, artificial organ and 
contact lens designing and most importantly in drug delivery. Efforts have focused 
primarily on designing smart hydrogel systems that make use of changes in pH and 
temperature to expand and contract, forming a hydrogel “switch” that releases drug in 
a controlled fashion. However, the applicability of hydrogels as controlled delivery 
release systems is hindered due to their high hydrophilic characteristics which 
eventually lead to burst release of drug. More so, hydrogels are particularly inefficient 
for loading and sustained release of hydrophobic drugs. Recently growing interest has 
focused on overcoming the inherent pharmacological limitations of hydrogels by 
incorporating particulate systems (microspheres, microemulsions, micelles, microgel, 
liposomes, cyclodextrins, etc.) into the hydrogel matrix to form composite or ‘‘plum 
pudding’’ hydrogel networks. Cyclodextrins (CDs) are of interest in this context given 
their hydrophilic exterior and hydrophobic interior. The hydrophilic exterior can be 
useful for effective partitioning into the hydrogel matrix and maintaining the bulk 
hydrophilicity and swelling state of the hydrogel and the hydrophobic interior can 
facilitate the entrapment and controlled release of hydrophobic drugs. Incorporation of 
cyclodextrins into polymeric drug release systems has been known to influence the 
mechanism by which the drug is released. A range of strategies have been explored to 
modify cyclodextrin integrated hydrogels to meet desired drug delivery profiles.  
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The present research work aimed at employing a simple and easy strategy for 
incorporating CDs to hydrogel matrix by loading preformed drug−CD ICs directly 
into the hydrogel to design an array of controlled delivery systems and exploring this 
possibility in greater details. 
To explore the efficacy of PVA hydrogels containing drug-CD ICs as controlled drug 
delivery systems, solid ICs of SA and IBF in CD were prepared and loaded to GA 
cross-linked PVA hydrogels. The formation of ICs was affirmed from FTIR, XRD, 
DSC, Optical Microscopy and 
1
H NMR studies. The hydrogels were also 
characterized by several analytical techniques. The swelling evaluation indicated the 
decreased swelling with increasing GA content for both PVA and PVA-CD hydrogels. 
The presence of CD in the hydrogel significantly prolonged the release of drugs 
showing a sustained release pattern. The drug release profiles from the hydrogels 
containing the IC shows a strong dependence on the degree of cross-linking. Among 
all the hydrogels studied P4-CD, having maximum degree of cross-linking, was found 
to show the slowest release of SA. The release of IBF, a relatively hydrophobic drug 
in comparison to SA and having higher binding efficiency towards CD, was found to 
be further prolonged than that of SA. Thus the nature of drug in terms of its binding 
efficiency with the CD plays an important role in the drug release process from these 
hydrogels. The preliminary kinetic analysis revealed the anomalous nature of drug 
release from all the hydrogels except P4-IC. The P4-D hydrogel, however, showed 
Case II transport mechanism indicating the dominant relaxational process. Thus the 
role of CD in the drug release process from hydrogels is not only because of its 
inclusion ability but also due to its effect on the polymer relaxation. In other words, it 
is the combined effect of drug diffusion and polymer relaxation that controls the 
overall drug release process from the hydrogels containing ICs. The cytotoxicity tests 
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ensured the hydrogels to be non-toxic and hence can be utilized as controlled delivery 
systems. 
Oral drug delivery systems targeting the lower part of the gastro intestinal track (GIT), 
including the intestine and colon, has attracted much interest for the delivery of an 
array of therapeutic agents. pH-Sensitive hydrogels with their unique ability to sense 
the differences in the pHs of GIT, have become quite an important class of systems 
used for controlled delivery formulations. With this rationale, pH-Sensitive CS−PVA 
IPN hydrogels with varying amount of PVA were synthesized, characterized and 
explored for the delivery of two NSAIDs; NX and DS. Hydrogels containing free drug 
and the ICs were prepared. The hydrogels exhibited pH-sensitive swelling with 
maximum swelling at neutral pH and lower swelling at acidic and alkaline pHs. The 
presence of CD did not have any significant effect on the swelling abilities of the 
hydrogel. The drug release from the hydrogels containing the ICs was much prolonged 
as compared to hydrogels containing the free drugs. The rate of drug release was 
found to decrease with increasing PVA content. The hydrogels released negligible 
amounts of drug in simulated gastric fluid (SGF) (< 5%) while the release amounts 
increased significantly in simulated intestinal fluid (SIF). The cytotoxic assay 
performed on the hydrogels ensured them to be nontoxic and biocompatible. Thus, it 
can be proposed that these hydrogels can be utilized as oral controlled delivery 
vehicles for the delivery of NSAIDs to the intestine. 
PVAPAA microspheres cross-linked with GA were synthesized and studied for the 
delivery of DX, one of the frequently used immunosuppressant drugs. The 
microspheres containing free DX, PM and ICs (CP and FD) were prepared in order to 
examine the effect of the method of preparation of IC on the release characteristics. 
The swelling studies indicated higher swelling in neutral pH than in acidic pH. At pH 
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1.2, the amounts of DX released from all microspheres were much lower than the 
release amounts at pH 7.4. Slowest release was observed from the microspheres which 
contained the FD. Approximately 5% of DX was released during the initial 2h in SGF 
but upon transfer to SIF, the rate of DX release increased significantly. Thus the 
synthesized microspheres containing ICs could be effectively employed for the 
controlled delivery of DX and their pHsensitivity could be exploited for the delivery 
to the intestine. Moreover, the compatibility of the synthesized microspheres with the 
living tissues further validates them as promising drug delivery systems.  
Controlled drug delivery features from thermo-responsive hydrogels comprising 
PNIPAAm and solid drug-CD ICs were also investigated. ICs of 5FU with CD were 
prepared by the freeze-drying method and characterized by different techniques. 
Temperature-responsive GGPNIPAAm hydrogels cross-linked by TEOS were 
synthesized. The hydrogels displayed temperature-dependent swelling characteristics. 
Incorporation of GG did not disturb the arrangement of PNIPAAm chains and the 
LCST remained invariant. Higher swelling was observed below the LCST (~33
o
C) 
while remarkable decrease in degree of swelling was seen above the LCST. The rate 
and amount of drug released at 25°C was always higher than that at 37°C. Presence of 
IC in the hydrogel matrix is capable of significantly controlling the drug release rate 
despite the fact that the matrix is undergoing a drastic morphological change above its 
LCST. Higher amount of GG in the hydrogels led to a decrease in the release rate 
from the hydrogels. The preliminary analyses of drug release indicated Case II type of 
mechanism from the hydrogels indicating the predominant effect of macromolecular 
relaxation on the drug release kinetics. The cytotoxicity assay certified these 
hydrogels to be safe, non-toxic and biocompatible with living tissues thereby 
establishing their potential as controlled drug delivery systems. 
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In order to evaluate the efficacy of hydrogels containing CD as part of network 
structure and those hydrogels containing drug-CD ICs, pHsensitive hydrogels 
composed of GG and PAA were synthesized using TEOS as cross-linker by varying 
the ratio of GG and PAA. The corresponding GG−PAA−CD hydrogels with CD as a 
part of the network structure were also synthesized for comparison. The swelling 
characteristics revealed maximum swelling at neutral pH. The incorporation of CD did 
not have any significant effect on the swelling capacity of the hydrogels. Controlled 
release of drug was obtained from CD-incorporated hydrogels as opposed to the fast 
release from the hydrogels without CD. The hydrogel comprising GG to PAA ratio of 
4:1 was found to be the best of the lot for controlled delivery of DX. Upon comparison 
it was found that the in situ method of incorporation of drug into the hydrogel matrix 
was found to be more favorable in terms of sustained release profile than loading the 
drug by equilibrium swelling. Moreover, hydrogels containing preformed ICs 
performed better in terms of controlled release characteristics than the hydrogels 
containing CD as a part of their network structure. The cytotoxicity study revealed the 
biocompatible and non-toxic nature of the hydrogels validating them as promising 
drug delivery systems.  
7.2 Scope for Future Work 
Considering the success of the strategy of incorporation of drug-CD ICs into the 
hydrogels to achieve a controlled delivery characteristic, this approach can be 
extended for the delivery of macromolecules such as proteins, peptides, growth factors 
and genes from hydrogels. Hydrogels with dual control i.e. pH as well as temperature 
sensitive, can be synthesized and similar work can be carried out. The possibilities of 
manipulating hydrogels to form a wide range of shapes and sizes, from nano to macro, 
and incorporating drug-CD ICs can open new perspectives for designing controlled 
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drug delivery systems. The hydrogel microspheres containing ICs can be subjected to 
surface functionalization for achieving target-specific controlled delivery of 
therapeutics.  
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